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Summary 
 
Bone morphogenetic proteins (BMP) have been heavily implicated in prostate cancer and bone 
metastasis. With various studies demonstrating a feedback loop between BMPs and their 
regulators, BMP antagonists, we aimed to investigate the role of this interplay in prostate cancer 
and osteoblastic bone lesion formation.  
 
We assessed the expression of BMPs, their antagonists, and their signalling components in 
different prostate cancer cell lines in the absence and presence of a bone matrix extract (BME) 
by RNA-Seq and qPCR. We also analysed GEO data from a prostate cancer cell line expression 
study, and microarray studies of LNCaP-osteoblast co-cultures and prostate cancer bone 
metastases. From these, we demonstrated evidence of a BMP/BMP antagonist feedback loop, 
especially between BMP-2 and Gremlin isoforms, GREM1 and GREM2. BMP antagonists Noggin, 
Follistatin isoform FST344, and Gremlin were then overexpressed in DU145 using the pEF6/V5-
HIS-TOPO® TA vector and the resultant cell lines DU145PEF, DU145NOG, DU145FST344 and 
DU145GREM were subjected to functional assays examining cell proliferation, invasion, adhesion 
and migration. Results demonstrated that Noggin and FST344 may have a protective effect 
against prostate cancer bone metastasis due to their inhibition of cell growth and migration, and 
stimulation of adhesion, although FST344 also caused an increase in invasion in BME. In contrast, 
DU145GREM showed an increase in cell growth and migration, with minimal effects from BME. 
qPCR analyses and the GEO data gave more evidence of a BMP/BMP antagonist relationship 
affecting EMT status and MMP expression profile of cancer cells, with further indication of a 
BMP-2/Gremlin interplay.  
 
iii 
 
Our study demonstrates the importance of a BMP/BMP antagonist interplay in the 
establishment of prostate cancer bone metastases. While further experimentation is required 
to decipher the precise molecular mechanisms underlying this interplay, this could present a 
novel therapeutic target for the prevention or treatment of prostate cancer and its related bone 
metastasis.
iv 
 
Publications 
 
Shi L, Resaul J, Owen S, Ye L, Jiang WG (2016). Clinical and Therapeutic Implications of Follistatin 
in Solid Tumours. Cancer Genomics Proteomics. 13(6): 425-435 
 
Zabkiewicz C, Resaul J, Hargest R, Jiang WG, Ye L (2017). Bone Morphogenetic Proteins, Breast 
Cancer, and Bone Metastases: Striking the Right Balance. Endocrine-Related Cancer. 24(10):349-
366 
 
Zabkiewicz C, Resaul J, Hargest R, Jiang WG, Ye L (2017). Increased Expression of Follistatin in 
Breast Cancer Reduces Invasiveness and Clinically Correlates with Better Survival. Cancer 
Genomics Proteomics. 14(4): 241-251 
 
 
 
 
 
 
 
 
 
v 
 
Contents 
 
 
 ...................................................................................................................................... 1 
1.1 Prostate cancer ............................................................................................................. 2 
1.2 Diagnosis ....................................................................................................................... 5 
 PSA testing ............................................................................................................ 5 
 Digital Rectal Examination .................................................................................... 6 
 Biopsy .................................................................................................................... 6 
1.3 Staging of Prostate Cancer ............................................................................................ 7 
 Gleason Grading System ....................................................................................... 7 
 TNM Staging ........................................................................................................ 10 
1.4 Pathophysiology of Prostate Cancer ........................................................................... 12 
 ASAP .................................................................................................................... 12 
 PIN and High-Grade PIN ...................................................................................... 13 
 Androgen Independence .................................................................................... 13 
1.5 Cancer Metastasis ....................................................................................................... 15 
 Local Invasion ...................................................................................................... 15 
 Cell migration ...................................................................................................... 16 
 Intravasation and Survival in the Circulation ...................................................... 17 
 Extravasation and Colonisation of Distant Sites ................................................. 18 
1.6 Prostate Cancer Metastasis ........................................................................................ 20 
 The Bone ............................................................................................................. 21 
 Pathophysiology of Bone Metastasis .................................................................. 24 
1.7 BMPs ........................................................................................................................... 28 
 Biochemical properties of BMP proteins ............................................................ 28 
 Structure of BMPs ............................................................................................... 29 
1.8 BMP Receptors ............................................................................................................ 31 
1.9 BMP signalling ............................................................................................................. 33 
 The Smad-dependent pathway ........................................................................... 34 
 The Smad-independent pathway ........................................................................ 36 
1.10 Regulation of BMP Signalling ...................................................................................... 38 
1.11 BMP Signalling in the Bone ......................................................................................... 39 
1.12 Aberrance of BMPs and their Implications in Prostate Cancer................................... 40 
1.13 BMP antagonists ......................................................................................................... 43 
 Noggin ................................................................................................................. 45 
vi 
 
 Follistatin ............................................................................................................. 46 
 Gremlin................................................................................................................ 47 
1.14 BMP antagonists and Prostate Cancer ........................................................................ 47 
1.15 Aims............................................................................................................................. 48 
 .................................................................................................................................... 51 
2.1 General Materials ....................................................................................................... 52 
 Cell lines .............................................................................................................. 52 
 Primers ................................................................................................................ 52 
2.2 Standard reagents and solutions ................................................................................ 57 
 Solutions for use in Cell Culture .......................................................................... 57 
 Solutions for use in Molecular Biology ............................................................... 59 
 Solutions for use in Cloning ................................................................................ 60 
2.3 Cell Culture, Maintenance, Storage and Transfection ................................................ 60 
 Preparation of Growth Media ............................................................................. 60 
 Cell Maintenance ................................................................................................ 61 
 Adherent Cell Trypsinisation and Cell Counting ................................................. 61 
 Transfection of Cells by Electroporation ............................................................. 63 
 Storage of Cell Stocks in Liquid Nitrogen ............................................................ 63 
 Cell Resuscitation ................................................................................................ 64 
2.4 Methods for RNA Detection ........................................................................................ 64 
 mRNA Isolation ................................................................................................... 64 
 RNA Quantification ............................................................................................. 66 
 Reverse Transcription ......................................................................................... 66 
 Reverse Transcription Polymerase Chain Reaction ............................................ 67 
 Agarose Gel Electrophoresis ............................................................................... 68 
 Quantitative Polymerase Chain Reaction ........................................................... 69 
 RNA sequencing .................................................................................................. 72 
2.5 Alteration of Gene Expression in Prostate Cancer Cell Lines ...................................... 74 
 TOPO Gene Cloning and Generation of Stable Transfectants ............................ 74 
 Gene Overexpression .......................................................................................... 75 
 Extraction of PCR products from Agarose Gel .................................................... 76 
 TOPO TA Gene Cloning ........................................................................................ 77 
 Transformation of Chemically Competent E. coli ............................................... 79 
 Colony Selection and Orientation Analysis ......................................................... 79 
 Vector Amplification, Purification and Quantification ........................................ 81 
 Establishment of Stably Transfected Mammalian Cell Lines .............................. 82 
2.6 In vitro Functional Assays ............................................................................................ 83 
vii 
 
 Cell Proliferation Assay ....................................................................................... 84 
 Matrigel Invasion Assay ...................................................................................... 85 
 Matrigel Adhesion Assay ..................................................................................... 87 
 Migration Assay (Wound Assay) ......................................................................... 89 
 ECIS ...................................................................................................................... 89 
2.7 Database Research ...................................................................................................... 91 
2.8 Statistical analysis ....................................................................................................... 92 
 .................................................................................................................................... 94 
3.1 Introduction ................................................................................................................ 95 
3.2 Materials and Methods ............................................................................................... 98 
 Cell lines and Treatments .................................................................................... 98 
 RNA isolation and cDNA synthesis ...................................................................... 98 
 RT-PCR ................................................................................................................. 99 
 RNA-Seq .............................................................................................................. 99 
 GEO Database ..................................................................................................... 99 
3.3 Results ....................................................................................................................... 100 
 Expression of BMPs in Prostate Cancer Cell Lines ............................................ 100 
 Expression of BMP antagonists in Prostate Cancer Cell Lines .......................... 101 
 Expression of BMPRs in Prostate Cancer Cell Lines .......................................... 103 
 Expression of Smads in Prostate Cancer Cell Lines ........................................... 104 
3.4 Discussion .................................................................................................................. 105 
 .................................................................................................................................. 111 
4.1 Introduction .............................................................................................................. 112 
4.2 Materials and Methods ............................................................................................. 115 
 Cell lines and Treatments .................................................................................. 115 
 RNA isolation and cDNA synthesis .................................................................... 115 
 qPCR .................................................................................................................. 116 
 RNA-Seq ............................................................................................................ 116 
 GEO database .................................................................................................... 116 
4.3 Results ....................................................................................................................... 117 
 Expression of BMPs in Prostate Cancer Bone Metastasis ................................. 117 
 Expression of BMP antagonists in Prostate Cancer Bone Metastasis ............... 120 
 Expression of BMPRs in Prostate Cancer Bone Metastasis .............................. 124 
 Expression of Smads in Prostate Cancer Bone Metastasis ............................... 126 
4.4 Discussion .................................................................................................................. 129 
 .................................................................................................................................. 135 
5.1 Introduction .............................................................................................................. 136 
viii 
 
5.2 Materials and Methods ............................................................................................. 138 
 Materials ........................................................................................................... 138 
 Cell lines and Treatments .................................................................................. 138 
 Amplification of Noggin, Follistatin and Gremlin Coding Sequences ............... 139 
 Cloning of Noggin, FST344 and Gremlin into pEF6/V5-HIS-TOPO® TA vectors 139 
 Prostate Cancer Cell Transfection and Generation of Stable Transfectants .... 140 
 RNA isolation, cDNA synthesis, RT-PCR and qPCR ............................................ 140 
 In vitro Cell Proliferation Assay ......................................................................... 141 
 In vitro Invasion Assay ....................................................................................... 141 
 In vitro Adhesion Assay ..................................................................................... 142 
 In vitro Migration Assay .................................................................................... 142 
 ECIS .................................................................................................................... 143 
5.3 Results ....................................................................................................................... 143 
 Overexpression of BMP Antagonists in DU145 ................................................. 143 
 BMP Antagonist Overexpression Affects Prostate Cancer Cell Growth ........... 144 
 Overexpression of BMP Antagonists Affects DU145 Cell Invasion ................... 146 
 BMP Antagonist Overexpression Affects DU145 Cell Adhesion ....................... 148 
 BMP Antagonist Overexpression and DU145 Cell Migration ............................ 150 
5.4 Discussion .................................................................................................................. 152 
 .................................................................................................................................. 157 
6.1 Introduction .............................................................................................................. 158 
6.2 Materials and Methods ............................................................................................. 161 
 Materials ........................................................................................................... 161 
 Cell lines and Treatments .................................................................................. 161 
 RNA isolation and cDNA synthesis .................................................................... 161 
 RNA-Seq ............................................................................................................ 162 
 qPCR .................................................................................................................. 162 
 GEO Database ................................................................................................... 162 
6.3 Results ....................................................................................................................... 163 
 Differential Expression of EMT markers and MMPs in Osteolytic and 
Osteoblastic Cell Lines ...................................................................................................... 163 
 Expression Profiles of EMT Markers and MMPs in Osteoblastic and Osteolytic 
Bone Lesions ..................................................................................................................... 165 
 Differential Expression of MMPs in Osteoblastic and Osteolytic Bone Lesions 167 
 The MMP Expression Profile of the BMP Antagonist Overexpression Cell Lines
 169 
 The BMP/BMP Antagonist Feedback Loop in the Bone Environment .............. 170 
ix 
 
 The EMT Marker Profile of BMP Antagonist Overexpression Cell Lines in the 
Bone Microenvironment ................................................................................................... 173 
6.4 Discussion .................................................................................................................. 174 
 .................................................................................................................................. 180 
Bibliography.............................................................................................................................. 187 
Appendix ................................................................................................................................... 212 
 
x 
 
List of Figures 
 
Figure  Page 
1.1 Age-specific incidence of prostate cancer (UK) 3 
1.2 Gleason Grading 7 
1.3 The four phases of bone remodelling 23 
1.4 The steps involved in cancer cell metastasis to the bone 27 
1.5 Schematic of BMP activation 29 
1.6 The structure of BMP-2 and BMPR-IA extracellular interaction 33 
1.7 The Smad-dependent and the Smad-independent signalling pathways 37 
1.8 Inhibition of BMPs by BMP antagonists 45 
2.1 Diagram depicting the principle behind qPCR using the Amplifluor™ 
Universal Detection System 
71 
2.2 Schematic representation of the Ion Torrent sequencing workflow 73 
2.3 Flow-chart depicting the TOPO® TA cloning procedure 74 
2.4 Schematic of the pEF6/V5-HIS TOPO® vector 77 
2.5 Verifying the insert orientation of newly generated Noggin, Follistatin 
and Gremlin overexpression vectors 
81 
2.6 Crystal Violet dilution curve 84 
2.7 Schematic illustration of the in vitro Matrigel invasion assay 86 
2.8 Representative image of Crystal Violet-stained cells attached to a 
Matrigel-coated well during an adhesion assay 
88 
3.1 Expression of BMPs in Prostate Cancer Cell Lines 100 
3.2 Expression of BMP antagonists in Prostate Cancer Cell Lines 102 
3.3 Expression of BMPRs in Prostate Cancer Cell Lines 103 
3.4 Figure 3.4: Expression of Smads in Prostate Cancer Cell Lines 104 
xi 
 
4.1 Expression of BMPs in BME-treated Prostate Cancer Cell Lines and in Prostate 
Cancer Bone Metastasis Samples 
118 
4.2 BMP expression profile during LNCaP-hOB co-culture 119 
4.3 Expression of BMP antagonists in BME-treated Prostate Cancer Cell 
Lines and in Prostate Cancer Bone Metastasis Samples 
121 
4.4 The differential expression of BMPs in osteoblastic and osteolytic 
bone metastatic lesions 
122 
4.5 BMP antagonist expression profile during LNCaP-hOB co-culture 123 
4.6 Expression of BMPRs in BME-treated Prostate Cancer Cell Lines and in 
Prostate Cancer Bone Metastasis Samples 
124 
4.7 BMPR expression profile during LNCaP-hOB co-culture 125 
4.8 Expression of Smads in Prostate Cancer Cancer Cell Lines and in 
Prostate Cancer Bone Metastasis Samples 
127 
4.9 Smad expression profile during LNCaP-hOB co-culture 128 
5.1 Overexpression of BMP antagonists in the DU145 cell line 144 
5.2 Effects of BMP antagonist overexpression on DU145 cell growth 145 
5.3 Effects of BMP antagonist overexpression on DU145 cell invasion 147 
5.4 Effects of BMP antagonist overexpression on DU145 cell adhesion 149 
5.5 Effects of BMP antagonist overexpression on DU145 cell migration 151 
6.1 Differential Expression of EMT markers and MMPs between osteolytic 
and osteoblastic cell lines 
164 
6.2 The EMT expression profile of osteoblastic and osteolytic bone lesions 165 
6.3 The MMP expression profile in in osteoblastic and osteolytic prostate 
cancer bone lesions 
168 
6.4 BMP-mediated expression of MMPs 169 
6.5 The BMP/BMP antagonist feedback loop behind cancer cell behaviour 
in the bone environment 
172 
xii 
 
6.6 The EMT profile of the BMP Antagonist Overexpression Cell Lines in 
the Bone Environment 
174 
xiii 
 
List of Tables 
 
Table  Page 
1.1 Gleason Grading for Prostate Cancer 9 
1.2 The 2017 TNM Classification for prostate adenocarcinoma 11 
2.1 Details of prostate cancer cell lines used in this study 53 
2.2 Primers used for conventional RT-PCR 54 
2.3 Primers used for qPCR 55 
2.4 Primers used for the cloning of Noggin, FST344 and Gremlin vectors 56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiv 
 
Abbreviations 
 
3D: 3-dimensional 
A: deoxyadenosine 
aa: amino acid 
ActR-IA: type-IA activin receptor 
ActR-IIA: type-IIA activin receptor  
ActR-IIB: type-IIB activin receptor 
ADT: androgen deprivation therapy 
AJCC: American Joint Committee on Cancer 
ALK: Activin like kinase receptor 
Ang: angiopoietin  
AR: androgen receptor 
ARE: androgen responsive element 
BAMBI: BMP and activin membrane-bound inhibitor 
BISC: bone morphogenetic protein-induced signalling complexes 
BM: basement membrane 
BME: bone matrix extract  
BMEC: bone marrow endothelial cells  
BMP: bone morphogenetic protein 
BMPR: bone morphogenetic protein receptor 
BPH: benign prostatic hyperplasia  
BRAM1: bone morphogenetic protein receptor associated molecule 1 
BSS: buffered salt solution 
CAF: cancer-associated fibroblast 
xv 
 
CAM: cell adhesion molecule 
Cbfa-1: core-binding factor subunit alpha-1  
CCLE: Cancer Cell Line Encyclopaedia 
cDNA: complementary deoxyribonucleic acid 
co-IP: co-immunoprecipitation 
Co-SMAD: common-Smad 
CSC: cancer stem-like cell 
CTC: circulating tumour cell 
CXCL12: C-X-C motif chemokine-12  
DAN: differential screening-selected gene aberrative in neuroblastoma 
DEPC: diethyl pyrocarbonate 
DHT: dihydrotestosterone 
Dlx5: distal-less homeobox-5 
DMEM: Dulbecco’s Modified Eagle’s Medium 
DRE: digital rectal examination 
DTC: disseminated cancer cell 
E-Cadherin: epithelial cadherin 
ECIS: Electric Cell-substrate Impedance Sensing®  
ECM: extracellular matrix 
EDTA: ethylebediaminetraacetic acid 
emPCR: emulsion polymerase chain reaction 
EMT: epithelial to mesenchymal transition 
EMT-TFs: EMT-inducing transcription factors 
ERK: extracellular signal-regulated kinase 
FBS: foetal bovine serum 
FGF: fibroblast growth factor 
xvi 
 
FKBP12: 12kDa FK506-binding protein 
FSD: Follistatin Domain 
FST: follistatin 
FSTL: follistatin-related protein 
GAPDH: glyceraldehyde 3-phosphate dehydrogenase 
GDF: growth differentiation factor 
GEO: Genomic Expression Omnibus  
GREM: Gremlin 
GTP: guanosine triphosphate 
H&E: haematoxylin and eosin  
HGPIN: high-grade PIN  
hOBs: primary human osteoblast 
HPC1: hereditary prostate cancer locus-1 
IGF: insulin-like growth factor 
I-Smad: inhibitory-Smad 
JNK: c-Jun amino-terminal kinase 
KLK3: kallikrein-3  
Mad: Mothers against decapentaplegic  
MAPK: mitogen-activated protein kinase 
MET: mesenchymal to epithelial transition 
MH1: Mad homology 1 
MH2: Mad homology 2 
miRNA: micro ribonucleic acid 
MMP: matrix metalloproteinase 
mPCL-TCP: medical grade polycaprolactone-tricalcium phosphate  
mRNA: messenger ribonucleic acid 
xvii 
 
MSC: mesenchymal stem cell 
MT1-MMP: membrane type 1 matrix metalloproteinase  
N-Cadherin: neuronal-cadherin 
NCBI: National Centre for Biotechnology Information 
ND: N-terminal Domain 
NGS: Next-Generation Sequencing 
NK: Natural Killer  
NOG: Noggin 
OPG: osteoprotegerin 
OPN: osteopontin  
PBS: phosphate buffer solution 
PDGF: platelet-derived growth factor 
PFC: pre-formed hetero-oligomeric complexes 
PI3 kinase: phosphoinositide 3-kinase  
PIN: prostatic intraepithelial neoplasia 
PKA: Protein kinase A 
PKC: Protein Kinase C 
PP: protein phosphatase 
PRDC: protein related to DAN and Cerberus 
PSA: prostate-specific antigen 
PTHrP: parathyroid-hormone-related peptide 
qPCR: quantitative polymerase chain reaction 
RANKL: receptor activator of nuclear factor-κB ligand 
RNA: ribonucleic acid 
RNA-Seq: ribonucleic acid sequencing 
RNASEL: Ribonuclease L 
xviii 
 
RPMI: Roswell Park Memorial Institute  
R-Smad: receptor-regulated Smad 
RT: reverse transcription 
RT-PCR: reverse transcription polymerase chain reaction 
Runx2: runt-related transcription factor 2  
SCID: severe combined immunodeficient mice 
SD: standard deviation 
SDF1: stromal cell-derived factor-1  
sEcad: E-cadherin  
SEM: standard error of the mean 
SHBG: sex hormone-binding globulin 
Smurf1: Smad ubiquitination regulatory factor-1 
SOC: Super Optimal broth with Catabolite repression 
T: deoxythymidine 
TAB1: TAK1 binding protein 
TAK1: TGF- β activated kinase 1 
TBE: tris-boric-acid 
TEB: human tissue engineered bone construct  
TEM: transendothelial migration 
TF: transcription factor 
TGF-β: transforming growth factor-β 
TIMP-1: tissue inhibitor of metalloproteinases-1  
TNF: tumour necrosis factor  
TNM: Tumour Nodal Metastasis 
TRUS: transrectal ultrasound-guided biopsy 
UICC: Union Internationale Contre le Cancer 
xix 
 
USAG-1: uterine sensitization-associated gene-1  
v: variant 
VEGF: vascular endothelial growth factor 
WT: wild-type 
XIAP: X-linked inhibitor of apoptosis protein 
Zeb1: zinc finger E-box binding homeobox 1  
1 
 
 
 
 
 
 
 
 
 
  
 
Introduction 
 
 
 
 
2 
 
1.1 Prostate cancer 
 
Prostate cancer is the most diagnosed male cancer in the developed world and is the second 
leading cause of cancer-related deaths in the UK, after lung cancer (ONS 2015, Bray, Ferlay et al. 
2018). A number of risk factors have been recognised to influence the development of this 
disease, the most significant factors of which include age, ethnicity, family history, geography 
and diet.  
 
Age is undoubtedly the most determining risk factor, with prostate cancer increasing in 
incidence in men over 50. Indeed, there seems to be a consistent trend whereby the probability 
of developing invasive prostate cancer increases directly with age. Prostate cancer statistics 
show that in the US for instance, men under the age 49 very rarely develop this disease, 
demonstrating odds of 0.2% only. However, this percentage sharply rises to 1.7% in 50 to 59-
year-olds, 4.8% in 60 to 69-year-olds and 8.2% in 70-year-olds and over (Siegel, Miller et al. 
2018). This is a trend that is reflected in mortality rates, with 41% of prostate cancer-related 
deaths occurring in men aged between 75 and 84, and the 30% occurring in men aged 85 years 
and over (Wright and Lange 2018). 
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The incidence of prostate cancer can also vary by race and ethnicity. Black men, in particular, 
seem to be disproportionately prone to this disease, so much so that incidence rates in Black 
populations (120.8 to 247.9 cases per 100,000) are more than double that of White populations 
(96.0 to 99.9 cases per 100,000) (CRUK 2014). Typically, a geographical variation is also seen in 
prostate cancer incidence rates, whereby rates in developed countries far exceed that of less 
developed ones, with rates varying more than 25-fold worldwide. In 2012, approximately 70% 
of prostate cancer cases occurred in the more developed countries. For example, Australia/New 
Zealand and North America had the highest prevalence with rates of 111.6 and 97.2 per 100,000 
respectively. In contrast, less developed countries like Eastern and South-Central Asia 
demonstrated a much lower prevalence at 13.9 and 5.0 per 100,000 respectively (Bray, Ferlay 
et al. 2018). Despite this trend in incidence rates, there is much less variation in mortality rates 
worldwide, with more developed countries having higher survival rates. These geographical 
disparities between incidence and mortality rates can mainly be attributed to the standard of 
medical care and detection by prostate-specific antigen (PSA) testing in these more developed 
countries. 
Figure 1.1: Age-specific incidence of prostate cancer (UK). Data was obtained from 
Cancer Research UK and represents the average number of new cases of prostate 
cancer per year for each age group between 2013 and 2015 (Cancer Research UK, 2018).  
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It is possible that geographical and racial influences on prostate cancer incidence may be 
overridden by environmental and lifestyle factors. For example, although prostate cancer 
incidence is relatively low in native Asian populations, it is greatly increased in Asian populations 
living in more developed countries (Shimizu, Ross et al. 1991, Ito 2014). This indicates that 
certain factors encountered in those countries may help drive the development of this disease. 
For instance, several studies have demonstrated a positive association between high fat and 
dairy product consumption and the risk of developing prostate cancer (Wynder 1979, Chan, 
Stampfer et al. 2001). Although the exact mechanisms in play are uncertain, the high calcium 
content in dairy products, for instance, is thought to act by suppressing the production of the 
most active form of vitamin D, 1,2,3(OH)2D3. The latter, along with other micronutrients, like 
vitamin E, lycopene, selenium, and soya milk have been shown to inversely correlate with 
prostate cancer risk (Dagnelie, Schuurman et al. 2004, Hwang, Kim et al. 2009). This may explain 
why Asian populations, which tend to have lower fat and higher soy protein intake, have lower 
prostate cancer incidence rates than Western populations. 
 
Genetics have been shown to be another important factor to consider in prostate cancer risk. 
The familial aggregation of this disease was first reported by Morganti and colleagues in 1956, 
who identified a higher prostate cancer risk in men with relatives affected by this disease 
(Morganti, Gianferrari et al. 1956). Indeed, men with first-degree relatives affected with 
prostate cancer have a two or three-fold increased risk  of developing prostate cancer - a 
probability that increases to tenfold if three or more members of the family are affected 
(Steinberg, Carter et al. 1990, Lesko, Rosenberg et al. 1996). Family history is estimated to be a 
deciding factor in 5% to 10% of all prostate cancers, with 40% of those cancers being diagnosed 
in men aged below 55 (Carter, Beaty et al. 1992, Bratt 2002). Several candidate genes have been 
identified to be potentially associated with prostate cancer. Prostate susceptibility was first 
mapped to Ribonuclease L (RNASEL) and named hereditary prostate cancer locus-1 (HPC1) 
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(Smith, Freije et al. 1996). Other studied polymorphisms are in the vitamin D-receptor, androgen 
receptor, ELAC/HPC2, SRD5A2 (5-reductase) and CYP17 (17- hydroxylase). 
 
1.2 Diagnosis 
 
Typically, prostate cancer is a slow growing cancer, especially in older men. In fact, most prostate 
cancers remain at a very early stage, where they do not cause any symptoms. However, prostate 
cancers that do display symptoms most commonly involve nocturia, bladder outlet obstruction, 
difficulty passing urine and deficiency in emptying the bladder. Advanced or metastatic cases 
are usually associated with pain in the back, hips, pelvis and other bony areas or haematuria. 
Three main strategies are used to detect prostate cancer, namely, prostate-specific antigen 
(PSA), digital rectal examination (DRE) or biopsy. 
 
 PSA testing 
 
PSA, also known as gamma-seminoprotein or kallikrein-3 (KLK3), is a serine glycoprotein that is 
produced by prostate epithelial cells. It is believed to act as a liquefying agent in ejaculated 
seminal fluid, allowing spermatozoa to navigate freely through the uterus (Lilja 1985). During 
the prostate cancer process, PSA is released into the circulatory system, causing its serum levels 
to increase up to 106-fold, therefore aiding in the diagnosis of advanced prostate cancer (Liljia, 
Ulmert and Vickers, 2008). PSA circulates in the blood in different forms, with 70-90% of serum 
PSA comprising of PSA that is complexed with protease inhibitors termed complexed PSA. The 
remaining free PSA has three free distinct isoforms: inactive PSA, BPSA and proenzyme-PSA 
(Özen and Sözen 2006). In general, men with PSA levels of around 5 ng/ml or above are usually 
referred for further tests. However, diagnosis using PSA can be difficult as its levels can be 
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affected by various factors, such as age, race, prostatitis, benign prostatic hyperplasia (BPH), as 
well as urine infections, recent prostate biopsies, prostate or bladder surgery, prostatic massage 
and recent prostate biopsies. This is because whilst PSA is a prostate specific marker, it is not 
prostate cancer specific. This raises controversy about its the efficacy of using this method for 
prostate cancer detection. 
 
 Digital Rectal Examination 
 
Digital rectal examination (DRE) was the first established method of prostate cancer detection. 
It is a relatively simple procedure that involves inserting a gloved and lubricated finger into the 
rectum of a patient to inspect the shape, size and surface of the prostate. Should any 
irregularities be found, such as hard or bumpy areas, patients are usually referred for further 
evaluation to assess whether these areas are cancerous or not. DRE, however, lacks sensitivity 
as only the posterior and lateral sections of the prostate are accessible to the examining finger. 
Although most prostate cancers arise in these areas, approximately 25-30% of cancers, located 
in the inaccessible areas, will be missed (McNeal, Bostwick et al. 1986). Moreover, it is possible 
that cancers that are palpable during DRE may be at more advanced stages. 
 
 Biopsy 
 
The most common test used for biopsies is transrectal ultrasound-guided biopsy (TRUS). During 
a TRUS biopsy, an ultrasound probe is inserted in the patient’s rectum to build an image of the 
prostate. The resulting image is then used to direct a spring-loaded 18-gauge biopsy needle to 
the abnormal areas in order to take small samples.  
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1.3 Staging of Prostate Cancer 
 
In order to decide on the best treatment course for prostate cancer patients, the aggressiveness 
of the disease first needs to be established. With the results from biopsies, the cancer can be 
graded and classified through the use of the Gleason grading system and Tumour Nodal 
Metastasis (TNM) classification. 
 
 Gleason Grading System 
 
 
Figure 1.2: Gleason Grading. The schematic depicts the Gleason grading system with histological 
representations of the different grades (adapted from Humphrey 2004 and Kolijn, Verhoef et al. 2015) 
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In 1966, Dr Donald F Gleason, a pathologist in Minnesota, developed a unique system of grading 
prostate carcinoma that is based entirely on the architecture of the tumour (Mellinger, Gleason 
et al. 1967, Gleason and Mellinger 1974, Humphrey 2004). This practice, which is still widely 
used throughout the world today, examines the histological pattern of prostate carcinoma cells 
in haematoxylin and eosin (H&E) prostatic tissue sections and categorises the disease by the 
extent of glandular differentiation and by the growth pattern of the tumour in the prostatic 
stroma (Gleason 1992).  
 
Based on an initial sample of 270 patients, Dr Gleason described five basic grade patterns (see 
figure 1.2), classified as ranging from 1 (least aggressive) to 5 (most aggressive). From these, the 
Gleason histological score, ranging from 2 to 10, is generated by adding the grades of the two 
most common patterns within the tissue sections, namely the primary and secondary patterns. 
However, if only one pattern is observed in the tissue sample, or if the secondary pattern is 
represented by less than 3% of the total tumour, the primary grade is doubled to obtain the 
corresponding Gleason score (Humphrey 2004). 
 
Despite the grading system, the histomorphological appearance of prostatic carcinoma is quite 
heterogenous. Therefore, each grade from grade 3 onwards is divided into different subpatterns 
to help with the recognition of the disease grade. Complete descriptions of the different 
patterns that can be observed are listed in table 1.1. 
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Pattern Tumour Shape 
and Borders 
Stromal 
Invasion 
Tumour Cell Arrangements Gland Size 
1 Nodular with 
well-defined and 
smooth edges 
Pushing Single, separate, closely packed, 
round to oval glands 
  
Medium 
2 Less defined and 
less confined 
masses 
Some gland 
separation 
at tumour edge 
Single, loosely packed, round to 
oval glands of variable shape and 
size with stromal separation  
 
Medium 
3A Ill-defined 
infiltrating edges 
Irregular 
extension 
Single, separate glands of 
variable shape and size, with 
elongated, angular and twisted 
forms, typically with wide 
stromal separation 
Medium 
3B Ill-defined 
infiltrating edges 
Irregular 
extension 
Similar to 3A but with smaller 
glands 
Small to very 
small 
3C Masses and 
cylinders with 
smooth, rounded 
edges 
Expansile Papillary and cribriform 
epithelium with no necrosis 
Medium to 
large 
4A Raggedly 
infiltrative 
Diffusely 
permeative 
Fused glands that create masses, 
cords, or chains 
Small, 
medium, or 
large 
4B Raggedly 
infiltrative 
Diffusely 
permeative 
Same as 4A, but cells have cleared 
cytoplasm (hypernephromatoid) 
Small, 
medium, or 
large 
5A Smooth and 
rounded cylinders 
Expansile Cribriform, papillary, or solid 
masses with central 
necrosis (comedocarcinoma) 
Variable 
5B Raggedly 
infiltrative 
Diffusely 
permeative 
Masses and sheets of anaplastic 
carcinoma, with a few tiny glands 
or signet ring cells 
Small 
 
Table 1.1: Gleason grading system for prostate cancer (adapted from Humphrey 2004) 
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 TNM Staging 
 
Although the TNM classification for the staging of cancer was developed in the 1940s by Pierre 
Denoix, it was only in 1992 that the TNM staging system for prostatic carcinoma was first 
introduced, when the American Joint Committee on Cancer (AJCC) and the Union Internationale 
Contre le Cancer (UICC) approved a unified TNM staging system for this disease (Greene and 
Sobin 2002, Cheng, Montironi et al. 2012). This system is based on the evaluation of the primary 
tumour (T), the regional lymph nodes (N), and the metastatic sites (M), with each category being 
examined through a series of tests (AJCC 1997). The T category is assessed by clinical 
examination, imaging, biopsy, endoscopy and biochemical tests, the N category is assessed only 
by clinical examination and imaging, and the M category is assessed by clinical examination, 
skeletal studies and biochemical tests (UICC 2017).  
 
Each category serves a specific purpose (see table 1.2). Clinical T staging, for example, describes 
the size of the primary tumour and whether it has spread beyond the prostatic capsule. In fact, 
it is the most important prognostic indicator for localised prostate cancer. N describes the 
spread to the regional lymph nodes and is a strong predictor of progression. The last category, 
M, describes distant metastasis, which in many advanced stages involved the bone. 
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T – Primary Tumour 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
T1 Clinically inapparent tumour that is not palpable 
T1a Tumour incidental histological finding in 5% or less of tissue resected 
T1b Tumour incidental histological finding in more than 5% of tissue resected 
T1c Tumour identified by needle biopsy (e.g., because of elevated PSA) 
T2 Tumour that is palpable and confined within prostate 
T2a Tumour involves one half of one lobe or less 
T2b  Tumour involves more than one half of one lobe, but not both lobes 
T2c Tumour involves both lobes 
T3  Tumour extends through the prostatic capsule 
T3a  Extracapsular extension (unilateral or bilateral) including microscopic bladder neck 
involvement 
T3b Tumour invades seminal vesicle(s) 
T4 Tumour is fixed or invades adjacent structures other than seminal vesicles: external 
sphincter, rectum, levator muscles and/or pelvic wall 
N – Regional Lymph Nodes 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
M – Metastatic Sites 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Non-regional lymph node(s) 
M1b Bone(s) 
M1c Other site(s) 
 
Table 1.2: The 2017 TNM classification for prostate adenocarcinoma (adapted from UICC 2017) 
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1.4 Pathophysiology of Prostate Cancer 
 
During the process of malignant transformation, cells undergo multiple alterations affecting 
normal cell function, gradually evolving from a benign to a malignant phenotype (Hanahan and 
Weinberg 2011). As such, premalignant lesions may be observed and have in fact been 
commonly described in many cancers, including that of the skin, gastrointestinal tract, bronchus, 
urothelium, breast and prostate (Brawer 2005). Indeed, premalignant lesions are frequently 
diagnosed upon prostatic biopsy, depicting this disease as progressing through a series of states, 
ranging from the premalignant atypical small acinar proliferation (ASAP), prostatic 
intraepithelial neoplasia (PIN) to invasive cancer, and androgen-independence.   
 
 ASAP 
 
It is possible, in around 1.5% to 2% of prostate biopsy specimens, to find a collection of atypical 
glands (Adamczyk, Wolski et al. 2014). These are known as ASAP lesions. Classically defined as a 
“a focus of small acinar structures formed by atypical epithelial cells”, the diagnosis of ASAP is 
proposed when is not possible to find certain key changes in cell morphology that would indicate 
prostate cancer (Koca, Calışkan et al. 2011, Adamczyk, Wolski et al. 2014). Therefore, with 
insufficient data to make a benign or malignant diagnosis, the presence of ASAP raises the 
suspicion of cancer. It has been reported that the rate of prostate cancer diagnosis in the second 
biopsy following ASAP diagnosis ranges from 17-70% (O'dowd, Miller et al. 2000, Postma, Roobol 
et al. 2004). 
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 PIN and High-Grade PIN 
 
PIN, which was first referred to as “intraductal dysplasia”, represents the pre-invasive, 
neoplastic growth of epithelial cells that occurs within the lining of prostatic acini or ducts. 
Although PIN lesions had been widely observed for many years, with initial references possibly 
dating back to between the 1920s to 1940s, it was only in 1965 that John E McNeal recognised 
the possible malignant nature of these neoplastic growths (Oertel 1926, Andrews 1949, McNeal 
1965). Thereafter, together with Bostwick, they described PIN as a biological precursor of 
invasive prostate cancer, and proposed diagnostic criteria for the recognition of these lesions, 
in the form of a three-grade classification system, PIN1, PIN2 and PIN3 (McNeal, Bostwick et al. 
1986). This grading system has since then been modified, whereby low-grade PIN replaced PIN1, 
and high-grade PIN (HGPIN) replaced PIN2 and PIN3. Since there is high level of interobserver 
variability in low-grade PIN observations, pathologists do not normally report this finding. In 
fact, nowadays the term PIN is used interchangeably with HGPIN (Bostwick, Liu et al. 2004, 
Bostwick and Qian 2004). With numerous studies having confirmed HGPIN as a precursor to 
some prostate carcinomas, it has become a clinically important finding in prostate biopsies for 
the prediction of cancer. Indeed, HGPIN is reported in 5-7% of prostate biopsies, with an 
associated risk of prostate adenocarcinoma varying between 25-79%, and an estimated 
timeframe to disease progression from initial HGPIN observation of between 29 and 36 months 
(Borboroglu, Comer et al. 2000, Klink, Miocinovic et al. 2012).  
 
 Androgen Independence 
 
Androgens, and the transcriptional programs they trigger through their cognate binding of the 
androgen receptor (AR), are absolutely critical for normal prostate development, growth and 
maintenance of post-natal physiological functions. Testosterone, the main circulating androgen, 
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is primarily secreted by testicular Leydig cells and circulates in the blood bound to albumin and 
sex hormone-binding globulin (SHBG), with a small fraction remaining freely dissolved in the 
serum (Dunn, Nisula et al. 1981, Rosner, Hryb et al. 1991). This free, unbound testosterone is 
able to enter prostate cells, where it is converted by the 5α-reductase enzyme to 
dihydrotestosterone (DHT), which has a 5- to 10-fold higher affinity for AR than its testosterone 
counterpart (Pienta and Bradley 2006). During physiological signalling, DHT, along with 
testosterone, can bind to ARs in the cytoplasm, inducing the translocation of the receptor-ligand 
complex to the nucleus. Once there, the AR is able to act as a transcription factor by localising 
to specific binding sequences known as androgen responsive elements (AREs), leading to the 
expression of genes involved in cell growth and survival (Feldman and Feldman 2001). 
 
Like with other signalling pathways in the cancer process, it is not surprising that the AR axis can 
be perverted into facilitating prostate carcinogenesis. Almost all cancers begin as androgen-
dependent, whereby AR signalling is required from the growth and survival of cancer cells. 
Indeed, androgen depletion therapy (ADT), which aims to devoid androgen-sensitive cells of 
their growth and survival stimulus, remains the most common prostate cancer treatment. Yet, 
ADT is not curative for all cases of prostate cancer, as a proportion of cancer cells may develop 
a number of cellular pathways in order to survive and thrive in an androgen-depleted 
environment. Documented mechanisms by which cells may become androgen-independent 
include AR amplification and mutation and alterations in AR co-regulators which bind the AR to 
either activate or suppress the expression of target genes (Saraon, Drabovich et al. 2014).  
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1.5 Cancer Metastasis 
 
Metastasis – the spread of cells from the primary neoplasm to distant organs – is one of the 
most devastating aspects of cancer. This process comprises of a cascade of events that includes 
multiple major steps: local invasion, cell migration, intravasation and circulation, and 
extravasation of tumour cells, followed by angiogenesis and colonisation of the secondary site 
(see figure 1.4).   
 
 Local Invasion 
 
Local invasion is one of the most crucial steps in the metastatic cascade. In fact, it is during this 
stage of cancer progression that malignant cells first acquire the subversive abilities they require 
to overcome the constraints of normal cellular architecture to eventually invade secondary sites. 
To do so, neoplastic cells must develop invasive potential by undergoing an epithelial and 
mesenchymal transition (EMT). In the normal prostate, epithelial cells have very limited 
migratory abilities due to the many different junctions that anchor them to other cells and to 
the basement membrane. Therefore, when a cell undergoes a malignant transformation to gain 
a more migratory phenotype, it must downregulate its cell-cell and cell-matrix adhesiveness, 
more specifically, through the alteration of the cell adhesion molecules (CAMs) (Mol, Geldof et 
al. 2007). Indeed, one of the major features of EMT is cadherin switching, whereby, epithelial 
(E) -cadherin (typically expressed in normal epithelial cells) is downregulated, and neuronal (N) 
-cadherin (typically expressed in mesenchymal cells) is upregulated (Thiery 2002, Hazan, Qiao et 
al. 2004). This is a molecular occurrence that has been reported in various metastatic cancers. 
In prostate cancer alone, tumour specimens from patients with high grade prostate cancer were 
shown to express lower levels of E-cadherin and higher levels of N-cadherin in comparison to 
patients with lower grade disease (Gravdal, Halvorsen et al. 2007). 
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In addition to becoming more motile, cancer cells also need to invade surrounding tissue for a 
tumour to spread. However, the extracellular matrix (ECM), which is comprised of the basement 
membrane (BM) and connective tissue, presents a dense, cross-linked barrier that tumour cells 
need to negotiate and overcome. Thus, through the use of various families of enzymes, the most 
typical of which being the matrix metalloproteinase (MMP) family, the invasive cells partially 
degrade the components of the ECM (Nagle, Knox et al. 1994, Egeblad and Werb 2002). In fact, 
both the levels of MMP-9 and ratios MMP-2/MMP-9 to MMP inhibitor, tissue inhibitor of 
metalloproteinases-1 (TIMP-1), have been associated with high Gleason score and poorer 
patient survival (Wood, Fudge et al. 1997). 
 
 Cell migration 
 
In prostate cancer, as well as others, cell motility and migration are integrally linked to guanosine 
triphosphate (GTP)-binding proteins, such as Ras and Rho. Members of the Ras family, for 
example, are known oncogenes in a variety of cancers. As they normally act as switches that 
regulate the signalling for such processes as cytoskeletal integrity, cell proliferation, gene 
transcription, apoptosis, and invasion (Oxford and Theodorescu 2003, Takashima and Faller 
2013), it is of no surprise that alterations in Ras signalling can ultimately lead to cancer. In fact, 
although quite rare in prostate cancer (3%), Ras mutations are estimated to be present in 
approximately 30% of solid tumours (Adjei 2001).  
 
The Rho family of GTPases, on the other hand, are best known for their key roles in cytoskeleton 
dynamics, leading to cell movements. Due to their inherent function, Rho GTPases have thus 
been linked to tumour cell migration and metastasis (Ridley 2015). In terms of prostate cancer, 
inhibition of the Rho GTPase, RhoC, has been shown to decrease the directed migration and 
invasion of the prostate cancer cell line, PC-3 (Yao, Dashner Ej Fau - van Golen et al. , Sequeira, 
Dubyk et al. 2008). 
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 Intravasation and Survival in the Circulation 
 
Like normal tissues, growing tumours require sustenance in the form of oxygen and nutrients, 
as well as a means to evacuate waste products and carbon dioxide. As such, once they reach a 
certain size and start to experience hypoxia, they develop a neovasculature that meets their 
metabolic needs – a process called angiogenesis. Several prolific families of angiogenic factors 
have been identified as players in tumour-induced vascular growth. Amongst these, members 
of the vascular endothelial growth factor (VEGF) family and angiopoietins (Ang) are the best 
characterised, with VEGF being established as the most potent and direct-acting factor and Ang2 
expression being correlated with the poor prognosis of several cancers (Shweiki, Itin et al. 1992, 
Ferrara and Davis-Smyth 1997, Metheny-Barlow and Li 2003).  
 
In addition to providing sustenance to the tumour, the new blood vessels also offer an escape 
route by which neoplastic cells can enter the body blood system through a process called 
intravasation. Alternatively, lymphatic intravasation (entry into the lymphatic system) is another 
pathway by which tumour cells may enter the circulation through the drainage of the lymph 
vessels into the venous system via the thoracic duct. The process of intravasation, however, is a 
very inefficient system. Following their dissemination into the circulatory system, the shear 
stress of blood flow alone may be enough to destroy circulating tumour cells (CTCs). Moreover, 
other stresses, such as immunological stress and collisions with other cells, like blood cells and 
endothelial cells lining the vessel wall, could affect CTC survival (Wirtz, Konstantopoulos et al. 
2011). In fact, only a tiny fraction of CTCs survive to generate clinically relevant metastases 
(Tarin, Price et al. 1984). For example, a 1-cm primary tumour (corresponding to approximately 
1 x 109 cancer cells), can shed 1 x 106 cells into the circulatory system per day (Fidler 2005). 
However, the comparative metastatic colonisation is very limited, with only as few as 0.01% of 
CTCs ultimately surviving (Fidler 1970).  
18 
 
Thus, metastasis cannot occur unless tumour cells find ways to evade and withstand the stresses 
mentioned above. Different murine studies have demonstrated one possible approach during 
which tumour cells directly interact with platelets and leukocytes to enhance their survival. 
According to these studies, the different associations created between the platelets and the 
tumour cells form small tumour emboli, which not only shield the tumour cells from shear 
forces, but also impede immune cell recognition by Natural Killer (NK) cells, thereby contributing 
to disease progression (Nieswandt, Hafner et al. 1999, Palumbo, Talmage et al. 2005).  
 
 Extravasation and Colonisation of Distant Sites 
 
Even in the 1800s, it was apparent to physicians and researchers that the distribution of the 
secondary growths arising from cancer metastasis were more than just a matter of chance. In 
1889, in an attempt to explain this phenomenon, Sir Stephen Paget set forth the ‘seed’ and ‘soil’ 
analogy. According to his theory, like a plant that goes to seed, neoplastic cells or ‘seeds’ 
disseminate from the primary tumour and migrate in all directions; but only those that reach 
specific organ microenvironments or ‘soil’ will be able to survive and form secondary cancers 
(Paget 1889). Impressively, after more than 100 years of research on the metastatic process, 
Paget’s concept still holds true. 
 
Following intravasation, for surviving CTCs to exit the circulatory system and colonise compatible 
sites, they must first bind the endothelium of the blood vessel wall. There are two ways by which 
CTCs may do so: physical occlusion and cell adhesion - the mechanism employed depending on 
the diameter of the local blood vessel. For instance, if a CTC enters a vessel whose diameter is 
less than that of the CTC, then arrest may occur due to the CTC being physically trapped 
(Chambers, Groom et al. 2002, Wirtz, Konstantopoulos et al. 2011). Extravasation of CTCs from 
larger blood vessels, however, is more tumour specific as it requires the adhesion of cells 
through the formation of specific interactions. Various in vitro studies have shown a wide range 
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of ligands and receptors, including cadherins, integrins, CD44, selectins, and immunoglobulin 
superfamily receptors, to contribute to the adhesion between CTCs and endothelial cells 
(Bendas and Borsig 2012, Reymond, d'Água et al. 2013). 
 
Once arrested, tumour cells can roll along or proliferate within blood vessels before 
extravasating (Al-Mehdi, Tozawa et al. 2000, Stoletov, Kato et al. 2010). Alternatively, the 
arrested cells can also transmigrate directly through the endothelial barrier as single cells during 
a process called transendothelial migration (TEM), after which, they then invade the BM 
surrounding the blood vessels (Gassmann, Haier et al. 2009). When tumour cells grow within 
the primary tumour, their survival is supported by a co-evolving microenvironment that 
suppresses immunosurveillance. However, once within the secondary site, this support is not 
immediately available to the cancer cells and thus, most of them die. Otherwise, extravasated 
tumour cells may follow two different routes: dormancy (whereby the cancer cells survive 
without any apparent increases in cell numbers), or colony formation (Chambers, Groom et al. 
2002). Which paths are followed partly depends on different factors such as interactions 
between tumour cells and the various constituents of the target organ parenchyma (for 
example, ECM components and host stromal cells). Indeed, tumour cell-ECM interactions have 
been established to be key in the establishment of secondary growths. For instance, studies have 
reported cell attachments mediated by α2β1 integrins and CD44 to be critical in the adhesion of 
prostate cancer cells to collagen type I in the bone and bone marrow endothelial cells (BMECs) 
respectively (Draffin, McFarlane et al. 2004, Lee, Jin et al. 2013, Sottnik, Daignault-Newton et al. 
2013), ultimately enabling prostate cancer colonisation of the bone. Furthermore, the multitude 
of growth factors present in the ECM, such as transforming growth factor-β (TGF-β), bone 
morphogenetic proteins (BMPs) and VEGF may also contribute to the survival and/or 
proliferation of extravasated tumour cells (Shibue and Weinberg 2011).
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1.6 Prostate Cancer Metastasis 
 
In the majority of cases, prostate cancer presents itself as a relatively slow-growing tumour, 
which means that it typically takes a number of years for the tumour to become large enough 
to be detectable, and even longer for it to spread beyond the prostate. However, a small 
percentage of men experience more rapidly growing, aggressive forms of the disease. During 
the early stages of the disease, the tumour remains confined to the prostate gland. However, as 
cancer cells acquire subversive characteristics as a result of genetic or environmental influences, 
they become more aggressive and begin to penetrate surrounding tissues like the bladder, 
seminal vesicles, erectile nerves and rectum. Meanwhile, as with other solid tumours, cancer 
cells may also colonise distant sites by intravasating into lymphatic or haematogenous routes, 
creating different metastatic patterns. For example, the lymphatic route may be involved in 
metastasis to the obturator, external iliac, presacral and presciatic areas while the leading 
metastatic sites for the haematogenous route is the lung, liver and most importantly, the bone 
(Golimbu, Morales et al. 1979, Bubendorf, Schöpfer et al. 2000). 
 
As mentioned earlier, it has long been recognised that cancers spread to distant sites with 
characteristic preference. The bone is the second most frequent site to be affected, with breast 
cancer and prostate cancer causing up to 70% of skeletal metastases (Cecchini, Wetterwald et 
al. 2005). Bone metastases are infrequently clinically silent, the most common symptom being 
severe pain. Other symptoms include pathological fractures due to the weakening of bones, 
hypercalcaemia and spinal compression, the latter of which may lead to numbness or weakness 
in the legs. Furthermore, since bone metastasis may involve the replacement of haematopoietic 
tissues by invading cancer cells, it can also lead to anaemia, therefore increasing the risk of 
infection. Ultimately, owing to their impact on haematopoiesis and bone structure, bone 
metastases are a major cause of morbidity (Cecchini, Wetterwald et al. 2005, Logothetis and Lin 
2005). Unfortunately, once patients show evidence of secondary bone metastases, the cancer 
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is deemed incurable, the only treatment options available at present focus on symptom 
management and slowing down the progression of the established cancer.  
 
 The Bone  
 
To fully appreciate the bone-prostate cancer microenvironment, an understanding of the basic 
structure and function of the bone is useful. The skeleton is composed of two main structural 
types of bone: the cortical bone and the trabecular (or cancellous) bone. The cortical bone, 
which makes up 80% of the skeleton, is the dense outer layer that surrounds the marrow, while 
the trabecular bone, which makes up the remaining 20% of the skeleton, is composed of a 
honeycomb-like network of trabecular plates and rods interspersed in the bone marrow-
containing compartments of bones (Clarke 2008, Theriault 2012). Bones are highly dynamic 
tissues that experience constant turnover in order to maintain bone strength and mineral 
homeostasis. This is achieved through the balanced contributions of specialised bone cells, 
osteoclasts and osteoblasts, that mutually carry out the resorption of old bone and formation 
of new bone respectively (Clarke 2008). Osteoclast and osteoblast activities are tightly coupled 
(Howard, Bottemiller et al. 1981). Indeed, bone remodelling events require communication 
between these two types of cells, which may occur in a number of ways: cell-cell contact, gap 
junctions, or diffusible paracrine factors. 
  
The bone remodelling cycle takes place in four sequential phases in response to stimuli like low 
blood calcium levels, loss of mechanical loading, or alterations in cytokines and hormones. These 
phases are activation, resorption, reversal, formation and termination (Rucci 2008). During the 
activation phase, changes in the bone environment are detected by osteocytes, which through 
their death, release regulatory factors that recruit precursors of the haematopoietic lineage 
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which fuse and differentiate into osteoclasts (Al-Dujaili, Lau et al. 2011). Once the osteoclasts 
are differentiated and activated, they are then able to proceed through to the next phase, 
resorption. During this phase, osteoclasts secrete enzymes like matrix metalloproteinase 
(MMP)-9, tartrate-resistant acid phosphatase, cathepsin K, and gelatinase, to digest the organic 
matrix. This liberates growth factors, including transforming growth factor-β (TGF-β), insulin-like 
growth factor (IGFs), platelet-derived growth factors (PDGFs) and bone morphogenetic proteins 
(BMPs), and other molecules that are abundant in the bone (Mundy 2002). Termination of this 
phase occurs with the programmed cell death of osteoclasts, thus ensuring the non-occurrence 
of excess resorption (Xing and Boyce 2005).  
 
The next phase, reversal, marks the transition from bone resorption to bone formation. 
Although this phase is still not completely understood, two events are thought to be key. These 
are the preparation of the freshly resorbed bone surface for the deposition of new bone matrix 
carried out by cells of an osteoblastic lineage, and the coupling of mechanisms of bone 
resorption and bone formation. Indeed, with studies showing the balanced loss and accretion of 
calcium in bone remodelling, this is thought to be a critical period for the osteoclast-osteoblast 
coupling (Matsuo and Irie 2008). The exact coupling signals linking the two ends of the bone 
remodelling spectrum are not yet completely elucidated, though it is known to include 
recruitment and differentiation of osteoprogenitors of the mesenchymal lineage. Candidate 
factors that may be involved in this process include those released from the bone matrix during 
bone resorption (Clarke 2008, Kenkre and Bassett 2018).  
 
Once recruited and differentiation, mature osteoblasts lead the remodelling process through to 
the next phase, formation. As part of this, successive layers of osteoblasts line the eroded bone 
surface and secrete an organic, type I collagen-rich matrix material termed osteoid. The latter is 
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mineralised over time, entrapping osteoblasts within the matrix, where they terminally 
differentiate into osteocytes (Kenkre and Bassett 2018).  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Activation 
Resorption 
Reversal 
Formation 
Figure 1.3: The four phases of bone remodelling. During the activation phase, apoptosis of 
osteocytes releases regulatory factors that help differentiate osteoclast precursors into mature 
osteoclasts. Once differentiated and activated, the osteoclasts are then able to proceed to the 
resorption phase, during which osteoclasts digest the organic matrix, releasing growth factors 
from the bone. The following phase, the reversal phase, marks the transition from bone 
resorption to bone formation. This is made possible through the recruitment and differentiation 
of osteoblast precursors into mature osteoblasts, a process that is triggered by the growth 
factors released during the resorption phase. The final phase of the bone remodelling process is 
the formation phase and involves osteoblasts lining the eroded bone surface to secrete osteoid, 
which mineralises over time to form new bone (adapted from Owen and Reilly 2018). 
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 Pathophysiology of Bone Metastasis 
 
Like with metastasis to other sites, the initial steps in the development of bone metastasis 
include local invasion of surrounding tissue, intravasation and survival in the circulation and the 
migration to distant organ sites (see section 1.5 and figure 1.4). However, as a cancer with such 
high incidences of bone metastasis, advanced prostate cancer metastasis poses an intriguing 
puzzle: why and how these cancer cells show predilection to the bone rather than other sites. 
The first attempt in explaining the preferential metastasis of different cancer types came, at the 
turn of the 20th century, from English surgeon, Dr Stephen Paget, when he proposed the ‘seed 
and soil’ theory. This concept explains that while cancer cells, much like seeds, disperse in all 
directions from their primary site, they will only be able to establish where the 
microenvironment, or soil, is favourable for their survival and growth (Paget 1889).  
 
It is apparent that the anatomical and molecular characteristics the bone possesses make it a 
favourable target for metastasis (Mastro, Gay et al. 2003). One anatomical characteristic that 
exemplifies the ‘seed and soil’ theory is the sluggish blood flow in the sinusoids of the 
metaphysis that enables initial cancer cell adhesion to the bone marrow endothelium (Phadke, 
Mercer et al. 2006). With its state of continuous and dynamic turnover, the bone matrix also 
provides a rich selection of resources, in the form of cells, growth factors, receptors and 
proteins, that prostate cancer cells can exploit for homing to and colonisation purposes. For 
instance, the specific homing of CTCs is mediated by the chemokine axis normally employed by 
haematopoietic stem cells (HSCs) to the bone marrow. By expressing the C-X-C motif receptor 
(CXCR)-4 and 7, metastatic cancer cells are able to respond to chemotactic gradients of C-X-C 
motif chemokine-12 (CXCL12), also known as stromal cell-derived factor-1 (SDF1), allowing them 
to mimic the vascular exit strategy of haematopoietic progenitors upon their return to the bone 
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marrow from the circulation (Taichman, Cooper et al. 2002, Chinni, Sivalogan et al. 2006, Wang, 
Shiozawa et al. 2008). 
 
Cross-talk between DTCs and the bone microenvironment is also critical for the establishment 
secondary colonies. Faced with the highly dense and protective bone matrix, cancer cells need 
employ a process called the “vicious cycle” to modify their surroundings for survival. As a result 
of this process, the delicate balance between the resorbing actions of the osteoclasts and the 
osteogenic functions of the osteoblasts is disrupted, causing a skew towards either extreme of 
the bone remodelling process. This ultimately results in the formation of osteolytic (bone 
resorbing) or osteoblastic (bone forming) bone lesions. Various growth factors have been shown 
to be involved in this process. For instance, during the osteoclastic vicious cycle, tumour cells 
produce osteoclast-activating factors, the most important of which being the parathyroid-
hormone-related peptide (PTHrP), to activate bone resorption (Mundy 2002). With the bone 
matrix acting as a storehouse for latent growth factors, like members of the TGF-β, IGF, PDGF 
and BMP families, the bone resorption process subsequently causes their release. These are 
then able to stimulate tumour cell proliferation, further increasing PTHrP levels, thus setting in 
motion the vicious cycle (Mundy 2002). 
 
Although the term “vicious cycle” is classically used to describe osteolytic lesion formation, a 
vicious cycle is also known to occur during the development of osteoblastic lesions, whereby 
prostate cancer cells produce various pro-osteoblastic factors, such as fibroblast growth factors 
(FGFs), TGF-β1 and TGF-β2, IGF-1 and IGF-2, PDGFs, WNT and BMPs, to induce the recruitment 
and differentiation of osteoblasts. As a result, the activated osteoblasts mediate the formation 
of woven bone, all the while secreting growth factors that tumour cells are able to use to 
potentiate their survival and growth. The growing number of cancerous cells then produce more 
pro-osteoblastic factors and thus, an osteoblastic vicious cycle is perpetuated. With prostate 
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cancer producing osteoblastic lesions in more than 95% of cases, this study is more interested 
in investigating the molecular mechanisms behind the formation of these types of lesions. More, 
particularly, the role of the pro-osteoblastic factor, BMP, in this process. 
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Figure 1.4: The steps involved in cancer cell metastasis to the bone. The primary neoplasm invades its immediate surroundings and promotes the formation of new 
blood vessels. This provides invading cells with an escape route which they can use to enter the circulation. Tumour cells and blood cells may eventually aggregate to 
form embolisms that arrest in distant capillaries in the bone. Tumour cells eventually adhere to vascular endothelial to extravasate into the bone matrix. In this new 
environment, they then trigger the “vicious cycle” to support their survival and growth, eventually forming bone metastases (adapted from Mundy 2002). 
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1.7 BMPs 
 
The BMP subfamily of the transforming growth factor-β (TGF-β) superfamily was first identified 
in 1965, by Urist (Ducy and Karsenty 2000), who discovered their ability to induce ectopic bone 
growth. It was not until the late 1980s, however, when the first BMPs were characterized and 
cloned, that individual BMPs could be studied biochemically (Wozney, Rosen et al. 1988). Since 
then, they have been shown to be important morphogens in embryogenesis and development, 
as well as the regulation of the maintenance of adult tissue homeostasis, by affecting a wide 
variety of cell types and processes beyond bone and osteogenesis. Indeed, BMP signalling is 
known to have a crucial role in heart, neural, renal, cartilage and lung development, including 
airway branching, as well as the maintenance of joint integrity, the initiation of fracture repair, 
and vascular remodelling by orchestrating cellular processes like cell growth, migration, invasion 
and adhesion. It is therefore no surprise that anomalies during BMP signalling have been 
implicated in several human diseases, including development disorders and cancers. In fact, for 
the last 20 years, BMPs have increasingly been studied in several malignancies, with aberrant 
expression patterns being reported in various cancers and bone metastases. 
 
 Biochemical properties of BMP proteins 
 
The BMP subfamily comprises over 20 members. Although they exhibit significant sequence 
homology, BMPs can be categorised into subgroups, based on their known functions and 
structural homology. For example, based on phylogenic similarity, BMP-2 and -4 form the 
BMP2/4 subgroup, BMP-5, -6, -7 and -8 form the OP-1 subgroup, BMP-9 and -10 form the 
BMP9/10 subgroup, and BMP-12, -13, -14 (Growth Differentiation Factor; GDF-5, -6 and -7) form 
the GDF-5 subgroup (Miyazono, Maeda et al. 2005, Wang, Green et al. 2014). 
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 Structure of BMPs 
 
Like other members of the TGF-β superfamily, BMPs are translated as large precursor proteins 
consisting of three components. The N-terminal signal peptide sequence, which is composed of 
20 amino acids (aa), directs the protein to the secretory pathway. The next region, the pro-
domain, whose role has not yet been completely elucidated, varies in length, but normally 
ranges from 240 to 320 aa. The final region, the C-terminal mature peptide, embodies the 
functional unit of the BMP protein (Kingsley 1994, Sebald, Nickel et al. 2004). 
 
 
 
 
 
 
 
 
 
 
BMP precursor proteins are formed in the cytoplasm as dimeric pro-protein complexes of about 
400 to 500 aa. For the BMP protein to become functionally active however, this precursor needs 
to be cleaved at the consensus site, Arg-X-X-Arg, present in pro-domain. Cleavage of the 
proprotein is catalysed by serine endopeptidases with the Trans-Golgi network releasing the C-
terminal from the N-terminal – a process that has been shown to be determined by the 
Signal 
sequence 
Pro-domain C-terminal 
Consensus site 
Mature BMP 
Figure 1.5: Schematic of BMP activation. The diagram depicts a simplified 
view of BMP activation from their large precursor form. The inactive BMP 
pro-protein consists of three components: the N-terminal signal sequence, 
the pro-domain and the C-terminal. For the BMP to be functionally active, 
the precursor needs to be cleaved at the consensus site Arg-X-X-Arg within 
the pro-domain – a process catalysed by serine endopeptidases. 
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downstream amino acid sequence adjacent to the cleavage site (Sieber, Kopf et al. 2009). In TGF-
β1, 2 and 3, and myostatin (GDF-8), the pro-domain remains non-covalently attached to the 
mature peptide, acting as a ‘straitjacket’ covering all receptor epitopes, hence keeping them in 
a latent state. In terms of BMPs, although the prodomain has also been reported to remain 
tethered to the mature forms of BMPs 4, 7, 9, 10, 11 and 12, there is no similar report of the 
latency effect. In fact, certain studies have observed a role for the proper folding and secretion 
of certain BMPs (Brown, Zhao et al. 2005, Sopory, Nelsen et al. 2006, Sengle, Ono et al. 2008). 
 
Following activation, the resultant, active, BMP dimer ranges from 50 to 100 aa, with seven 
highly conserved cysteines in each monomer. Of these seven cysteines, six are stabilised by 
three intramolecular disulphide bonds, with two pairs forming a ring and the third penetrating 
the ring, completing a 3-dimensional (3D) structure known as the cysteine knot motif. The 
seventh cysteine forms the disulphide bond between the BMP monomers, thus forming the 
biologically active BMP dimer (Butler and Dodd 2003). Bar BMP-3, GDF-9 and BMP-15, which 
lack a seventh cysteine but are nonetheless biologically active as monomers, all BMPs are 
biologically active as either homo- or hetero-dimers once processed and activated. For example, 
heterodimerisation of BMP-2/5, BMP-2/6, BMP-2/7, BMP-4/7 and BMP-7/GDF-7 have been 
observed in vitro and in vivo, with certain studies reporting an increase in functional efficiency 
in these forms in comparison to their respective homodimeric forms. 
 
Several BMPs, including BMP-2 (Scheufler, Sebald et al. 1999, Kirsch, Sebald et al. 2000), BMP-7 
(Griffith, Keck et al. 1996, Greenwald, Groppe et al. 2003), BMP-9 (Brown, Zhao et al. 2005) and 
GDF-5 (Scheufler, Sebald et al. 1999), have been previously crystallised, enabling the elucidation 
of their structure. The characteristic scaffold of the BMP monomer has been described to be 
reminiscent of a left hand, with a wrist, thumb and two outstretched fingers (Sebald, Nickel et 
al. 2004). The structure of the “wrist”, also known as the “core” of the protein, is primarily 
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determined by the seven conserved cysteines. The “thumb” is formed by an α-helix, whilst the 
“fingers” are formed by two parallel β-sheets. The fingers, denominated as finger 1 and finger 
2, extending in opposite directions within the dimer, with side-chains clustering together at the 
back, forming the “knuckle” epitope (Slobodan and Sampath 2002). Interestingly, it is the fingers 
and the α-helix of the thumb that convey much of the structural variation between BMP family 
members. The wrists of the ligands are highly structural similar despite their overall sequences 
being only about 30-40% identical (Brown, Zhao et al. 2005).  
 
1.8 BMP Receptors 
 
Members of the BMP subfamily transduce their signal by interacting with two diverse 
subfamilies of serine/threonine kinase receptors, termed Type-I and Type-II. Both BMP receptor 
(BMPR) types are structurally similar, encompassing a cysteine-rich short extracellular domain, 
a single-spanning transmembrane domain and a highly conserved intracellular serine/threonine 
kinase domain at their carboxyl-terminal. Although differences exist in the extracellular domains 
of the two receptor subtypes, it is actually the presence of two additional motifs within the type-
I receptor that is used for classification (Mueller and Nickel 2012). The first is a 20 aa 
juxtamembrane glycine-serine rich regulatory domain (TTSGSGSG motif), known as the GS box, 
which precedes the kinase domain and is required for phosphorylation (Shi and Massagué 2003, 
de Caestecker 2004). The second, a short region of 8 aa, is termed the L-45 loop and is found 
within the type-I receptor kinase (Sieber, Kopf et al. 2009). 
 
For BMP signalling to take place, dimers of both receptor types are required - the wrist epitopes 
of BMPs is a high affinity binding site for type-I receptors, whilst the knuckle epitope is a low 
affinity binding site for type-II receptors (Hinck 2012). Mechanistically speaking, as type-I and 
type-II receptors are single-spanning transmembrane receptors, it is their assembly with their 
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cognate BMP dimers that induces downstream signalling, as demonstrated by various studies.  
This is further supported by the fact that type-II receptors are constitutively active. Therefore, 
bridging both receptor types with ligands would enable the transphosphorylation of the GS box 
within the type-I receptors by the type-II receptors (Sieber, Kopf et al. 2009).  
 
Overall, for the human TGF-β superfamily of ligands, there are a total of seven type I receptors 
(Activin Like Kinase Receptors, ALK1-7), three of which are known to interact with BMPs: type-
IA BMP receptor (BMPR-IA or ALK3), type-IB BMP receptor (BMPR-IB or ALK6), and type-IA 
activin receptor (ActR-IA or ALK2). Of the five known TGF-β family type-II receptors, three bind 
BMPs: type-II BMP receptor (BMPR-II), type-IIA activin receptor (ActR-IIA), and type-IIB activin 
receptor (ActR-IIB) (Mueller and Nickel 2012). It is rather surprising therefore, that the number 
of available receptors has remained so low throughout evolution, despite such a high number 
of TGF-β ligands. With several studies aiming to elucidate this mystery, in vitro binding analyses 
have demonstrated that not only are most TGF-β receptors shared between ligands, but one 
TGF-β may also bind to several TGF-β receptors. For example, while BMPR-IA, BMPR-IB, and 
BMPR-II are specific to BMPs, ActR-IA, ActR-IIA, and ActR-IIB can function as receptors for 
activins, which are also members of the TGF-β superfamily. Moreover, the three type-II BMPRs 
are able to interact similarly with any member of the BMP-2/4, BMP-5/6/7/8 and GDF-5/6/7 
subgroups. This phenomenon has been coined “ligand-receptor promiscuity” and has been 
shown to be particularly present in the BMP subfamily (Mueller and Nickel 2012). However, 
different type-I and type-II receptor homo- or heterodimer combinations should allow for 
selectivity and specificity of ligand binding and the consequent intracellular signalling triggered. 
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1.9 BMP signalling  
 
The classical paradigm of ligand-receptor interaction depicts a ligand-induced receptor-
oligomerisation. Although that is still the case during BMP signalling, it is also possible for ligands 
to bind to preformed oligomeric complexes, the existence of which adds an additional layer of 
intricacy. Indeed, if the BMP dimer binds to preformed receptor complexes, the Smad-
dependent pathway is triggered. In contrast, if the receptor complex is formed as a result of 
ligand binding, the Smad-independent, p38 mitogen-activated protein kinase pathway (MAPK) 
is activated (Nohe, Hassel et al. 2002, Nohe, Keating et al. 2004). Figure 1.7 depicts both 
signalling pathways. 
Finger 1 
Finger 2 
A. 
Knuckle 
Wrist 
B. 
Figure 1.6:  The structure of BMP-2 and BMPR-IA extracellular 
interaction. The two monomers (blue and yellow) of BMP-2 
homodimer interact with the ectodomains of BMPR-IA (green). 
A. demonstrates the side view of the interaction with annotation 
of the α-helix thumb and the two outstretched fingers (1 and 2) 
formed by parallel β-sheets. B. demonstrates the top view of the 
BMP-2/BMPR-IA interaction. Shown in red are the wrist and 
knuckle epitopes (adapted from Kirsch, Sebald et al. 2000). 
Thumb 
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 The Smad-dependent pathway 
 
The canonical Smad-dependent pathway is the best-studied BMP signalling pathway. Activated 
by ligands through their interaction with pre-formed hetero-oligomeric complexes (PFC) of type-
I and type-II receptor dimers, this pathway requires the participation of transcription factors 
Smads for the propagation of the intracellular signal.  
 
Smads are a group of related proteins ranging from about 400 to 500 aa that are critical for the 
downstream intracellular transmission of type-I TGF-β and BMP receptor signalling from the cell 
surface to the nucleus (Attisano and Lee-Hoeflich 2001). The prototypic members of the Smad 
family were first identified as products of the Mothers against decapentaplegic (Mad) and Sma 
genes, respectively found in Drosophila and C. Elegans (Sekelsky, Newfeld et al. 1995, 
Kretzschmar and Massagué 1998, Massague 1998). Shortly thereafter, many orthologs were 
discovered in worms and verterbrates and were named “Smad”, as a contraction of the gene 
names of the founder members (Attisano and Lee-Hoeflich 2001, Derynck and Zhang 2003).  
 
The human genome encodes eight Smad family members, which can be grouped into three 
subfamilies based on their structure and function. The first group, the receptor-regulated Smads 
(R-Smads), includes Smad1, 2, 3, 4, 5 and 8/9, of which Smad1, 5, 8/9 are BMP-specific. The R-
Smad group constitutes the only direct substrates of the TGF-β superfamily receptors. The 
second group of Smad proteins, the common Smad (Co-Smads), comprises solely of Smad4, and 
the third group, termed the inhibitory Smads (I-Smads), comprises Smad6 and Smad7. Typically, 
Smads consist of an N-terminal Mad homology 1 (MH1), involved in DNA binding (Kim, Johnson 
et al. 1997), a divergent proline-rich linker segment (L) of variable length, and a C-terminal Mad 
homology 2 (MH2), involved in Smad oligomerisation, cofactor binding, and receptor interaction 
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(Attisano and Lee-Hoeflich 2001). The R-Smads and the Co-Smad particularly have a highly 
conserved MH1. Conversely, the I-Smads have a MH2 domain, but no distinct MH1 domain, 
which is instead replaced by differing amino-acid termini that contain regions of similarity 
between members of the I-Smad subgroup (Attisano and Lee-Hoeflich 2001).  
 
Each subgroup of Smad proteins plays a distinct role during Smad-dependent TGF-β and BMP 
signalling. For the signals to be relayed intracellularly from the cell surface, the 
transphosphorylated type-I receptor first releases a 12 kDa FK506-binding protein (FKBP12), 
which normally acts as a silencer of kinase activity by binding the unphosphorylated GS regions 
of the receptor (Okadome, Oeda et al. 1996). Once freed of FKBP12, the GS box is able to recruit 
and subsequently activate R-Smads (Huse, Muir et al. 2001). Specific R-Smad/receptor 
interactions are mediated via the aforementioned L45 loop within the type-I receptor and the 
L3 loop and adjacent α-helix1 in the MH2 domain of the R-Smad (Chacko, Qin et al. 2001). As 
such, the different receptors are able to discriminate between the different R-Smads, with TGF-
β receptors targeting Smad2 and Smad3 specifically, and BMPRs preferentially binding to 
Smad1, 5 or 8/9. When bound to the type-I receptor, the specific R-Smad is directly 
phosphorylated on the last two serines of a conserved SSXS motif located at the extreme 
carboxyl terminus of its MH2 domain (Souchelnytskyi, Tamaki et al. 1997), creating an acidic 
knob that binds to the MH2 domain of Smad4 or to homologous MH2 domains of other R-Smads 
(Massagué, 2012). Thus, when the R-Smad dissociates from the type I receptor following 
phosphorylation at its C-terminal, it is able to form an oligomeric complex with another R-Smad 
and the Co-Smad, Smad4. This oligomeric complex, with the help of nuclear import and export 
factors, then transits into the nucleus where it binds to other DNA-binding transcription factors 
to facilitate target gene recognition and consequently, the regulation of the transcription of the 
target gene.  
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 The Smad-independent pathway 
 
The alternative, non-canonical, signalling pathway that BMPs can also trigger is Smad-
independent. During this pathway, BMPs usually first bind to type-I receptors due to their higher 
affinity for these receptors, and then recruit type-II receptors to form the hetero-oligomeric 
complex known as BISC (BMP-induced signalling complexes). Once the type-I receptor is 
phosphorylated by the constitutively active type-II receptor, subsequent signalling typically 
proceeds through one or more Mitogen-activated protein kinase (MAPK) signalling pathways to 
indirectly bring about changes in target gene transcription. For instance, it thought that pathway 
activation is achieved through the specific interaction of BMPR-IA with BRAM1 (Bone 
Morphogenetic Protein Receptor Associated Molecule 1) or XIAP (X-linked Inhibitor of Apoptosis 
Protein), which mediate the interaction of the receptor with downstream signalling molecules 
TAK1 (TGF-β Activated Kinase 1) and TAB1 (TAK1 binding protein). Both adaptor proteins, 
BRAM1 and XIAP, interact with BMPRIA via its cytoplasmic domain, enabling the recruitment of 
TAB1, which crucial for the activation of TAK1. Thereafter, the activated TAK1 can in turn activate 
the MAPK pathways, such as extracellular signal-regulated kinase (ERK), map kinase p38 and C-
jun N-terminal kinase (JNK). The Smad-independent is not as well studied as the Smad-
dependent pathway. For example, it is unclear whether there is a causational difference 
between BRAM1 or XIAP recruiting the TAB1-TAK1 complex to BMPR1A. It is also unclear if the 
adaptor proteins interact with other type I receptors, although XIAP has been reported to 
interact with ActRII. BMP signal transduction can be complex in vivo and although the mode of 
initiation remains unknown, BMPs have also been reported to trigger and cross-talk with other 
pathways, for example, phosphoinositide 3-kinase (PI3 kinase), Protein Kinase (PKA), Protein 
Kinase (PKC) (Haÿ, Lemonnier et al. 2001), Wnt and NOTCH signalling pathways (Walsh, Godson 
et al. 2010). 
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Figure 1.7: The Smad-dependent and the Smad-independent signalling pathways. The canonical Smad-dependent pathway is triggered when BMP homo- or hetero-dimers bind to 
a PFC of type-I and type-II BMPR homodimers. As part of this pathway, the ligation of the BMP ligand to the receptor complex causes the phosphorylation of the GS boxes within the 
type-I receptors. Phosphorylated GS boxes then recruit and phosphorylate R-Smads 1, 5 or 8/9, which in turn form oligomeric complexes with the Co-Smad, Smad 4. The resulting 
complexes subsequently transit into the nucleus where they bind to transcription factors (TFs), facilitating target recognition and thus, the regulation of the of target gene 
transcription. The non-canonical BMP signalling pathway, on the other hand, involves the recruitment of type-II BMPR dimers following the ligation of BMP ligands to type-I receptors. 
This forms a receptor complex known as BISC. Transduction of this pathway is thought to occur through the interaction of the type-I receptors with XIAP, which mediates the 
interaction of these receptors with downstream signalling molecules TAB1/2/3 and TAK1. Highlighted in red are different regulators of BMP signalling. Among the intracellular 
regulators, I-Smads, Smad6 and 7, compete with R-Smads for the binding of type-I receptors, inhibiting their R-Smad phosphorylation. Meanwhile, Smurf-1 specifically targets Smad1 
and 5 for ubiquitination, and phosphatases PP-1 and -2A, dephosphorylate activated BMPRs and their associated R-Smads. Extracellular regulators of BMP action include the 
pseudoreceptor BAMBI, which inhibits BMP signalling by obstructing the formation of functional receptor complexes, and BMP antagonists which attach to and sequester BMP 
ligands, preventing them from binding to cognate BMPRs. 
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1.10 Regulation of BMP Signalling  
 
Due to their vast roles in embryogenesis, post-natal developmental programs, and homeostasis, 
BMPs have evolved with numerous multi-level regulatory mechanisms in order to fine-tune 
signalling outcome (see figure 1.7). Regulation starts in the nucleus where BMP RNA transcript 
levels may be suppressed via promoter methylation/hypermethylation (Walsh, Godson et al. 
2010). These transcripts may then face further silencing in the cytoplasm by action of miRNAs, 
such as miR-22, which has been shown to regulate BMP-6 and 7 in the kidney (Long, Badal et al. 
2013). Intracellular modulation of BMP signalling also occurs through blockade of the different 
mediators of BMP signalling. For instance, I-Smads, Smad6 and Smad7, compete with R-Smads 
to bind BMPRs, thereby inhibiting R-Smad phosphorylation by the receptor (Imamura, Takase et 
al. 1997, Souchelnytskyi, Nakayama et al. 1998). Smad signalling is also targeted by Smad 
ubiquitination regulatory factor-1 (Smurf1), which specifically targets Smad1 and 5 for 
ubiquitination, and by protein phosphatases (PP)-1 and 2A, which dephosphorylate activated 
BMPRs and their associated R-Smads (Zhu, Kavsak et al. 1999, Wrighton, Lin et al. 2009).  
 
On top of these regulatory mechanisms, BMP signalling is also modulated extracellularly. The 
pseudoreceptor BMP and activin membrane-bound inhibitor (BAMBI) participates in this 
process by preventing the formation of functional receptor complexes (Onichtchouk, Chen et al. 
1999). Furthermore, the BMP signalling pathway is regulated by a key family of structurally 
diverse, extracellularly secreted antagonists known as BMP antagonists. The latter attach to and 
sequester BMP ligands, thus preventing them from binding their cognate receptors by blocking 
their binding sites.  
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1.11 BMP Signalling in the Bone  
 
Among the 20 BMPs that have been identified and characterised, BMP-2, 4, 5, 6, 7 and 9 have 
all exhibited to have strong osteogenic capacity (Luu, Song et al. 2007, Abula, Muneta et al. 
2015). In fact, BMPs are important not only for skeletal development but also for the 
regeneration and homeostasis of the bone matrix, with numerous studies demonstrating the 
impairment of skeletal development upon deletion of these growth factors as well as that of the 
different components of their signalling pathway.  
 
One of the ways BMPs exert their influence on bone and cartilage formation is by stimulating 
the differentiation of osteoblasts (Itoh, Udagawa et al. 2001, Nishimura, Hata et al. 2008). Many 
factors are known to be involved in this process, however amongst these, BMPs are uniquely 
potent. This is because they are able to influence the different stages of differentiation, from 
the development of pre-osteoblasts to the maturation into osteoblasts (Gazzerro and Canalis 
2006). Osteoblasts, like other cells that make up connective tissue (chondrocytes, fibroblasts, 
myoblasts and adipocytes), are derived from cells of a mesenchymal lineage, known as 
mesenchymal stem cells (MSCs), with the fate of these pluripotent cells being decided by 
selective expression of so-called “master transcription regulators” (Grigoriadis, Heersche et al. 
1988, Pittenger, Mackay et al. 1999, Jensen, Gopalakrishnan et al. 2010). For the differentiation 
of osteoblasts, this means the expression of transcription factor runt-related transcription factor 
2 (Runx2), also known as core-binding factor subunit alpha-1 (Cbfa-1), a process which is in fact 
driven by the BMP Smad-dependent and Smad-independent pathways (Wu, Chen et al. 2016). 
This is not achieved directly, but through the BMP-mediated expression of the transcription 
factor distal-less homeobox-5 (Dlx5), which in turn induces Runx2 expression (Heo, Lee et al. 
2017). 
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Although indirectly, BMPs may also influence the differentiation of osteoclasts from HSCs. This 
is due to one of key haematopoietic factors in this process, receptor activator of nuclear factor-
κB ligand (RANKL), and its inhibitor osteoprotegerin (OPG) being produced by osteoblasts (Itoh, 
Udagawa et al. 2001, Boyle, Simonet et al. 2003).  
 
1.12 Aberrance of BMPs and their Implications in Prostate Cancer 
 
Due to the importance and complexity of BMP function in normal physiology, mis-regulation of 
the various components of their pathway may bring about serious pathophysiological 
consequences. These may include congenital, bone and cardiovascular diseases, as well as 
different types of cancer (Bokobza, Ye et al. 2009, Wang, Green et al. 2014). In terms of cancer, 
the expression BMPs remains controversial due to studies reporting pro-oncogenic or anti-
oncogenic roles for specific BMPs. However, there is increasing evidence for the potential of 
BMPs and their signalling components as novel biomarkers with substantial therapeutic 
implications for cancer treatment (Bach, Park et al. 2018). Among the various cancers in which 
BMPs have been implicated, prostate and breast have particularly been represented in cancer 
studies due to their unique characteristic of metastasis to the bone. In fact, what with the BMPs’ 
innate osteogenic capacities, they have been heavily implied to have a role in the induction of 
new bone as frequently seen in the lesions formed during prostate cancer. In order to gain 
insight into the relationship between prostate cancer cells and the bone microenvironment, 
numerous studies have examined the expression of BMPs in prostate carcinoma and prostate 
cancer bone metastases.  
 
The first study of this sort was undertaken in the early 90s by Bentley and colleagues, who 
demonstrated the presence of BMPs 1-6 in prostatic adenocarcinoma and reported BMP-6 to 
be selectively expressed in bone-scan positive metastatic disease (Bentley, Hamdy et al. 1992). 
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Thereafter, Bobinac and colleagues, with the aim to investigate the role of BMPs in the different 
stages of prostate cancer, demonstrated the expression of BMP-2, -4, -5, -6 and -7 in normal 
prostate tissue, and the predominant expression of BMP-2 and -4 in prostate carcinoma 
samples, along with significantly decreased levels of BMP-7 (Bobinac, Marić et al. 2005). Another 
study, by Spanjol et al (2010), reported mostly similar findings by also showing an increased 
expression of BMP-6 and decreased levels of BMP-7 in localised prostate cancers, and high levels 
of BMP-2, -4, -6 and -7 in bone metastases. However, slightly conflicting with the data by Bentley 
et al, Spanjol and colleagues showed decreased expression levels of BMP-2/4, -6 and -7 in 
metastatic prostate cancer samples. Despite the varying expression patterns highlighted, the 
overall evidence suggests BMP-2, -4, -6, and -7 to be potential players in the pathophysiology 
behind skeletal metastases produced by prostate cancer.  
 
This is further supported by findings from other studies. For instance, on top of confirming BMP-
2 expression data by Spanjol et al, Horvath et al and Tae et al also reported a negative correlation 
between BMP-2 expression and Gleason score, describing a decrease in relapse-free survival 
resulting from a decrease in BMP-2 expression as well. Both studies subsequently concluded 
that this BMP may serve as a marker of poor prognosis (Horvath, Henshall et al. 2004, Tae, Cho 
et al. 2018). Furthermore, in vitro experimentation have demonstrated that BMP-2 not only 
contributes to the migration of prostate cancer cells but also, along with BMP-7, may have a role 
for angiogenesis and protection against apoptosis through the upregulation of SDF1/CXCL12 in 
cancer-associated fibroblasts (Lai, Fong et al. 2008, Yang, Pham et al. 2008). As for BMP-4, while 
most studies investigating the role of this BMP in bone metastasis have been focussed on breast 
cancer, Lee et al demonstrated a potential role in progression of prostate cancer and its related 
osteogenesis (Lee, Cheng et al. 2011). On the other hand, BMP-6 has been heavily implicated in 
prostate cancer, most particularly with the more aggressive form of the disease. Indeed, 
expression studies concentrated on this BMP have confirmed findings by Bentley et al, 
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describing its expression to be closely associated with high Gleason scores and established 
secondary skeletal metastases, with studies by Autzen et al, Yuen et al, and Lee et al going as a 
far as to postulate BMP-6 as a potential predictor of prostate cancer metastasis  (Hamdy, Autzen 
et al. 1997, Autzen, Robson et al. 1998, Darby, Cross et al. 2008, Yuen, Chan et al. 2008, Lee, 
Kang et al. 2014). In vitro results supported these findings by demonstrating BMP-6 to promote 
the migration and invasion of prostate cancer cells, even stimulating the proliferation of these 
cells in androgen-deprived conditions (Dai, Keller et al. 2005, Darby, Cross et al. 2008, Lee, Kang 
et al. 2014).  
 
Although the present study will be investigating all the BMPs discussed above, BMP-7 is of 
particular interest to us. As a BMP that is normally highly expressed in normal prostate tissue, 
Thomas et al (1998) demonstrated that this expression is dependent upon the presence of 
testosterone and DHT. However, numerous studies have demonstrated that this expression 
decreases drastically in early prostate adenocarcinoma, then rises to higher than normal levels 
in metastatic bone lesions prostate, with Morissey et al reporting BMP-7 levels to be strikingly 
increased in castration-resistant prostate cancer in comparison to androgen-dependent 
prostate cancer (Masuda, Fukabori et al. 2003, Masuda, Fukabori et al. 2004, Buijs, Rentsch et 
al. 2007, Ye, Lewis-Russell et al. 2007, Morrissey, Brown et al. 2010). Thus, this creates an 
intriguing overall picture, where the changes in BMP-7 expression could reflect the shift of 
prostate cancer from an androgen-dependent phenotype to androgen-independent phenotype 
as the disease gets more aggressive.  
 
Various studies have aimed to study the role of BMP-7 in prostate cancer, with conflicting 
results. For instance, the in vivo study by Buijs et al (2007) demonstrated BMP-7 expression to 
be significantly correlated with E-cadherin, suggesting a role for BMP-7 in controlling and 
preserving the epithelial human prostate. Another study, by Kobayashi et al (2011), indicated a 
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critical role for this BMP in inducing senescence of prostate cancer stem-like cells (CSCs). Thus, 
both studies suggested the potential therapeutic utility of BMP-7 in the treatment against 
metastatic prostate cancer. In vitro studies have also demonstrated prostate cancer inhibiting 
abilities of BMP-7, with Miyazaki et al (2004) reporting its inhibition of the proliferation of 
prostate cancer cell lines, PC-3 and DU145, and previous work from our own laboratory 
demonstrating the increased motility and invasiveness of PC-3 as a result of decreased BMP-7 
expression (Ye, Lewis-Russell et al. 2007). However, other studies have reported differently. 
Yang et a, for example, demonstrated the BMP-7-mediated induction of EMT in PC-3 cells, as 
well as inhibition of the serum-starvation-induced apoptosis of prostate cancer cells, LNCaP, and 
their bone variants, C4-2B cells (Yang, Zhong et al. 2005, Yang, Pham et al. 2008). Dai et al (2004) 
described a role for BMP-7 in the enhancement of pro-osteoblastic activity of C4-2B through the 
upregulation of VEGF. Additionally, Lim et al (2011) reported filamentous outgrowths from 3D 
spheroid PC-3 cultures, which was accompanied with a downregulation of E-cadherin, and an 
increase in invasiveness through the upregulation of MMP-1 and MMP-13. Although taken 
together this provides a possible dual mechanism of BMP-7 function in prostate cancer 
metastasis, it is possible that other signalling molecules that have an impact on BMP function 
also need to be taken into consideration, such as BMP antagonists.  
 
1.13 BMP antagonists 
 
Out of all the regulators of BMP signalling, BMP antagonists have been shown to be uniquely 
integral to BMP function. Indeed, the interplay that exists between BMPs and their antagonists 
has been demonstrated to govern the cellular processes underlying diverse developmental 
programmes such as limb-bud patterning, joint formation in the skeleton and induction of neural 
tissue (Reddi 2001, Wessely, Agius et al. 2001, Khokha, Hsu et al. 2003).  
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Like BMPs, the BMP antagonist structure comprises of a cysteine knot, the size of which is used 
to classify the antagonists into subfamilies. These are: the CAN family (Cerberus and DAN 
(differential screening-selected gene aberrative in neuroblastoma); eight-membered ring), 
twisted gastrulation (nine-membered ring), and Chordin and Noggin (ten-membered ring). The 
CAN family can also be further divided into four subsets based on a conserved arrangement of 
additional cysteine residues: Gremlin and protein related to DAN and Cerberus (PRDC); Cerberus 
and Coco; DAN; and uterine sensitization-associated gene-1 (USAG-1) and Sclerotin (Avsian-
Kretchmer and Hsueh 2004). BMP antagonists typically range from 170 to 250 aa in length for 
the CAN family, while multidomain antagonists like Chordin subfamily of antagonists and 
Follistatin (FST) are significantly larger. Also consistent with BMPs is the presence of a latent 
domain in their N-terminus that needs to be cleaved for the antagonists to reach their mature 
form. In fact, cleavage of the 20 aa propeptide domain enables the N-terminus to form a BMP-
interacting domain, known as a clip or finger domain (Groppe, Greenwald et al. 2002).  
 
Although they are canonically known to act as inhibitor of BMP function, more and more 
evidence has demonstrated the importance of BMP antagonists for proper BMP function. 
Indeed, some BMP antagonists may actually stimulate BMP action when expressed at low 
concentrations (Walsh, Godson et al. 2010, Ali and Brazil 2014, Salazar, Gamer et al. 2016). 
Furthermore, as with BMPs, the expression of BMP antagonists is under tight spatio-temporal 
control and therefore, alterations to their levels may lead to deformities in limb, bone and 
kidney development amongst others. For instance, Noggin-mediated BMP antagonism has been 
shown to be integral in the development of the heart, and prostate (Choi, Stottmann et al. 2007, 
Cook, Vezina et al. 2007). 
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 Noggin 
 
Noggin (NOG) is a 67 kDA homodimeric glycoprotein that exists as a dimer of identical subunits. 
The structure of Noggin has been described as a flat “butterfly-like” shape, with the body of the 
butterfly represented by the two subunits in close contact, and wings consisting of the β-strands 
projecting outward at around 45o away from the axis of symmetry of the dimer (see figure 1.8A). 
Contact with BMPs occurs through the tips of these β-strand loops, therefore with their loops 
being longer than those in BMPs, Noggin is able to extend over them, obscuring the binding sites 
Figure 1.8: Inhibition of BMPs by BMP antagonists. A. The diagram depicts the inhibition 
of BMP-7 by BMP antagonist Noggin. The latter exists as a homodimer (shown in purple) 
with BMP-interacting domains known as a clip or finger domain (red). Like BMPs, BMP 
antagonists comprise of a cysteine knot, shown in green. B. The schematic demonstrates 
the inhibition of a BMP-7 ligand dimer by Follistatin. Unlike Noggin, FST monomers 
completely surround each plane of the target, whereby the head-to-tail contacts between 
the N-terminal (ND) and the follistatin domain 3 (FSD3) create a neutralised complex (A. 
was adapted from Walsh, Godson et al. 2010 and B. was adapted from Lin et al 2006).  
Noggin 
BMP-7 
A. 
Follistatin 
BMP-7 dimer 
B. 
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for their cognate receptors (Groppe, Greenwald et al. 2002, Greenwald, Groppe et al. 2003). Like 
the other BMP antagonists, Noggin is able to bind to a number of BMPs, although with a varying 
degree of preference. BMPs that Noggin may bind include BMP-2, 4, 6, 7 and 14 (Krause, Guzman 
et al. 2011).  
 
 Follistatin 
 
Follistatin (FST) is a multidomain, secreted glycoprotein that may exist as three isoforms. Two 
isoforms, namely FST288 and FST315, arise from the alternative splicing of the approximately 6 
kb FST gene precursor from the respective splice variants FST317 and FST344. FST288, the 
membrane-bound form of FST, comprises of an N-terminal domain (ND) and three FST domains 
(FSD1, FSD2 and FSD3), while the FST315 isoform represents the serum-circulating form of the 
antagonist and includes a C-terminal acidic region (Shimasaki, Koga et al. 1988, Shimasaki, Koga 
et al. 1988). The third FST variant, FST303, is produced from the post-translational truncation of 
this C-terminus (Sugino, Kurosawa et al. 1993). Interestingly, most FST mRNA corresponds to the 
FST315 form of the antagonist, with <5% of FST mRNA coding for the FST288 isoform (Schneyer, 
Wang et al. 2004). 
 
Although FST was originally identified as an Activin antagonist, this antagonist has since been 
shown to also BMP-2, 4 and 7, with higher affinities for the latter (Iemura, Yamamoto et al. 
1998). This antagonist also shares substantial structural and functional homology with 
antagonists known as Follistatin-Like (FSTL)-1, 3, 4 and 5, that also inhibit BMP action (Sylva, 
Moorman et al. 2013), with all FST and FSTL antagonists showing the same BMP-inhibiting mode 
of action. This inhibitory action is actually dissimilar to that of Noggin, in that rather than a clip 
or finger obscuring the  BMPR binding sites within BMPs, FST acts as a peripheral clamp that 
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completely surrounds one plane of its target ligand, forming head to tail contacts between the 
N- and C-terminals between each of the FST monomers (Lin, Lerch et al. 2006). 
 
 Gremlin 
 
Gremlin (GREM) is a 20.7 kDa, highly conserved 184 aa glycoprotein that is part of the DAN family 
of BMP antagonists. Two isoforms of this antagonist exist, namely Grem1 and Grem2, although 
the latter is also known as PRDC (Mulloy and Rider 2015). Both isoforms are known to bind BMP-
2 and 4, with Grem1 also showing some affinity for BMP-7. Grem1 can exist in both secreted 
and cell-associated forms, and contrary to the antagonists discussed above, it exerts its BMP 
inhibitory effects not only by preventing BMP interaction with their cognate receptors but also 
by blocking BMP secretion and increasing BMP endocytosis (Sun, Zhuang et al. 2006, Wordinger, 
Zode et al. 2008, Alborzinia, Schmidt-Glenewinkel et al. 2013).  
 
1.14 BMP antagonists and Prostate Cancer 
 
Since the dysregulation of BMP function has been linked, in either a pro- or anti-tumourigenic 
capacity, to cancer, numerous studies have recognised the potential role of BMP antagonists in 
this process, reporting an effect on basal cell carcinoma, melanoma, colorectal cancer, breast 
cancer and lung cancer, to name a few. (Sneddon, Zhen et al. 2006, Gao, Chakraborty et al. 2012, 
Kim, Yoon et al. 2012, Karagiannis, Musrap et al. 2015). However, like with BMPs, conflicting 
results have been reported in assessing the role of BMP antagonists in prostate cancer and its 
related bone metastasis.  
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For instance, suggesting Noggin as a potential therapeutic modality against bone metastasis, 
Feeley et al (2006) demonstrated the Noggin-mediated inhibition the expansion of osteolytic 
lesions in vivo, while Schwaninger et al (2007) reported its abolishment of the osteoblast 
response of intraosseous xenografts, blaming a lack of Noggin for the osteoblastic response of 
prostate cancer bone metastasis. In contrast, studies by Secondini et al (2011) and Al-Shaibi et 
al (2018) have proposed the suppression of Noggin as a potential anti-bone metastasis therapy 
due to their results showing a limitation of tumour growth and osteolysis in PC-3 bone xenograft 
models resulting from Noggin-silencing, and the Noggin-mediated suppression of osteoblast 
differentiation in bone metastases. 
 
Other than Noggin, FST has also been shown to have a role in prostate cancer. In aiming to 
investigate keys genes in the progression of prostate cancer to its more aggressive phenotype, 
Varaala et al (2000) uncovered the increase of FST in the LNCaP androgen-independent variant. 
These findings are expanded upon by Tumminello et al (2010) who demonstrated a positive 
correlation between circulating levels of FST and the presence of bone metastases. 
 
1.15 Aims 
 
Taken together, the information outlined in this chapter describes an intimate interplay 
between BMPs and their antagonists that is critical in various developmental programmes, and 
that could also be in play a role in pathophysiological conditions during prostate cancer. Previous 
reports have hinted at this concept, such as Feeley et al (2006) who demonstrated the inhibition 
of BMP-2 and BMP-4-mediated migration and invasion of PC-3 cells by Noggin. AlShaibi et al 
(2018) also indicated this BMP/BMP antagonist balance in prostate cancer by describing high 
levels of BMP-6, in addition to those of Noggin, in prostate cancer cells, a finding which is 
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confirmed by Haudenschild et al (2004). Van der Poel (2003) additionally reported that an 
increase in BMP-4, which was induced by rapamycin in their experiments, was accompanied by 
a decrease in FST levels in PC-3 and DU145 cells. Furthermore, previous work from our own 
laboratory has demonstrated the decrease of Noggin and FST levels due to BMP-7 knockdown 
(Ye, Lewis-Russell et al. 2007). As a result of this study, Ye et al suggested that the increased 
motility and invasiveness of BMP-7-knockdown PC-3 cells, may have been facilitated by the 
noted decrease of these BMP antagonists.  
 
Therefore, we hypothesised that, due to BMPs being established, powerful osteoinductive 
factors, the close feedback loop that exists between them and their BMP antagonists has a role 
in the development of prostate cancer and the related osteoblastic bone metastases. 
 
The aims of the study were: 
 
1. To screen for the baseline levels of BMP-2, 4, 6 and 7, their antagonists, Noggin, FST344, 
and Gremlin, and related signalling components in prostate cancer cell lines, PC-3, 
DU145, LNCaP and VCaP so as to assess the differences in gene expression between 
osteolytic lesion and osteoblastic lesion-causing cell lines.  
 
2. To examine changes in the above gene expression levels when cell lines are within the 
bone environment as mimicked by a bone matrix extract (BME; see section 2.2.1 for full 
details), and to assess the differences in these BMP signalling components between 
osteolytic and osteoblastic bone lesions. 
 
3. To assess the functionality of BMP antagonists, Noggin, FST344 and Gremlin in prostate 
cancer cell behaviour by overexpressing levels of these antagonists, and investigating 
the changes incurred within the bone environment (again, as mimicked by BME). 
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4. To identify key molecular mechanisms underlying the changes in cell behaviour incurred 
following Noggin, FST344 and Gremlin overexpression. 
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Materials and Methods 
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2.1 General Materials 
 
 Cell lines 
 
The current study made use of four prostatic cell lines, PC-3, DU145, LNCaP and VCaP - all of 
which were obtained from the American Type Culture Collection (ATCC, Rockville, Maryland, 
USA). Full details are supplied in Table 2.1.  
 
 Primers 
 
All the primers used in the present study were designed with the use of the program Primer-
BLAST available from NCBI, and were synthesized by Sigma-Aldrich (Poole, UK). Primers were 
diluted in nuclease-free water upon receipt according to the manufacturer’s specifications. The 
forward and reverse primers used for reverse transcription polymerase chain reaction (RT-PCR) 
and quantitative polymerase chain reaction (qPCR) are shown in Tables 2.2 and 2.3 respectively. 
Primers used for the amplification of the coding sequences of Noggin, FST344 and Gremlin and 
the verification of clonal vectors are provided in Table 2.4.
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Cell line Organism Morphology Ethnicity Gender Age Disease Tissue Features 
PC-3 
 
Homo sapiens 
(Human) 
Epithelial Caucasian Male 62 
 
Grade IV, 
Adenocarcinoma 
Prostate; derived from 
metastatic site: Bone 
Isolation date: 1979 
Culture properties: Adherent 
Antigen Expression: HLA A1, A9 
Androgen Receptor status: -ve 
Cell type: Osteolytic 
DU145 
 
Homo sapiens 
(Human) 
Epithelial Caucasian Male 69 Carcinoma Prostate; 
Derived from metastatic 
site: Brain 
Isolation date: 1978 
Culture properties: Adherent 
Antigen expression: Blood Type O; Rh+ 
Androgen Receptor status: -ve 
Cell type: Osteolytic 
LNCaP 
 
Homo sapiens 
(Human) 
 
Epithelial Caucasian Male 50 Carcinoma Prostate; derived from 
metastatic site: Left 
supraclavicular lymph 
node 
Isolation date: 1977 
Culture properties: Adherent 
Cellular Products: human prostatic acid phosphatase; prostate 
specific antigen 
Androgen Receptor status: +ve 
Cell type: Mixed osteolytic/osteoblastic 
VCaP Homo sapiens 
(Human) 
Epithelial Caucasian Male 59 Cancer Prostate; derived from 
metastatic site: 
vertebral metastasis 
 
Isolation date: 1997 
Culture properties: Adherent 
Antigen Expression: cytokeratin-18; Homo sapiens, expressed p53 
antigen; Homo sapiens, expressed prostate specific antigen (PSA); 
Homo sapiens, expressed prostatic acid phosphatase (PAP); Homo 
sapiens, expressed Rb protein; Homo sapiens, expressed 
Androgen Receptor status: +ve 
Cell type: Osteoblastic 
 
Table 2.1. Details of prostate cancer cell lines used during this study. 
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Table 2.2. Primers used for conventional RT-PCR. 
 
 
Gene Primer name         Primer sequence Annealing 
Temperature  
Expected 
size (bps) 
 
BMP-7 
 
BMP7F8 CTTTCTTCAAGGCCACGGAG 55°C 332 
BMP7R8 TTCCGGGTTGATGAAGTGGA  
 
Noggin 
 
NogginF11 TACAGATGTGGCTGTGGTCG 55°C 252 
NogginR11 TGCACTCGGAAATGATGGGG  
 
FST344 
 
FST344F11 TGAGGGAAAGTGTATCAAAGCAAA 55°C 267 
FST344R11 TCGGTGTCTTCCGAAATGGAG  
 
FST317 
 
FST317F11 AAGTGTATCAAAGCAAAGTCCTGT 55°C 267 
FST317R11 ATGGCTCAGGTTTTACGGGC  
 
Gremlin 
 
GremlinF8 CTGCTGAAGGGAAAAGAA 55°C 264 
GremlinR8 GATGGATATGCAACGACACT  
 
Smad 1 
 
Smad1F8 GTCGTGAGTTTCCTTTTGG 55°C 504 
Smad1R8 CACAGTGTTTTGGTTCCT  
 
Smad 2 
 
Smad2F8 TAACAGAACTTCCGCCTC 55°C 495 
Smad2R8 CACTTAGGCACTCAGCAAA  
 
Smad 3 
 
Smad3F8 CTGGACGACTACAGCCATT 55°C 501 
Smad3R8 GTTGGGAGACTGGACAAAA  
 
Smad 4 
 
Smad4F8 ATTTCCAATCATCCTGCTC      55°C 543 
Smad4R8 GTCATCAACACCAATTCCA       
 
Smad 5 
 
Smad5F8 CCTGTTGCCTATGAAGAGC 55°C 491 
Smad5R8 TGATATTCTGCTCCCCAAC  
 
Smad 8a 
 
Smad8aF8 CCAGAGAGTCCCTATCAACA 55°C 621 
Smad8bR8 CCAACCCTTAACAAAACTCA  
 
BMPR-Ia 
 
BMPRIAF8 
BMPRIAR8 
GACCAGTCACAAAGTTCTGG 55°C 470 
 TTTTTGCTCTTTAGGTCTCG 
 
BMPR-Ib 
 
BMPRIBF8 TGTAGTTTGCTCTTGGTCCT 55°C 501 
BMPRIBR8 CATTGATTTAGCGTCTAGGG  
 
BMPR-II 
 
BMPR2F8 GCACACCTTTGACTATAGGG 55°C 500 
BMPR2R8 AGTAGGCAGAACATCAGGAA  
 
ActRIa 
 
ACTRIAF8 TGGTGTAACAGGAACATCAC 55°C 518 
ACTRIAR8 ATGTCTGAAGCAATGAAACC  
 
ActRII 
 
ACTR2F8 ACTTGTTCCAACTCAAGACC 55°C 463 
ACTR2R8 ACTTTTGATGTCCCTGTGAG  
 
ActRIIb 
 
ACTR2BF8 TCATGTGGACATCCATGAG 55°C 493 
ACTR2BR8 GTCGCTCTTCAGCAATACAT  
 
GAPDH 
 
GAPDHF10 AGCTTGTCATCAATGGAAAT  55°C 593 
GAPDHR10 CTTCACCACCTTCTTGATGT  
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Table 2.3. Primers used for qPCR. ACTGAACCTGACCGTACA represents the Z sequence. 
Gene Primer 
name 
Primer sequence Annealing 
Temp. 
Expected 
size (bps) 
 
BMP-7 
 
BMP7F24 TTCCGGATCTACAAGGACTA 55°C 119 
BMP7Zr24 ACTGAACCTGACCGTACACTGTCGAGCAGGAA
GAGAT 
 
 
Noggin 
 
NogginF14 AGGGCTAGAGTTCTCCGAGG 55°C 91 
NogginZR14 ACTGAACCTGACCGTACACGACCACAGCCACAT
CTGTA 
 
FST344 
FST344F1 TGAGGGAAAGTGTATCAAAGCAAA 55°C 80 
FST344ZR1 ACTGAACCTGACCGTACATTCCTCCTCTTCCTCG
GTGT 
 
Gremlin GremlinF8 CTGCTGAAGGGAAAAGAA 55°C 89 
GremlinZr ACTGAACCTGACCGTACACACGAACTACGCACA
AGCAG 
BMP-2 BMP2F1 AGACCACCGGTTGGAGAG 55°C 120 
BMP2Zr ACTGAACCTGACCGTACAGTTGTTTTCCCACTCG
TTT 
 
BMP-4 BMP4F1 CAACACCGTGAGGAGCTT 55°C 134 
BMP4Zr ACTGAACCTGACCGTACATGAGGTTAAAGAGG
AAACGA 
 
BMP-6 BMP6F1 AGTCTTACAGGAGCATCAGC 55°C 141 
BMP6Zr ACTGAACCTGACCGTACAACAACCCACAGATTG
CTAGT 
Snail SnailF1 CAGAAAGTTTTCCACCAAAG 55°C 106 
SnailZr ACTGAACCTGACCGTACAAAATGTGAGCAATTC
TGCTT 
Slug SlugF1 ATTCTCAACCCCATCT 55°C 110 
SlugZr ACTGAACCTGACCGTACATTCTCCACTTGATTTC
CATT 
MMP2 MMP2F1 CAGGGAATGAGTACTGGGTCTATT 55°C 102 
MMP2ZR1 ACTGAACCTGACCGTACAACTCCAGTTAAAGGC
AGCATCTAC  
 
MMP7 
 
 
MMP7F1 AAATGGACTTCCAAAGTGGT  55°C 110 
MMP7ZR1 ACTGAACCTGACCGTACATTCCCCATACAACTTT
CCTG  
 
MMP9 MMP9F1 AACTACGACCGGGACAAG  55°C 106 
MMP9ZR1 ACTGAACCTGACCGTACAGGAAAGTGAAGGGG
AAGA  
 
MMP12 MMP12F1 ACCCACGTTTTTATAGGACC  55°C 112 
MMP12ZR1 ACTGAACCTGACCGTACAGATAACCAGGGTCCA
TCATC  
 
MMP14 MMP14F1 AACTACGACCGGGACAAG 55°C 105 
MMP14ZR1 ACTGAACCTGACCGTACAACTCCAGTTAAAGGC
AGCATCTAC 
 
ID1 ID1 TCAACGGCGAGATCAG 55°C 57 
ID1Zr ACTGAACCTGACCGTACAGATCGTCCGCAGGA
A 
 
 
GAPDH 
 
GAPDHF CTGAGTACGTCGTGGAGTC  55°C 93 
GAPDHZR ACTGAACCTGACCGTACACAGAGATGATGATG
ACCCTTTTG    
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Gene Primer name Primer sequence Expected size (bps) 
 T7F TAATACGACTCACTATAGGG  
 BGHR TAATACGACTCACTATAGGG  
 
Noggin 
NogginExF1 ATGGAGCGCTGCCCCAGCCTAGGGGTCA 696 
NogginExR1  GCACGAGCACTTGCACTCGGAAATGA  
 
FST344  
FST317ExF1 ATGGTCCGCGCGAGGCA 1299 
 FST344ExR1 TTACCACTCTAGAATAGAAGATATAGG 
 
GREM1V1 
GremlinExF1 ATGAGCCGCACAGCCTAC 555 
 GremlinExR1 TTAATCCAAATCGATGGATATGCAA 
 
Table 2.4. Primers designed for the cloning of Noggin, FST344 and Gremlin overexpression 
vectors.  
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2.2 Standard reagents and solutions 
 
 Solutions for use in Cell Culture 
 
Phosphate Buffer Solution (PBS) 
50 ml of 10X stock solution of PBS (Sigma-Aldrich, Poole, UK) was diluted in 450 ml of distilled 
water and autoclaved.  
 
Buffered Salt Solution (BSS) 
79.5 g of NaCl (Sigma-Aldrich, Poole, UK), 2.1 g of KH2PO4 (BDH Chemical Ltd., Poole, UK), 2 g of 
KCl (Fisons Scientific Equipment, Loughborough, UK) and 1.1 g of Na2HPO4 (BDH Chemical Ltd., 
Poole, UK) were dissolved in 10 L of distilled water and the pH was adjusted to 7.4. 
 
0.05 M Ethylebediaminetraacetic acid (EDTA)  
1 g of KCl (Fisons Scientific Equipment, Loughborough, UK), 5.72 g of Na2HPO4 (BDH Chemical 
Ltd., Poole, UK), 1 g of KH2PO4 (BDH Chemical Ltd), 40 g of NaCl (Sigma-Aldrich, Poole, UK) and 
1.4 g of EDTA (Duchefa Biochemie, Haarlem, The Netherlands) were dissolved in 5 L of distilled 
water and adjusted to pH 7.4. This solution was then autoclaved and stored until needed.  
 
Trypsin/EDTA (25 mg/ml)  
500 mg of trypsin (Sigma-Aldrich, Poole, UK) was dissolved in 20 ml of the 0.05 M EDTA solution 
detailed above, mixed and filtered through a 0.2 µm minisart filter (Sartorius, Epsom, UK). This 
solution was split into 250 μl aliquots and stored at -20°C for further use. When needed for cell 
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culture, one aliquot of the trypsin stock was further diluted in 10 ml of 0.05 M EDTA and used 
as required for the trypsinisation of cells. 
 
100X Antibiotic Cocktail Mix 
5 g of streptomycin, 3.3 g of penicillin, and 12.5 g of amphotericin B in DMSO were dissolved in 
500 ml of PBS, filtered and divided into 5 ml aliquots and stored at -20°C for further use. One of 
the thawed 5 ml aliquots was then directly added to 500 ml bottles of media during the 
preparation of standard culture medium.  
 
Bone Matrix Extract (BME) 
Femur bone tissues were collected from patients undergoing total hip replacements at the 
Trauma and Orthopaedic Department of University Hospital of Wales and Llanddough Hospital. 
The collection was performed after receiving written consent from the donors and was 
implemented with strict adherence to a protocol ethically approved by the Bro Taf Research 
Ethics Committee (Panel B) for the Bro Taf Health Board, Cardiff, UK. The proximal femur 
samples collected consisted of the femoral head and part of the femoral neck. Once removed 
during the hip replacement process, the bone tissues were placed in sterile containers and 
stored at -20°C until the end of the operation. The samples were then transferred and stored at 
-80°C until use or further processing. For the extraction of BME, the femur samples first needed 
to be crushed using a Noviomagus bone mill with +/- 0.5 to 1 mm milling drums (Spierings 
Orthopaedics B.V., Nijmegen, The Netherlands). The resultant fragments were then further 
crushed by hand (5ml bone fragments: 20 ml of BSS) using a pestle and mortar, while on ice. 2.5 
ml aliquots of the crushed fragments were then transferred to 15 ml centrifuge tubes, to which 
10 ml of sterile BSS was added. This mixture was placed in a Bioruptor (Diagenode, Seraing, 
Belgium) and subjected to 5 minutes of uninterrupted pulses, 30 seconds on, 30 seconds off, in 
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an ice-cold water bath. Debris were subsequently removed by centrifuging the samples at 3000 
rpm at 4°C for 5 minutes and the supernatants were transferred to fresh tubes. This was 
repeated five times for each sample. Total protein content of the bone extracts was then 
quantified using a Bio-Rd DC protein assay kit (Bio-Rad Laboratories, Hemel Hempstead, UK) 
before being standardised to 2 mg/ml. 1ml aliquots were prepared and stored at -80°C. 
 
 Solutions for use in Molecular Biology 
 
Diethyl pyrocarbonate (DEPC) water 
500 μl of diethylpyrocarbonate (DEPC; Sigma-Aldrich, Poole, UK) was made up to 500 ml using 
deionised water. The solution was then left overnight and autoclaved.  
 
Tris-Boric-Acid-EDTA (TBE) 
Premixed 10X stock solutions of TBE was purchased from Sigma-Adrich (Poole, UK) and diluted 
1:10 in distilled water when needed. 
 
Loading buffer (used for agarose gel electrophoresis) 
25 mg of bromophenol blue and 4 g of sucrose (Fisons Scientific Equipment, Loughborough, 
UK) were dissolved in 10 ml of distilled water and stored at 4°C until needed. 
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 Solutions for use in Cloning 
 
LB agar 
10 g of tryptone (Duchefa Biochemie, Haarlem, The Netherlands), 15 g of agar, 5 g of yeast 
extract (Duchefa Biochemie) and 10 g of NaCl (Sigma-Aldrich, Poole, UK) were dissolved in 1 L of 
distilled water. The pH was adjusted to 7.0 and the solution was autoclaved. For the preparation 
of agar plates, the solidified agar was melted and cooled. Selective antibiotics were then added, 
and the solution was poured into 10 cm Petri dishes (Bibby Sterilin Ltd, Staffs, UK). The plates 
were left to cool until the agar hardened and were subsequently inverted and stored at 4°C. 
 
LB broth 
10 g of tryptone (Duchefa Biochemie, Haarlem, The Netherlands), 10 g of NaCl (Sigma-Aldrich, 
Poole, UK) and 5 g of yeast extract (Duchefa Biochemie) was dissolved in 1 L of distilled water. 
The pH was then adjusted to 7.0 and the solution was autoclaved and kept at room temperature 
until needed. Selective antibiotics were then later added as required. 
 
2.3 Cell Culture, Maintenance, Storage and Transfection 
 
 Preparation of Growth Media 
 
Dubelcco’s Modified Eagle’s Medium (DMEM/Ham’s F-12 with L-glutamine; Sigma-Aldrich, 
Poole, UK), pH 7.3, containing 2 mM L-glutamine and 4.5 mM NaHCO3, supplemented with 10% 
heat-inactivated Foetal Bovine Serum (FBS; Sigma-Aldrich, Poole, England, UK) and an antibiotic 
cocktail (described in section 2.2.2), was routinely used to culture the PC-3, DU145 and VCaP cell 
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lines. Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% FBS and 
the antibiotic cocktail was used to culture LNCaP cells. 
 
Cell lines transfected with the pEF6/V5-His-TOPO® vector (Life Technologies, Paisley, UK) were 
initially cultured in a “selection” medium, consisting of the cell line’s preferred culture medium 
supplemented with 5 μg/ml Blasticidin S (Melford Laboratories Limited, Suffolk, UK) for up to 7 
days. Surviving cells were then transferred to and grown in a “maintenance” medium containing 
0.5 μg/ml Blasticidin S. Resultant cell lines were continuously cultured in the maintenance 
medium thereafter to ensure that the cells retained the vector for subsequent in vitro studies. 
 
 Cell Maintenance 
 
All cell lines were cultured in 25cm2 and 75cm2 tissue culture flasks (Greiner Bio-One Ltd, 
Gloucestershire, UK) with loosely fitted caps in a humidified incubator at 37°C, 5% CO2 and 95% 
humidity. Cell confluency was assessed by visually approximating the percentage of cells 
covering the culture surface of the tissue culture flask using a light microscope. Once they 
reached a confluency of approximately 85-90%, cells were then sub-cultured or collected if 
needed for experimental work, as described in section 2.3.3. All cell work was carried out 
aseptically, using a Class II Laminar Flow Cabinet (ThermoFisher Scientific, Massachusetts, USA) 
with sterile and autoclaved equipment and consumables. 
 
 Adherent Cell Trypsinisation and Cell Counting 
 
Once cells had reached a confluency of approximately 85-90%, the medium was aspirated, and 
the cells were briefly rinsed with sterile PBS to wash away any traces of serum, which would 
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otherwise inhibit the effect of trypsin. Depending on the size of the flask cells were cultured in, 
0.5-1 ml of Trypsin/EDTA (0.01% trypsin, 0.05% EDTA in BSS) was used to detach adherent cells 
by incubating them with the trypsin for approximately 5 minutes at 37°C. Once detached, cells 
were collected in their respective media containing FBS to stop the trypsinisation reaction and 
transferred to 20 ml universal containers (Greiner Bio-One Ltd, Gloucestershire, UK) before 
being pelleted at 1,000 rpm for 5 minutes. The supernatant was then aspirated, and the cell 
pellet was resuspended in the appropriate medium. Cells were either split and transferred to 
fresh tissue culture flasks for re-culturing or counted using a haemocytometer (Fuchs Rosenthal, 
Hawksley, UK) and a light microscope at 10X magnification for subsequent use in experimental 
assays. 
 
Throughout this study, a haemocytometer was used to assess cell count. The haemocytometer 
allows for the calculation of cell density in a predetermined volume of fluid contained in the 
counting chamber. This value can be converted to obtain the number of cells per millilitre in the 
overall cell suspension, from which the volume of cell suspension needed to obtain the 
appropriate cell concentration for experimental needs. The haemocytometer counting grid is 
divided into 16 large square areas with dimensions of 1 mm x 1 mm x 0.2 mm (0.2 mm2), which 
are each subdivided into 16 squares. For better accuracy in the determination of cell density, 
cells were counted in the 4 large corner squares. Cell number was calculated using the following 
equation: 
 
𝑪𝒆𝒍𝒍 𝒏𝒖𝒎𝒃𝒆𝒓 𝒑𝒆𝒓 𝒎𝒍 = (
𝑻𝒐𝒕𝒂𝒍 𝒏𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝒄𝒆𝒍𝒍𝒔 𝒊𝒏 𝟒 𝒄𝒐𝒓𝒏𝒆𝒓 𝒔𝒒𝒖𝒂𝒓𝒆𝒔
𝟐
𝟒⁄ ) 𝒙 𝟏𝟎^𝟒 
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 Transfection of Cells by Electroporation 
 
1 - 2 μg of empty control vector, and vectors encompassing the coding sequences of the genes 
studied were used to transform DU145 cells. Confluent, low passage wild type DU145 cells were 
detached from tissue culture flasks and resuspended in serum-free medium. A cell suspension 
of approximately 1 x 106
 
cells in 800μl per transfection was prepared and added to sterile 0.4 
cm gap electroporation cuvettes (Eurenetech, Southampton, UK), which were then placed on 
ice. Subsequently, 5 - 10 μg of purified vector was added to the corresponding cuvette (see 
section 2.5.8), mixed briefly using the pipette tip before it was subjected to an electrical pulse 
from a Gene Pulser Xcell™ Electroporation System (Bio-Rad Laboratories, Hemel Hampstead, 
UK) set to 290 V, 700 µM. Following this pulse, the cell and vector suspension was quickly 
transferred to a 25 cm2
 
tissue culture flask containing 5 ml of pre-warmed medium containing 
FBS and antibiotics and left in an incubator at 37°C overnight to allow cells to recover and 
adhere. 
 
 Storage of Cell Stocks in Liquid Nitrogen 
 
Cells were trypsinised as described above in section 2.3.3 and resuspended in the appropriate 
growth medium. 5-10% Dimethyl sulphoxide (DMSO; Sigma-Aldrich, Poole, UK) was added to 
the cell suspension and 1 ml aliquots were transferred into pre-labelled 1.8 ml cryovials (Nunc, 
Fisher Scientific, Leicestershire, UK), which were then wrapped in protective tissue paper before 
being stored at -20°C for approximately 3 hours, then overnight at 80°C, and finally transferred 
to liquid nitrogen tanks for long term storage, until required.  
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 Cell Resuscitation 
 
In order to resuscitate frozen down cells, cryovials were taken from liquid nitrogen storage and 
placed on dry ice. They were then rapidly thawed in a water bath at 37°C before being 
transferred into a universal container containing 10 ml of pre-warmed medium to immediately 
dilute the DMSO present. Traces of the DMSO were removed from the cells by centrifuging them 
at 1,400 rpm for 10 minutes, and the supernatant was aspirated. The cell pellet was resuspended 
in 5ml of medium before being transferred to a fresh 25 cm2 tissue culture flask and maintained 
in a humidified incubator at 37°C and 5% CO2. After 24 hours, the revived cells were examined 
under the microscope to visually assess the viability of the adherent cells. The medium was 
aspirated and replaced with fresh, pre-warmed medium to remove any residual DMSO. The flask 
was returned to the incubator and the previous standard subculture techniques were carried 
out when necessary. 
 
2.4 Methods for RNA Detection 
 
 mRNA Isolation 
 
TRI reagent® (Sigma-Aldrich, Poole, UK) was used for the extraction of mRNA and the protocol 
was completed as described by the manufacturer. Cells were grown in a monolayer and allowed 
to reach a confluency of approximately 85-90% before the medium was aspirated and the cells 
washed with PBS. TRI reagent® (1 ml per 5-10 x 106 cells) was then added to induce cell lysis. To 
ensure the detachment of cells, the cell monolayer was scraped off using a cell scraper and the 
homogenate was passed several times through a pipette tip to produce a homogenous lysate, 
which was then transferred into a 1.5 ml Eppendorf. The lysate was then allowed to incubate at 
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room temperature for 5 minutes to ensure the complete dissociation of nucleoprotein 
complexes. This was followed by the addition of 100 µl (per 1 ml of TRI reagent® used) of 1-
bromo-3-chlopropane (Sigma-Aldrich, Poole, UK) and immediate, vigorous shaking for 15 
seconds. The homogenate was then left to incubate at room temperature for 15 min before 
being centrifuged at 12,000 x g for 15 minutes at 4°C (Mikro 200R, DJB labcare, Buckinghamshire, 
UK). Under these acidic conditions, the homogenate is separated into three phases – a pink 
lower organic phase containing protein, a white interphase containing DNA, and finally a clear 
upper aqueous phase containing the RNA. This aqueous phase, which normally constitutes 
around 40-50% of the total volume, was then carefully removed and transferred into a fresh 
Eppendorf. 500 µl of isopropanol (Sigma-Aldrich, Inc., Poole, UK) was added to the RNA, briefly 
mixed by inversion and the sample was left to incubate for 10 minutes at room temperature. 
After centrifugation at 12,000 x g, 4°C for 10 minutes, the RNA precipitate forms as a white pellet 
on the bottom of the Eppendorf. The supernatant was then discarded, and the RNA pellet was 
washed by vortexing it with 750 µl of 75% ethanol (3:1 ratio of pure ethanol and 
diethylpyrocarbonate, DEPC water) and subsequently centrifuging the sample at 7,500 x g for 5 
minutes at 4°C. Once the ethanol was aspirated, the RNA pellet was briefly dried at 55°C for 5-
10 minutes, in a Techne, Hybridiser HB-1D drying oven (Wolf laboratories, York, UK), or air-dried 
at room temperature, so as to remove any remaining traces of ethanol. The final step was to 
dissolve the RNA pellet in 20-50 μl (depending on pellet size) of DEPC water by vortexing for a 
short while. Finally, the concentration of the resultant mRNA was assessed using a 
NanoPhotometer (Implen, München, Germany; see section 2.4.2) and standardised to 0.5 µg/ml 
whenever possible.  
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 RNA Quantification 
 
Once the isolation was complete, 1 μl of the sample was used to measure the concentration and 
purity of the extracted RNA. This was carried out using a NanoPhotometer (Implen, München, 
Germany) set to detect single-stranded RNA (µg/µl) at the wavelength of 260nm, using DEPC 
water as a blank. The purity of the RNA was estimated using the A260/A280 nm ratio.  
 
 Reverse Transcription 
 
The GoScript™ Reverse Transcription System (Promega, Southampton, UK) was used to convert 
extracted RNA into first-strand complementary DNA (cDNA). 4 µl of isolated RNA of a known 
concentration was made up to 5 µl with the Oligo(dT)15 in a thin-walled 200 µl PCR tube. This 
mix was then placed at 70°C for 5 minutes, after which it was immediately placed on ice and left 
to chill for at least 5 minutes. Following this incubation period, samples were centrifuged for 10 
seconds, and placed on ice until the reverse transcription (RT) mix was added. The RT mix was 
made up using the following components: 
 
 
 
 
 
 
 
 
 
Component Volume (µl) 
GoScript 5X™ Reaction Buffer 4 
1.5 mM MgCl2 1.2 
PCR Nucleotide Mix 1 
Recombinant RNasin® Ribonuclease Inhibitor  0.5 
GoScript™ Reverse Transcriptase 1 
Nuclease-Free Water 7.3 
 
Total 
 
15 
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The above RT mix was added to each sample and the resultant mix was heated in an Applied 
Biosystems 2720 Thermal Cycler (Life Technologies, Paisley, UK) using the following conditions: 
• Step 1 – Annealing at 25°C for 5 minutes 
• Step 2 – Extending at 42°C for 1 hour 
• Step 3 – Inactivation of the reverse transcriptase at 70°C for 15 minutes  
The cDNA was diluted in nuclease-free water in the ratio needed. cDNA Samples were stored at 
-20°C. 
 
 Reverse Transcription Polymerase Chain Reaction 
 
 RT-PCR was carried out using a GoTaq® Green Master Mix (Promega, Southampton, UK). 
Reactions were set up in thin walled 200 µl PCR tubes or 96 well plates, as shown below: 
 
 
 
 
 
 
 
Once prepared, the reactions were briefly vortexed and centrifuged. All reactions were run 
alongside a negative control, which consisted of using nuclease-free water instead of cDNA 
templates to ensure there was no contamination of the GoTaq® Green Master Mix and primer 
mix. A loading control probing for GAPDH expression was also run for each sample to confirm 
Component Volume (µl) 
2X GoTaq® Green Master Mix 8 
Forward primer (10 pmol) 1 
Reverse primer (10 pmol) 1 
Nuclease-free water 5 
cDNA template 1 
 
Total 
 
16 
68 
 
similar concentrations of cDNA were present in each reaction prepared.  
The PCR tubes or 96 well plates were sealed, briefly centrifuged, and placed in a 2720 Thermal 
Cycler (Applied Biosystems, Paisley, UK) and subjected to the following temperature shifts: 
• Step 1 – Initial denaturation at 94°C at 5 minutes 
Followed by 25-42 cycles of: 
• Step 2 – Denaturation at 94°C for 30 seconds 
• Step 3 – Annealing at 55°C for 30 seconds 
• Step 4 – Elongation at 72°C for 1.5 minutes 
And finally: 
Step 5 – Final elongation at 72°C for 10 minutes 
 
 Agarose Gel Electrophoresis 
 
DNA fragments were fractionated according to size using agarose gel electrophoresis. Samples 
were loaded onto 0.8% - 2.5% agarose gels, depending on the predicted size of the DNA 
products. Agarose gels were prepared by adding the required amount of agarose (Melford 
Chemicals, Suffolk, UK) to the appropriate volume of 1X TBE buffer (Sigma-Aldrich, Poole, UK). 
The mix was then heated until the agarose was fully dissolved and 1:15000 SYBR safe DNA gel 
stain (Invitrogen, Paisley, UK) was added. The agarose was left to cool slightly before being 
poured into the removable gel casting tray and it was allowed to set around the teeth of a plastic 
comb, creating wells. Once set, the gel was submerged in 1X TBE buffer and the plastic comb 
was removed. 8 µl of the PCR samples were loaded in each well, alongside 5 µl of a 100 bp or 1 
Kb DNA ladder (Genscript, Piscataway, NJ, USA). The samples were subjected to electrophoresis 
69 
 
using a power pack (Gibco, Paisley, UK) at 110 V, 100 mA, 50 W for approximately 1 hour and 
the gels were finally visualised and imaged using a U:Genius3 gel doc system (Syngene, 
Cambridge, UK).  
 
 Quantitative Polymerase Chain Reaction 
 
Quantitative PCR (qPCR), also known as real-time PCR is a simple and elegant method used to 
relatively quantify the amount of a target sequence or gene present in a sample. The current 
study utilised the Amplifluor™ Universal Detection System (Intergen Company, New York, USA), 
which allows for the simultaneous amplification and detection of the nucleic acid sequence of 
interest within a closed reaction vessel. This system operates by using two target-specific DNA 
primers and a universal primer, called the Uniprimer™, to incorporate a fluorescent signal into 
the PCR product amplified using a qPCR master mix (PrecisionFAST qPCR Master Mix; Integrated 
Sciences, Sydney, Australia). This is enabled through the addition of an 18-base oligonucleotide 
tail called the Z sequence (ACTGAACCTGACCGTACA) to the 5’ end of one of the target-specific 
primers, called the Z primer. During the initial stages of amplification, the Z primer is extended 
following its hybridisation to the target sequence. This creates a new template for the next 
amplification step, during which the other target specific primer (Primer F; see Figure 2.1) is 
extended, synthesising a sequence that is complementary to the Z sequence (Z’). Since the 
Uniprimer™ structure also includes a 3’ Z sequence, as well as a 5’ hairpin structure linking a 
fluorophore (FAM) and quencher (DABSYL), it is able to anneal to the Z’ sequence of the new 
template and gets extended. Thus, when this Uniprimer™ amplicon becomes the template for 
DNA polymerisation in the final cycle of amplification, the 5’ to 3’ exonuclease activity of the 
DNA polymerase is able to degrade and unfold the hairpin structure, increasing the distance 
between the fluorescein and DABSYL moieties, thereby allowing the emission of fluorescence. 
The resulting fluorescence signal emitted during each PCR cycle can then be directly correlated 
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to the exponential increase of DNA amplified in this process. The Amplifluor™ qPCR process is 
illustrated in Figure 2.1. 
 
The cDNA used in qPCR was generated as described in section 2.4.3 and diluted 1:8 using 
nuclease-free water; this cDNA was then used to make up a reaction mixture outlined below: 
 
 
 
 
 
 
 
Each sample was loaded into a 96 well plate (Bio-Rad Laboratories, Hemel Hampstead, UK) in 
triplicate and sealed with optically clear Microseal (Bio-Rad Laboratories). The qPCR was carried 
out using StepOnePlus™ Real-Time PCR System (ThermoFisher Scientific Scientific, 
Massachusetts, USA) set with the following experimental parameters:  
• Step 1 – Initial denaturation at 94°C for 5 minutes  
• Step 2 – Denaturation at 94°C for 10 seconds 
• Step 3 – Annealing at 55°C for 15 seconds 
• Step 4 – Elongation at 72°C for 20 seconds 
Steps 2-4 were repeated for 100 cycles.  
 
Component Volume (µl) 
PrecisionFAST 2X qPCR Master Mix 5 
Forward primer (10pmol) 0.3 
Reverse Z primer (1pmol) 0.3 
UniPrimer™ (10pmol) 0.3 
cDNA template and nuclease-free water 4 
 
Total 
 
9.9 
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The fluorescent signal was detected at the annealing stage by a camera. A threshold cycle (CT 
value) was then set at which point the fluorescence in each sample was used to comparatively 
measure transcript copy numbers between the samples tested. Results were analysed using 
ΔΔCT normalisation to the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) (Livak and Schmittgen 2001), the levels of which were measured in parallel to the target 
genes. 
 
 
 
 
Figure 2.1. Diagram depicting the principle behind qPCR using the Amplifluor™ 
Universal Detection System. 
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 RNA sequencing 
 
RNA sequencing (RNA-Seq), a revolutionising approach for the study of the transcriptome of 
cells, refers to high-throughput techniques used to determine the primary sequence and relative 
abundance of RNA fragments within given samples. In this study, the targeted-sequencing of a 
selection of prostate cancer cell lines was carried out using the Ion Torrent Personal Genome 
Machine™ (PGM™; ThermoFisher Scientific, Massachusetts, USA). The Ion Torrent method is a 
multistep process (see figure 2.2), the first step of which is to generate a barcoded library with 
the help of the Ion AmpliSeq™ Transcriptome Human Gene Expression Kit. To do so, the 
SuperScript® VILO™ cDNA Synthesis Kit, supplied as part of the gene expression kit, is used to 
generate cDNA from mRNA samples. Then, specific cDNA fragments are targeted and amplified 
by PCR and the products are flanked by Ion Torrent adapters. This creates the barcoded library, 
which is subsequently purified, quantified and diluted to 100 pM. Following library preparation, 
the next step is to prepare the templates, whereby, using the Ion PI™ Template OT2 200 v3 Kit, 
the diluted library fragments are clonally amplified onto Ion Sphere™ particles (ISPs) by emulsion 
PCR (emPCR). The enriched ISPs are then deposited in the chip wells of an Ion PI™ Chip v2 by a 
short centrifugation step before placing the chip on the PGM™, and the samples are sequenced 
using the Ion PI™ Sequencing 200 Kit v3 chemistry. 
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For this study, targeted-sequencing of low passage PC-3 WT (passage 4) and VCaP WT (passage 
5) was undertaken. These cells were seeded into the wells of a 6-well plate and incubated in 
DMEM supplemented with 5% FBS and antibiotics overnight. The cells were then incubated with 
either fresh 5% FBS DMEM or 50 µg/ml BME in 5% FBS DMEM for 3 hours 37°C, 5% CO2. 
Following the incubation period, the media were discarded, and the cells were washed in PBS 
and subsequently collected in TRI Reagent®. mRNA extraction was then carried out as described 
in section 2.4.1, and the concentration of the samples was determined using a NanoPhotometer 
(Implen, München, Germany). 10 ng of total RNA extracted from the prostate cancer cell lines 
was subsequently used for RNA sequencing. 
 
 
 
 
 
 
 
Figure 2.2. Schematic representation of the Ion Torrent sequencing workflow. 
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2.5 Alteration of Gene Expression in Prostate Cancer Cell Lines 
 
 TOPO Gene Cloning and Generation of Stable Transfectants 
 
In order to assess the potential roles that BMP antagonists, Noggin, Follistatin and Gremlin, play 
in prostate cancer progression and bone metastasis, their gene expression profiles were altered 
in the mammalian cell line, DU145, using vectors encompassing their coding sequences to assess 
any consequential phenotypic changes. 
 
 
 
Figure 2.3. Flow-chart depicting the TOPO® TA cloning procedure. 
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 Gene Overexpression 
 
The amplification of the coding sequences of Noggin, FST344 and Gremlin was carried out by 
touchdown PCR using the JumpStart™ AccuTaq™ LA DNA Polymerase Mix (Sigma-Aldrich, Poole, 
UK). Primers capable of amplifying the complete coding sequences of these BMP antagonists 
were designed using Primer-BLAST, and cDNA transcribed from normal prostate tissue mRNA 
was used as a template. The reactions set up for each BMP antagonist were as follows: 
 
 
 
 
 
 
 
 
The touchdown PCR cycling program was then carried out to maximize the specificity of PCR 
reaction by gradually decreasing the annealing temperature of the reaction every 5 cycles. The 
cycling conditions were as follows: 
• Step 1 – Initial denaturation period, 94°C for 5 minutes  
• Step 2 – Denaturation 93°C for 20 seconds 
• Step 3 – Annealing at 64°C for 20 seconds, 62°C for 20 seconds, 60°C for 20 seconds 
and 58°C for 20 seconds  
• Step 4 – Elongation 72°C for 1.5 minutes 
 
 
Component Volume (µl) 
JumpStart™ AccuTaq™ LA DNA Polymerase Mix 12.5 
Forward primer (10 pmol) 1 
Reverse primer (10 pmol) 1 
Nuclease-free water 9.5 
cDNA template 1 
 
Total 
 
25 
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Steps 2-4 were repeated over 5 cycles for each annealing temperature. The final amplification 
was as follows: 
• Step 5 – Denaturation at 93°C for 20 seconds 
• Step 6 – Annealing at 56°C for 30 cycles  
• Step 7 – Final elongation at 72°C for 10 minutes 
 
Following the touchdown PCR, 5 µl of loading buffer was added to each reaction and they were 
run and visualised on a 1.5% agarose gel.  
 
 Extraction of PCR products from Agarose Gel 
 
Following the agarose gel electrophoresis of the touchdown PCR products (from section 2.6.2), 
bands corresponding to the expected sizes of the genes of interest were excised from the gel 
using a clean and sharp scalpel and transferred to tared 1.5 ml Eppendorf tubes, taking care to 
trim away any excess gel. The GenElute™ Gel Extraction Kit (Sigma-Aldrich, Poole, UK) was then 
used to extract these PCR products from the agarose gel according to the manufacturer’s 
instructions.  
 
First, the weight of the gel in the tared tubes was determined so that the gel pieces could be 
resuspended in 300 µl of Gel Solubilisation Solution per 100 mg of agarose gel. Upon addition of 
the solubilisation solution, the gel slices were then incubated at 55°C for approximately 10 
minutes, or until they were dissolved, ensuring complete dissolution of the gel by vortexing the 
mix every 2-3 minutes throughout the incubation period. Meanwhile, the binding columns were 
prepared. This was achieved by placing binding columns, GenElute™ Binding Column G, into the 
provided 2 ml collection tubes, adding 500 µl of the Column Preparation Solution to each 
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column, and centrifuging them at 14 000 x g for 1 minute. The flow-through was discarded. 
When the gel slices were completely dissolved, 100 µl of 100% isopropanol (Sigma-Aldrich, 
Poole, UK) per 100 mg of gel was added to each solubilised gel solution and the mix was loaded 
into the prepared columns. Following a brief centrifugation period of 1 minute at 14 000 x g, the 
flow-through was again discarded and the binding columns were washed with 700 µl of Wash 
Solution. Once more, the flow-through was discarded and the collection tubes were centrifuged 
again to remove any excess ethanol. Finally, the PCR products were eluted in fresh Eppendorf 
tubes using 50 µl of Elution Solution and the products were kept at -20°C until needed. 
 
 TOPO TA Gene Cloning 
 
The pEF6/V5-HIS-TOPO® TA Expression Kit (Invitrogen, Paisley, UK) provides a highly efficient, 
one-step cloning strategy for the insertion of selected Taq polymerase-amplified PCR products 
into a vector suited for high-level constitutive expression in mammalian cells.  
 
 
 
Figure 2.4. Schematic of the pEF6/V5-HIS TOPO® vector (taken 
from the pEF6/V5-HIS-TOPO® TA Expression Kit protocol). 
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The one-step TOPO TA cloning system offers a direct approach to cloning that does not require 
the use of any ligases, post-PCR procedures or PCR primers. This is made possible as the 
pEF6/V5-HIS-TOPO® vector provided in the above expression kit is supplied linearised with single 
3’ deoxythymidine (T) overhangs and two topoisomerase I enzymes covalently bound to the 
vector (also referred to as an “activated vectors”; see figure 2.4). As such, since Taq polymerase 
has a non-template-dependent tendency to add single deoxyadenosine (A) residues to the 3’ 
ends of PCR products, these amplified gene sequences are able to efficiently ligate to the 3’ T 
overhangs of the vector. 
 
The cloning procedure was undertaken as specified by the manufacturers. TOPO cloning 
reactions were in pre-labelled microfuge tubes set up as shown below and the reactions were 
mixed gently before being incubated for 5 minutes at room temperature. 
 
 
 
 
 
 
 
The cloning reactions were stored on ice until needed for transformation of the vectors into 
chemically competent E. coli.  
 
 
 
 
Component Volume (µl) 
PCR product 4 
Salt Solution 1 
TOPO vector 1 
 
Total 
 
6 
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 Transformation of Chemically Competent E. coli 
 
To transfer the cloned vectors into bacteria, 5µl of TOPO TA cloning reaction was added to 25 µl 
of One Shot® TOP10 Chemically Competent E. coli (Invitrogen, Paisley, UK) and gently mixed by 
stirring using the pipette tip. The mix was incubated on ice for 30 minutes, heat-shocked at 42ᵒC 
for 30 seconds, and immediately transferred back to ice. Then, to each vector-bacteria mix, 250 
µl of room temperature Super Optimal broth with Catabolite repression (SOC) medium was 
added, and the tubes were shaken at 225 rpm on a horizontal orbital shaker (Bibby Stuart 
Scientific, UK) at 37ᵒC for 1 hour. Following the incubation period, the transformed E. coli were 
spread in different seeding densities on pre-warmed agar petri dishes supplemented with 100 
µg/ml ampicillin. Plates were incubated overnight at 37ᵒC.  
 
 Colony Selection and Orientation Analysis 
 
Since the pEF6/V5-HIS-TOPO® structure includes selection markers that allow cells expressing 
the vector to grow in the presence of ampicillin and/or blasticidin (see figure 2.4), any E. coli 
colonies which grew on selective agar plates following the transformation procedure were 
deemed to be positive for the vector. However, to confirm this and to verify the correct 
orientation of the incorporated PCR product within the vector, further testing was needed. This 
was achieved by testing 10 colonies on each petri dish and using a primer combination of target 
specific forward primers and vector specific primers (T7F or BGHR) to run two PCR reactions for 
each colony. The two reaction mixes set up for each colony are outlined below: 
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Component Volume (µl) 
Reaction 1 
2X GoTaq® Green Master mix 8 
Vector specific T7F 1 
Target specific forward primer 1 
Nuclease-free water 6 
Reaction 2 
2X GoTaq® Green Master mix 8 
Vector specific BGHR 1 
Target specific forward primer 1 
Nuclease-free water 6 
 
 
Once the reaction mixes were combined, samples of colonies were added. To do so, 10 individual 
colonies were selected and labelled. Then, the reaction mixes were inoculated with the 
corresponding colony using a sterile pipette tip. The samples were placed in a thermal cycler 
and subjected to the PCR cycling conditions described above (see section 2.4.6), before being 
run electrophoretically on a 1% agarose gel. The diagram below demonstrates the results 
obtained when verifying colonies picked during the process of cloning Noggin, Follistatin and 
Gremlin overexpression vectors.  
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 Vector Amplification, Purification and Quantification 
 
Following the identification of colonies expressing vectors with correct insert orientation, single 
colonies were transferred aseptically from the petri dishes and each used to inoculate 10 ml of 
LB broth supplemented with 100 µg/ml ampicillin. The inoculated broths were then shaken 
overnight at 220 rpm while incubated at 37ᵒC, and the resultant recombinant E. coli cultures 
were pelleted at 5,000 rpm for 10 minutes, discarding the supernatant.  
 
Vector extraction was undertaken using the GenElute™ Plasmid MiniPrep Kit (Sigma, Poole, UK) 
based on the protocol provided. Once pelleted, the bacterial cultures were resuspended 
thoroughly with 200 µl of Resuspension Solution containing RNase A and transferred to 1.5 ml 
Eppendorf tubes. The resuspended cells were then lysed by adding 200 µl of Lysis Solution and 
immediately mixed by gentle inversions (6-8 times), all the while ensuring that the lysis reaction 
did not exceed 5 minutes so as to avoid permanent plasmid denaturation. Lysis of the E. coli 
Figure 2.5. Verifying the insert orientation of newly generated Noggin, Follistatin and 
Gremlin overexpression vectors. The (-) lane demonstrate PCR reactions carried out 
using Noggin, Follistatin or Gremlin forward primers and T7F, while reactions shown in 
the (+) lane were carried out using the same target specific forward primers and BGHR. 
Colonies that demonstrated bands in (-) lanes or in both (-) and (+) consisted of cells 
expressing vectors with inserts in the wrong orientation. Colonies showing bands in the 
(+) lanes only were selected for amplification and further use in experiments.  
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cultures using the highly alkaline Lysis Solution creates a white precipitate that consists of large 
chromosomal DNA, lipids and proteins. Therefore, to remove these cell debris, 350 µl of 
Neutralisation Solution was added to each tube and they were gently inverted 6 times before 
being centrifuged at 12,000 x g for 10 minutes. Meanwhile, the binding columns were prepared 
by inserting GenElute Miniprep Binding Columns in microfuge tubes, adding 500 µl of Column 
Preparation Solution to each column and centrifuging them at 12,000 x g for 1 minute. The flow-
through was discarded. The clear lysates obtained from the neutralisation step were then 
transferred to the binding columns and they centrifuged again at 12,000 x g for 1 minute, 
discarding the flow-through. To clean up the plasmid DNA from any residual salts and debris, 
700 µl of Wash Solution (containing ethanol) was added to the Miniprep binding columns, which 
were centrifuged at 12,000 x g for 1 minute before discarding the flow-through. Any excess 
ethanol from the Wash Solution was removed by centrifugation at 12,000 x g for 1 minute, and 
the binding columns were transferred to fresh collection tubes. Finally, plasmid DNA was eluted 
by centrifuging 50 µl of Elution Solution through the binding columns at 12,000 x g for 1 minute. 
The eluted vectors were quantified using a NanoPhotometer set to detect double-stranded DNA 
(µg/µl), using the Elution Solution as blank. The plasmid DNA was then immediately used or 
stored at -20°C until needed. 
 
 Establishment of Stably Transfected Mammalian Cell Lines 
 
Once the Noggin, Follistatin and Gremlin overexpression vectors were amplified, isolated and 
quantified, they were ready to be introduced into low passage DU145 cells by electroporation, 
as outlined in section 2.3.4. Empty pEF6/V5-HIS-TOPO® vectors were also transfected into cells 
using the same method. To ensure that the transfected cells established stable cell lines carrying 
these vectors, a selection process was implemented whereby the blasticidin resistance marker 
of pEF6/V5-HIS-TOPO® was exploited. Following transfection, surviving cells that were left to 
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adhere and recover overnight were subjected to an initial 7-day period of intense selection by 
incubating them in DMEM supplemented with 5 μg/ml of Blasticidin S (selection medium). After 
this initial selection period, cells were transferred to, grown in and continuously cultured in 
maintenance DMEM containing 0.5 μg/ml of Blasticidin S, therefore ensuring long-term 
transformation. 
 
All the recombinant cell lines were tested by RT-PCR and qPCR initially and routinely, as well as 
following cell revival to verify the efficacy and stability of the expression of the overexpression 
vectors. Once the cell lines had been verified to stably express the desired gene, they were then 
subjected to various in vitro functional assays. 
 
2.6 In vitro Functional Assays 
 
To assess the effect of BMP antagonists and the bone microenvironment on prostate cancer 
progression and metastasis, the generated cell lines, DU145 pEF, DU145 Noggin, DU145 FST344 
and DU145 Gremlin, were subjected to in vitro functional assays whilst incubated in either 
Blasticidin S maintenance DMEM or 50 µg/ml BME in maintenance DMEM. As such, the data 
presented were standardised against the pEF control in maintenance DMEM. With the aim to 
minimise the inherent effect of growth factors present in FBS on the cells, the FBS content of 
the maintenance DMEM used in these assays was reduced to 5%, with overnight incubation of 
the cells in this medium prior to experiments. The cell proliferation, invasion and Matrigel 
adhesion assays were all carried out using the Crystal Violet method, whereby cells were fixed 
and stained using the dye, and subsequently subjected to spectrophotometry to obtain relative 
cell density (Bonnekoh, Wevers et al. 1989).  
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 Cell Proliferation Assay 
 
The overexpression cell lines and the control cell line were trypsinised and cell concentrations 
(per millilitre) were determined as previously described in section 2.3.3. The cell suspensions 
were then pipetted into 12 replicate wells of three 96-well plates (NUNC, Greiner Bio-One, 
Stonehouse, UK) at a seeding density of 3 x 103
 
cells/100 μl and topped up with an additional 
100 μl of maintenance DMEM or BME treatment medium, making up the total volume in each 
well to 200 µl. Plates were subsequently incubated for 1-, 3- or 5-day periods at 37°C with 5% 
CO2, after which, following the appropriate incubation period, the medium was removed and 
cells were fixed in 4% formaldehyde (v/v) in BSS for 10 minutes. Adhered cells were then stained 
in 0.5% crystal violet (w/v) in distilled water for 10 minutes, and the excess stain was washed off 
with water before leaving the plates to dry at room temperature for 24 hours. To determine the 
cell density in each well, the dye staining fixed cells was solubilised in 200 μl of 10% acetic acid 
and the absorbance was measured at 540 nm using a plate reading spectrophotometer (BIO-
TEK, Elx800, UK). Growth rates were then calculated by comparing the absorbance 
Figure 2.6: Crystal Violet dilution curve. The diagram 
demonstrates the absorbance at 540nm against a known number 
of seeded cells. The dilution curve demonstrates that the method 
is quite a sensitive method, as long as cell numbers are not too low. 
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measurements obtained for the 3-day or 5-day incubation periods against the baseline 
absorbance taken at day 1. The equation below was used: 
 
𝐺𝑟𝑜𝑤𝑡ℎ 𝑟𝑎𝑡𝑒 =
(𝑑𝑎𝑦 3 𝑜𝑟 𝑑𝑎𝑦 5 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒) − 𝑑𝑎𝑦 1 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒
𝑑𝑎𝑦 1 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒
 
 
 
 Matrigel Invasion Assay 
 
The invasive capacity of the cell lines used in this study was determined using an in vitro Matrigel 
invasion assay (modified from (Albini, Iwamoto et al. 1987). This technique aims to mimic an in 
vivo environment, complete with basement membrane, through which the cancer cells are able 
to invade and migrate. To do so, the assay made use of Transwell inserts (Falcon, 24-well format, 
Greiner Bio-One, Stonehouse, UK) with a polycarbonate membrane and 8 μm pores, the latter 
being large to allow cells to migrate through. The surface of this membrane was then coated 
with a gelatinous protein mixture, Matrigel (BD Matrigel™ Basement Membrane Matrix; BD 
Biosciences, New Jersey, USA), to form the artificial basement membrane. The following method 
outlines how the experiment was set up.  
 
Duplicate Transwell inserts per cell line were aseptically placed into the wells of a 24-well plate 
(NUNC, Greiner Bio-One). Then, once the Matrigel had completely thawed on ice, a stock 
Matrigel solution of 0.5 mg/ml in serum-free DMEM was prepared. 100 µl aliquots of this 
Matrigel solution were pipetted into the inserts, bringing the total amount of Matrigel in each 
insert to 50 µg. The inserts were then placed in a drying oven for approximately 2 hours at 55°C 
to dry out the Matrigel, forming thin gel layers. The latter were rehydrated prior to use with 100 
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µl of serum-free medium for 40 minutes at room temperature. When the Matrigel layers were 
rehydrated, the serum-free medium was then aspirated and replaced with 100 µl of either 
Blasticidin S maintenance medium or BME treatment medium, to which 3 x 104 cells/100 μl of 
cell suspension was added. 3 x 104 cells of each cell line were also added to spare wells of the 
24-well plate so as to get a baseline measurement of cell growth during the 72-hour incubation 
period. 450 µl of maintenance medium was then pipetted into these spare wells as well as the 
wells containing the inserts in order to sustain any cells that migrated through the insert pores 
(see figure 2.6). The plates were incubated for 72 hours at 37°C, 5% CO2 and 95% humidity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blasticidin S  
maintenance medium  
Blasticidin S 
maintenance medium or 
BME treatment medium 
50 µg Matrigel 
Transwell insert 
with 8 µm pores 
Well in 24-well 
plate 
Invasive cells 
degrading Matrigel 
and migrating through 
insert pores 
Figure 2.7. Schematic illustration of the in vitro Matrigel invasion assay. Following 
an incubation period, during which the cells are allowed to invade through the 
Matrigel and pores of the inserts, the Matrigel is wiped away and cells adhered to 
the underside of the insert are fixed and stained using Crystal Violet and viewed 
under the microscope as seen by the representative image above. 
0.4 µm pore 
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After the 72-hour incubation period, all the media in the inserts and the wells were discarded. 
The Matrigel together with any non-invaded cells inside the inserts were thoroughly cleaned off 
using tissue paper and cotton swabs, and the inserts were replaced in their corresponding wells 
on the 24-well plate. Cells on the underside of the inserts were then fixed in 4% formaldehyde 
(v/v) in BSS for 10 minutes before being stained in 0.5% crystal violet solution (w/v) in distilled 
water, also for 10 minutes. Following staining, the excess crystal violet solution was washed off 
using water and the inserts were left to dry at room temperature for 24 hours. To measure the 
invasiveness of the cells tested, the crystal violet dye was completely solubilised in 650 µl of 10% 
acetic acid and 100 µl aliquots of the resultant solution was subsequently transferred from each 
well to 6 replicate wells of a 96-well plate. This was also carried out for wells set up for baseline 
cell growth measurement. Cell density was then measured by spectrophotometry at 540 nm. 
Invasion rates were calculated by normalising absorbance readings from the insert containing 
wells against the corresponding baseline cell growth measurements. This was done to eliminate 
any bias caused by differing growth rates.  
 
 Matrigel Adhesion Assay 
 
For each cell line tested, 12 replicate wells of a 96-well plate were coated with 5 µg of Matrigel 
in serum-free DMEM and left to dry for approximately 2 hours at 55°C in a drying oven. The 
dried gel layers were then rehydrated for 40 minutes at room temperature using 100 µl of 
serum-free DMEM, which was subsequently aspirated and replaced with 100 µl of maintenance 
DMEM or BME treatment medium. 2 x 104 cells/100 µl of cell suspension was seeded in each of 
the Matrigel-coated wells and the cells were allowed to adhere to the gel layer for 40 minutes 
at 37°C, 5% CO2. After the incubation time, any non-adhered cells were discarded together with 
the media by gently inverting the plate over a sink, and the wells were washed once with 200 µl 
of BSS, taking care not to wash away the Matrigel layer. The adherent cells were then fixed in 
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4% formaldehyde (v/v) in BSS for 10 minutes before being stained in 0.5% crystal violet solution 
(w/v) in distilled water for 10 minutes. The plate was left to dry for at least 24 hours at room 
temperature. To determine the density of cells adhered to the Matrigel, the crystal violet stain 
was solubilised in 10% acetic acid and the absorbance was measured by spectrophotometry at 
540 nm. To negate the effect of the Matrigel on the dell density measurements, wells without 
any cell suspension were also set up, fixed, stained and measured at 540 nm along with the 
experimental wells.  Readings from the experimental wells were then normalised against these 
Matrigel control wells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8: Representative image of Crystal Violet-stained cells attached to a 
Matrigel-coated well during an adhesion assay. The Matrigel adhesion assay was 
carried out as outlined in section 2.6.3, whereby cells were seeded at a density of 2 
x 10
4
 cells. Following 40 minutes of incubation time, nonadherent cells were washed 
away, leaving the adhered cells to be fixed and stained using Crystal Violet. 
Background readings from the stained Matrigel was negated by setting up wells with 
only Matrigel to be stained and then subtracting these readings from test readings. 
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 Migration Assay (Wound Assay) 
 
Cells were harvested in maintenance DMEM as previously described (section 2.3.3) and seeded 
into duplicate wells of a 24-well plate at a concentration of 6 x 105/500 µl cells for DU145pEF, 
DU145NOG and DU145GREM, and 1 x 106/500 µl cells for DU145FST344. They were then allowed to 
attach and reach confluency overnight at 37°C, 5% CO2. The following morning, 200 µl pipette 
tips were used to scratch the cell monolayers, creating a wound, and the medium was aspirated 
to remove any floating cells. 500 µl of maintenance DMEM or BME treatment medium was then 
pipetted into the wells and the plate was placed at 37°C, 5% CO2 for 15 minutes to allow the cells 
to settle. To image the cell migration across the wound, the 24-plate was then placed in the 
onstage incubator of an EVOS™ FL Auto Cell Imaging System (ThermoFisher Scientific, 
Massachusetts, USA) set to image the wound each hour for 20 hours at 37°C, 5% CO2. Images 
were analysed using ImageJ Software (National Institutes of Health, Bethesda, Maryland, USA). 
The migration rate was calculated using the following equation: 
 
𝑀𝑖𝑔𝑟𝑎𝑡𝑖𝑜𝑛 𝑟𝑎𝑡𝑒 =
(𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑎𝑡 𝑇0 − 𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑎𝑡 𝑇𝑡)
𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑎𝑡 𝑇0
 
 
 
 ECIS 
 
The Electric Cell-substrate Impedance Sensing® Zθ instrument (ECIS® Zθ; Applied Biophysics, 
Troy, New York, USA) offers a real-time, in vitro approach to monitoring and quantifying the 
ability of cells to attach to a surface and achieve a spread morphology. As part of this method, 
cells are seeded and grown in special culture dishes equipped with small gold-film electrodes 
across which a small constant alternating current is applied. As cells adhere and spread on these 
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electrodes, their insulating membranes obstruct and constrain the current flow, causing a 
change in impedance. This change can subsequently be used to infer morphological information 
on the attached cells. In fact, the two parameters, resistance and capacitance, derived from 
impedance readings of cells respectively provide information on the quality and function of the 
cell barrier, and electrode cell coverage. Moreover, ECIS® offers the possibility to measure the 
impedance over a range of frequencies, enabling the study of morphological and functional cell 
properties based on cell-cell and cell-substrate interactions (Szulcek, Bogaard et al. 2014). The 
experiment was set up as follows. 
                                                    
A 96-channel array holder was connected to an ECIS Zθ® controller and pre-warmed at 37°C, 5% 
CO2 and 95% humidity in an incubator. Meanwhile, 200μl of serum-free DMEM was aseptically 
pipetted into each well of a 96-well array (Applied Biophysics), which was subsequently secured 
on the array holder. A connection check and stabilisation were then performed using the Applied 
BioPhysics-ECIS Software V 1.2.135 (Applied Biophysics). Once this was complete, the serum-
free DMEM was aspirated and 12 replicate wells per cell line were seeded with 6 x 104 cells/100 
µl for DU145pEF, DU145NOG and DU145GREM, and 8 x 104 cells/100 µl for DU145FST344. The wells 
were then supplemented with 100 µl of either maintenance DMEM or BME treatment medium.  
The 96-well array was replaced on the array holder and the software was configured to measure 
the resistance to the current flow at 4,000 Hz. Data was normalised using the resistance readings 
from the first time-point.  
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2.7 Database Research 
 
Analysis of Genomic Expression Omnibus (GEO) datasets was performed using the GEO2R 
function of Pubmed-National Centre for Biotechnology Information (NCBI). The terms 
“prostate”, “cancer”, “osteoblastic” and “osteolytic” were used as search terms. GEO data from 
three previous studies was used. Heatmaps were generated using RStudio (see readings and bar 
graphs in appendix). 
 
The first dataset (GSE36139) was obtained from the Cancer Cell Line Encyclopaedia (CCLE). The 
latter was generated from a large-scale genomic study of 947 cell lines, complete with 
pharmacological profiling of 24 compounds across approximately 500 of these cell lines. The 
CCLE encompasses cell lines relating to 36 tumour types, and mutational information was 
obtained by Next-Generation Sequencing (NGS) of 1,600 genes and by mass spectrometric 
genotyping, interrogating 492 mutations in 33 known oncogenes and tumour suppressors 
(Barretina, Caponigro et al. 2012). By assembling the CCLE, Barretina et al have provided us with 
the ability to obtain a comprehensive view of BMP signalling across a variety prostate cancer cell 
lines, against which we can compare or confirm our own findings. 
 
The second dataset (GSE44143) comprised of microarray analyses of LNCaP-primary human 
osteoblast co-cultures performed by Sieh et (2014). This study aimed to investigate the 
pathophysiology of bone metastasis by establishing a 3D indirect co-culture model and assessing 
the paracrine interactions between prostate cancer cells and human primary osteoblasts (hOBs). 
This was achieved by embedding LNCaP cells within polyethylene glycol hydrogels and co-
culturing them with hOBs grown on medical grade polycaprolactone-tricalcium phosphate 
(mPCL-TCP) scaffolds to form a tissue engineered bone construct (TEB). Microarray gene 
expression analysis was then performed to assay differences between LNCaP monocultures, 
hOB monocultures and LNCaP-hOB co-cultures. They accomplished this by hybridising extracted 
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RNA to a custom Agilent 4x180K oligo array assay (Agilent Technologies, Santa Clara, California) 
which incorporated the Agilent human gene expression probes with additional probes to detect 
protein-coding and non-coding RNAs. As a result of this study, Sieh et al have presented a novel 
3D in vitro model that allows for the study of not only cellular, but also molecular changes 
occurring in prostate cancer cells and osteoblasts that arise from their cross-talk, the latter being 
relevant to the metastatic colonisation of the bone. As such, this presents an important of data 
to incorporate within the present study. 
 
 
 
The third dataset (GSE41619) was obtained from Larson et al (2013). As part of this study, the 
gene expression profiles of 14 prostate cancer metastases from 11 patients were assessed by 
microarray analysis, with 7 of the samples identified as highly osteoblastic and the remaining 7 
as highly osteolytic. These frozen bone core samples were then analysed using Agilent 44K whole 
human genome expression oligonucleotide microarrays (Agilent Technologies, Santa Clara, 
California) and pooled equal amounts of RNA isolated from prostate cancer cells, PC-3, DU145, 
LNCaP and CWR22, were used as a reference standard RNA. This data therefore provides the 
opportunity to dissect and examine relative changes in gene expression between osteolytic and 
osteoblastic lesions, enabling the identification of key genes in each type of lesion. 
 
2.8 Statistical analysis 
 
Statistical analysis was performed using GraphPad Prism (GraphPad Software, California, USA). 
Each experimental protocol was performed at least three times (unless stated otherwise) and 
data obtained were presented as the mean of the repeats with standard error of the mean 
(SEM). Unpaired t-test with Welch’s correction, unpaired t-test using the Holm-Sidak method, 
one-way ANOVA and two-way ANOVA were performed to test for statistical significance, with a 
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P-value of ≤ 0.05 considered to be statistically significant. Asterisk (*) notations were used to 
signify significances: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 and **** p ≤ 0.0001.
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3.1 Introduction 
 
Advanced-stage prostate cancer is often associated with skeletal complications related to the 
spread of this disease to its preferred metastatic site, the bone. In fact, approximately 90% of 
patients that die as a result of prostate cancer have bone metastases (Bubendorf, Schöpfer et 
al. 2000). Typically, when the disease reaches this stage, a mixed osteolytic/osteoblastic bone 
response can be seen in the same patient at different metastatic sites (Roudier, Morrissey et al. 
2008), although the interactions between the prostate cancer cells and the bone matrix 
predominantly yield an osteoblastic response. While the pathological events that take place 
during prostate cancer metastasis are well established, there is only a limited understanding of 
the exact molecular events involved. So far, studies have implicated a few protein families in this 
process (Coleman 2006), the BMP family being one of them.  
 
As previously discussed, there are over 20 members of the BMP family which exert their effects 
through a heteromeric complex of two types of serine threonine kinase transmembrane 
receptors, termed type-I and type-II (Bragdon, Moseychuk et al. 2011). The extracellular BMP 
homo- or hetero-dimers utilise three type-I receptors, BMPRIA, BMPRIB and ActRIA, and three 
type-II receptors, BMPRII, ActRIIA and ActRIIB. When the BMP ligands bind to the BMPRs, they 
initiate the Smad-dependent or the Smad-independent pathway to subsequently modulate the 
transcription of target genes affecting key cellular processes like cell survival, apoptosis, 
migration and differentiation (see figure 1.7 for schematic of signalling pathways). The Smad-
dependent pathway is initiated when the BMP dimer binds to a preformed complex of 
homodimeric type-I and type-II BMPRs, resulting in the phosphorylation of a regulatory domain 
within the type-I receptor, known as the GS box. The catalytically activate type-I receptor then 
recruits and phosphorylates BMP-specific intracellular members of the Smad family, R-Smads 1, 
5 or 8/9, on their conserved SSXS motif. Once activated, the R-Smads dissociate from the type-I 
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receptor, presumably due to a change in conformation, and form an oligomeric complex with 
another R-Smads and a Co-Smad (Smad4), which, with the help of nuclear import and export 
factors, transits into the nucleus to regulate the transcription of target genes. In addition to this 
type of pathway, BMP signalling may also exert its effects by completely bypassing the use of 
Smads via a pathway known as the Smad-independent pathway. For this pathway to be 
triggered, the BMP dimer needs to interact with just one of the BMPR dimers, triggering the 
recruitment of a second BMPR dimer for the formation of the heteromeric BMPR complex. This 
pathway then typically proceeds through one or more MAPK signalling pathways (ERK, p38 or 
JNK) to indirectly bring about changes in target gene transcription.  
 
Since BMPs are most commonly known for their inherent osteoinductive capacities, many have 
hypothesised their involvement in osteoblastic lesion formation arising in advanced prostate 
cancer. This was a theory that was first brought forward by Bentley and colleagues in the early 
90s, who, by screening for the mRNA expression of BMPs, demonstrated the presence of BMPs 
1-6 in prostatic adenocarcinoma (Bentley, Hamdy et al. 1992). As part of this study, they also 
compared the expression levels of these BMPs between patients with skeletal metastases and 
those without, reporting BMP-6 to be selectively expressed in bone-scan positive metastatic 
disease. Henceforward, the expression of BMPs has been examined in the different stages of 
prostate cancer to assess their roles in this disease. For example, Bobinac et al (2005) reported 
the expression of BMP-2, -4, -5, -6 and -7 in normal prostate tissue, while prostate carcinoma 
samples predominantly expressed BMP-2 and -4, with significantly decreased levels of BMP-7. 
Spanjol et al (2010) reported mostly similar findings, demonstrating an increased expression of 
BMP-6 and decreased levels of BMP-7 in localised prostate cancers, and bone metastases 
expressing high levels of BMP-2, -4, -6 and -7. Contrary to Bentley et al however, Spanjol and 
colleagues reported decreased expression levels of BMP-2/4, -6 and -7 in metastatic prostate 
cancers. Thus, despite the slightly conflicting data from these expression studies, the evidence 
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gathered has indicated BMP-2, -4, -6, and -7 to be potential players in the pathophysiology 
behind skeletal metastases produced by prostate cancer.  
 
Physiologically, BMPs constitute a pivotal group of morphogenetic signals that orchestrate 
nearly all of tissue architecture throughout the vertebrate body (Hogan 1996). As such, BMP 
activity is tightly regulated at different levels of signalling, from the intracellular phosphatases 
and I-Smads, to the extracellular pseudoreceptor BAMBI, and BMP antagonists. Interestingly, 
BMP antagonists have been shown to be particularly integral to BMP function, not only due to 
their canonical inhibitory capacities but also as agonists when present in low concentrations 
(Walsh, Godson et al. 2010). This dual feedback between BMPs and their antagonists is mainly 
demonstrated in developmental studies. For instance, while it is well established that BMPs, 
BMP-2, BMP-4 and BMP-7 more specifically, are critical in limb-bud development, their activity 
is carefully modulated by their antagonists, with disruptions or alterations in this ligand-
antagonist balance leading to congenital malformations (Walsh, Godson et al. 2010, Pignatti, 
Zeller et al. 2014). Furthermore, BMP antagonist action has also been shown to be crucial in 
bone formation, with BMP exposure inducing the production of such antagonists as Noggin, 
Follistatin and Gremlin by osteoblasts, thus binding and sequestering BMP action ultimately 
enabling proper skeletal development (Gazzerro, Gangji et al. 1998, Pereira, Economides et al. 
2000, Abe, Abe et al. 2004). For example, studies on Noggin null mice have reported a failure to 
initiate joint formation in test mice, as well as excessive cartilage amongst other skeletal 
anomalies, which were likely brought on due to excessive BMP action (Tylzanowski, Mebis et al. 
2006).  
 
Given the information gathered above, we hypothesise that since the feedback between BMPs 
and BMP antagonists is so crucial in physiological conditions that perturbations in this feedback 
could also participate in the progression of prostate cancer and more particularly, the spread of 
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this disease to the bone. Indeed, due to the impact BMPs and their antagonists have on skeletal 
phenotype, it is possible that alterations in their relationship may have a role in the type of 
lesions produced during prostate cancer related bone metastasis. The study presented in this 
chapter aims to investigate this hypothesis by assessing the expression profiles BMP and their 
antagonists in prostate cancer cell lines associated with different bone lesion phenotypes. By 
also evaluating the expression profiles of related receptors and some of the intermediate 
signalling molecules, we also hope to elucidate parts of BMP signalling that could be in play. 
 
3.2 Materials and Methods 
 
 Cell lines and Treatments 
 
A total of four prostate cancer cell lines were used in this study. PC-3 WT, DU145 WT and VCaP 
WT cells were maintained in DMEM with 10% FBS and antibiotics. LNCaP WT cells were 
maintained in RPMI with 10% FBS and antibiotics. All cell lines were kept at 37°C, 5% CO2 and 
95% humidity. To stabilise BMP signalling, cells were pre-treated with 5% FBS DMEM overnight.  
 
 RNA isolation and cDNA synthesis 
 
RNA was extracted from transfected cells using the TRI reagent® kit (Sigma-Aldrich, Poole, UK), 
and synthesised into cDNA by reverse transcription using the GoScript™ Reverse Transcription 
System (Promega, Southampton, UK), as respectively described in sections 2.4.2 and 2.4.3.  
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 RT-PCR  
 
RT-PCR was carried out using the GoTaq® Green Master Mix (Promega, Southampton, UK) under 
the following cycling conditions: initial denaturation of 5 minutes at 94°C, 32 cycles of 
denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds and elongation at 72°C 
for 1.5 minutes, before a final elongation step at 72°C for 10 minutes. The PCR products were 
then run on a 1% agarose gel and visualised using SYBR safe DNA gel stain (Invitrogen, Paisley, 
UK).  
 
 RNA-Seq 
 
For this study, targeted-sequencing of low passage PC-3 WT and VCaP WT was undertaken. Cells 
were incubated with fresh 5% FBS DMEM for 3 hours 37°C, 5% CO2. Following the incubation 
period, cells were collected in TRI Reagent® and mRNA extraction of the samples was carried 
out. 10 ng of total RNA extracted from the prostate cancer cell lines was subsequently used for 
RNA sequencing. Heatmaps were generated using Microsoft Excel. 
 
 GEO Database  
 
GEO datasets from a study by Barretina et al (2012), who characterised a total of 947 cancer cell 
lines at the genomic level, was accessed on NCBI using the accession number GSE36139. 
Expression levels of genes of interest were extracted and heatmaps were generated using 
RStudio. 
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3.3 Results 
 
 Expression of BMPs in Prostate Cancer Cell Lines  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C. 
Figure 3.1: Expression of BMPs in Prostate Cancer Cell Lines. A. Representative RT-PCR images 
demonstrate the expression of BMP-7, BMP-2, BMP-4 and BMP-6 in prostate cancer lines used 
in our laboratory. B. The heatmap illustrates the expression of BMPs 1 – 15 in PC-3 and VCaP, 
as shown by Ion Ampliseq™ RNA-Seq of these cell lines. C. The heatmap illustrates the 
expression of BMPs 1 – 15 in the cancer cell lines PC-3, DU145, LNCaP, VCaP and MDA Pca 2b. 
Data was analysed from the Cancer Cell Line Encyclopaedia GEO database (GSE36139). 
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The expression of different BMPs was assessed in different prostate cancer cell lines by RT-PCR 
and RNA-Seq, and results were compared with GEO datasets from the CCLE (GSE36139). The RT-
PCR results (see figure 3.1A) demonstrated that cell lines PC-3 and DU145 appeared to express 
BMP-4 mostly, with DU145 also expressing slight levels of BMP-7 and BMP-6. VCaP cells 
expressed all of the BMPs tested, with the exception of BMP-6. On the other hand, LNCaP cells 
did not appear to express any of the BMPs. The findings obtained for PC-3 and VCaP cells were 
mostly replicated in the RNA-Seq results (figure 3.1B), although they did show VCaP cells to 
express BMP-6 more intensely than BMP-4, which seems to disagree with the RT-PCR results. 
Since RNA-Seq is a high throughput method, we were also able to assess the expression of other 
BMPs, showing that both cell lines expressed BMP-1, BMP-8A, BMP-8B and BMP-11, while BMP-
3 was expressed only by PC-3 and BMP-5 was only expressed by VCaP. None of the other BMPs 
were expressed by the two cell lines. According to the CCLE datasets (see figure 3.1C), PC-3 
expressed higher levels of BMP-4 and BMP-13, and slight levels of BMP-2, BMP-7 and BMP-14. 
DU145 cells expressed slight levels of most BMPs, with the exception of BMP-1, -2, -3, -8A, -8B 
and -15. VCaP cells expressed higher levels of BMP-13, and slight levels of BMP-2, -3, -7, - 10, -
11 and -14. MDA PCa 2b cells only appeared to express BMP-13. 
 
 Expression of BMP antagonists in Prostate Cancer Cell Lines 
 
As seen in figure 3.2A, RT-PCR analyses demonstrated that BMP antagonists were not very well 
expressed in the different prostate cancer cell lines tested. In fact, out of the cell lines tested, 
PC-3 expressed Noggin and Gremlin, and VCaP expressed Gremlin only. In contrast, RNA-Seq 
results (figure 3.2B) demonstrated that neither PC-3 nor VCaP expressed Noggin. They also 
showed high expression of FST and FSTL1 in PC-3, while VCaP showed high levels of FSTL1 and 
low levels of FSTL3 and FSTL4. Data from the CCLE (figure 3.2C) seem to corroborate some of 
the RT-PCR findings. For example, PC-3 expressed higher levels of Noggin and Grem1 and Grem2, 
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as well as FSTL1. Contrary to our data, DU145 showed expression of antagonists Noggin, FST, 
FSTL3, FSTL4, Grem1 and Grem2, although at lower levels. LNCaP showed low levels of Grem2 
only, while VCaP only expressed FSTL5. MDA PCa 2b cells expressed none of the antagonists.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C. 
B. 
Figure 3.2: Expression of BMP antagonists in Prostate Cancer Cell Lines. A. Representative 
RT-PCR images demonstrate the expression of Noggin, FST344, FST317 and Gremlin in 
prostate cancer lines used in our laboratory. B. The heatmap illustrates the expression of 
Noggin, FST, FSTL1, FSTL3, FSTL4, FSTL5, GREM1 and GREM2 in PC-3 and VCaP, as shown by 
Ion Ampliseq™ RNA-Seq of these cell lines. C. The heatmap illustrates the expression of 
Noggin, FST, FSTL1, FSTL3, FSTL4, FSTL5, GREM1 and GREM2 in the cancer cell lines PC-3, 
DU145, LNCaP, VCaP and MDA PCa 2b. Data was obtained from the CCLE (GSE36139). 
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 Expression of BMPRs in Prostate Cancer Cell Lines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RT-PCR analyses of the different prostate cancer cell lines in figure 3.3A demonstrated that most 
of the BMPRs were well expressed, with the exception of Act-RIIB, which seemed to be 
expressed in LNCaP cells only. RNA-Seq showed some conflicting results (figure 3.3B), with PC-3 
showing low levels of BMPR-IB and highest levels of ActR-II. VCaP showed expression of all 
BMPRs tested, with ActR-II being expressed most strongly, again. The CCLE datasets showed that 
PC-3 did not seem to express any of the BMPRs (figure 3.3C). According to their data, DU145 
appeared to express low levels of BMPR-IA, ActR-IA and ActR-II only and LNCaP appeared 
C. 
Figure 3.3: Expression of BMPRs in Prostate Cancer Cell Lines. A. Representative RT-PCR images 
demonstrate the expression of BMPR-IA, BMPR-IB, ActR-IA in prostate cancer lines used in our 
laboratory. B. The heatmap illustrates the expression of BMPR-IA, BMPR-IB, ActR-IA, BMPR-II and 
ActR-II in PC-3 and VCaP, as shown by Ion Ampliseq™ RNA-Seq of these cell lines. C. The heatmap 
illustrates the expression of BMPR-IA, BMPR-IB, ActR-IA, BMPR-II and ActR-II in the cancer cell 
lines PC-3, DU145, LNCaP, VCaP and MDA Pca 2b. Data was obtained from the CCLE (GSE36139). 
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expressed low levels of BMPR-IB and ActR-Ia, and higher levels of BMPR-II. MDA PCa 2b 
appeared to not express any of the BMPRs tested, while VCaP only seemed to express slight 
levels of ActR-II.  
 
 Expression of Smads in Prostate Cancer Cell Lines 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RT-PCR analyses in figure 3.4A demonstrated that most of the Smads were well expressed in the 
different cell lines. All the cell lines expressed most Smads, except Smad7. Only DU145 seemed 
to express low levels of Smad4 and only VCaP did not seem to express Smad6. Again, RNA-Seq 
shown in figure 3.4B seemed to show slightly conflicting data. For example, contrary to the RT-
PCR results, RNA-Seq showed that PC-3 expressed Smad4 and very high levels of Smad3, and 
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Figure 3.4: Expression of Smads in Prostate Cancer Cell Lines. A. Representative RT-PCR images 
demonstrate the expression of Smads 1 – 9 in prostate cancer lines used in our laboratory. B. The 
heatmap illustrates the expression of Smads 1 – 9 in PC-3 and VCaP, as shown by Ion Ampliseq™ 
RNA-Seq of these cell lines. C. The heatmap illustrates the expression of Smads 1 – 9 in the cancer 
cell lines PC-3, DU145, LNCaP, VCaP and MDA Pca 2b. Data was obtained from the CCLE (GSE36139). 
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VCaP expressed high levels of Smad4 and moderate levels Smad7. Data acquired from the CCLE 
(figure 3.4C) demonstrated that PC-3 showed high levels of Smad1 and low levels of all the other 
Smads. Their data also showed that DU145 expressed Smad1, 3, 5 and 6, and that LNCaP 
expressed low levels of Smad 2 – 7. VCaP, on the other hand, only expressed only Smad3 and 6, 
while MDA PCa 2b showed no expression of any Smads.  
 
3.4 Discussion 
 
Despite the wealth of studies documenting the potential roles of BMPs during prostate cancer, 
the exact underpinnings of their effects are as of yet unknown. The study presented in this 
chapter was aimed to assess the role of the BMP/BMP antagonist relationship in prostate cancer 
by examining their expression profiles in prostate cancer cell lines representing different 
characteristics of the disease. With this aim, a range of cell lines, namely PC-3, DU145, LNCaP, 
VCaP and MDA PCa 2b, were selected for comparison. These were isolated from different sites: 
PC-3 and MDA PCa 2b were both isolated and established from bone metastases, DU145 was 
isolated from brain metastasis, LNCaP from lymph node metastasis, and VCaP from vertebral 
metastasis (Stone, Mickey et al. 1978, Kaighn, Narayan et al. 1979, Horoszewicz, Leong et al. 
1983, Navone, Olive et al. 1997, Korenchuk, Lehr et al. 2001). In order to simulate the 
heterogeneity of prostate cancer, these cell lines comprise of different features, for example, 
hormone-sensitivity, with PC-3, DU145 and VCaP being androgen-insensitive, and LNCaP and 
MDA PCa 2b being androgen-sensitive (Stone, Mickey et al. 1978, Kaighn, Narayan et al. 1979, 
Horoszewicz, Leong et al. 1983, Navone, Olive et al. 1997, Korenchuk, Lehr et al. 2001). The cell 
lines also differ in the types of bone lesion phenotypes they are associated with, with PC-3 and 
DU145 causing osteolytic lesions, VCaP and MDA PCa 2b causing osteoblastic lesions and LNCaP 
causing mixed osteolytic/osteoblastic lesions (Nemeth, Harb et al. 1999, Yang, Fizazi et al. 2001, 
Kirschenbaum, Liu et al. 2011). 
106 
 
A couple of techniques were used to evaluate the BMP signalling profiles in the different cell 
lines, namely RT-PCR and RNA-Seq. Expression datasets were also obtained from a large-scale 
genomic project, the CCLE, for further comparison with our findings. Overall, slight variations in 
expression levels were observed between the results obtained from the different methods for 
most of the molecules assessed. In fact, when looking at previous BMP research, fluctuations 
like these seem to be common between different studies (see table A1). For example, while 
results by Miyazaki et al (2004) were consistent with the present findings in showing no visible 
expression of BMP-7 in PC-3, a previous study undertaken in our laboratory (Ye, Lewis-Russell et 
al. 2007) showed moderate expression of this BMP. There are a number of factors that could 
contribute to these variations, first being the nature of BMPs themselves. In fact, as growth 
factors, BMPs could already be present in the FBS supplemented in the growth medium of the 
different cell lines. Bentley et al (1992) investigated this by evaluating the expression of BMPs 
1-6 in PC-3 and DU145 in the presence or absence of serum and found no difference. However, 
other studies have stated differences cell behaviour following treatment with certain BMPs, 
such as BMP-7, in the presence or absence of serum (Miyazaki, Watabe et al. 2004, Alarmo, 
Pärssinen et al. 2009). As such, a routine practise in the study of BMPs is to negate this effect by 
undertaking their experiments in serum-starvation. Contrary to this, we have opted to limit FBS 
action by reducing serum levels in our culture medium from 10% to 5% as a compromise 
between in vitro testing of BMP action and a more accurate simulation of the in vivo 
environment of cancer cells. 
 
To begin with, we examined the mRNA expression of different BMPs in the prostate cancer cell 
lines PC-3, DU145, LNCaP and VCaP by RT-PCR. Since one of the aims of this study is to evaluate 
prostate cancer-related bone metastasis as a result of BMP signalling, we particularly focussed 
on the expression of BMP-2, -4, -6 and -7, which have been shown to be of potential importance 
due to their aberrant expression in prostate cancer bone metastases. According to our RT-PCR, 
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PC-3 cells only expressed BMP-4, while DU145 cells seemed to express low levels of BMP-7 and 
high levels of BMP-4. On the other hand, VCaP cells appeared to express all of the BMPs tested, 
except BMP-6, while LNCaP did not express discernible levels of any BMPs (figure 3.1A). To 
confirm these findings, we then performed RNA-Seq on two representative cell lines associated 
with either the osteoblastic or osteolytic bone lesion phenotypes – these were PC-3 and VCaP. 
As a result of comparing findings from both assays, however, some discrepancies were noted. 
For instance, while the RNA-Seq data demonstrated the expression of BMP-2 in both cell lines, 
at levels that are not too dissimilar, the RT-PCR results showed this BMP to be expressed in VCaP 
cells alone. Furthermore, although the RNA-Seq data showed the expression of BMP-6 in both 
the cell lines tested, albeit at relatively low levels in the osteolytic PC-3, the RT-PCR analyses 
demonstrated no expression of the BMP in either cell lines (see figure 3.1). Therefore, this may 
indicate that, even though both methods aim to assess gene expression levels of target genes, 
comparing their results poses some limitations. In fact, RT-PCR represents an end-point analysis 
of cDNA quantification, where relative cDNA levels are assessed by the intensity of bands, which 
may be manipulated through changing the number of cycles of the protocol used. In contrast, 
RNA-Seq allows for more absolute expression values when aligned to a reference sequence. As 
such, an absolute corroboration between the two methods would be difficult. 
 
Further mRNA expression analysis was also performed using the CCLE datasets. These 
demonstrated that PC-3 slightly overexpressed BMP-2 and BMP-7, while DU145 slightly 
overexpressed BMP-4, BMP-6 and BMP-7. Like with RT-PCR and RNA-Seq, these datasets 
demonstrated that BMP levels in LNCaP cells remained unchanged, while VCaP cells slightly 
overexpressed BMP-2 and BMP-7. Furthermore, through this data, we were also able to evaluate 
the BMP expression profile in another osteoblastic prostate cancer cell line, MDA PCa 2b, which 
demonstrated expression unchanged levels of BMP-2, -4, -6 and -7. Similarly to comparing RT-
PCR and RNA-Seq results, using data from other laboratories in the form of GEO datasets also 
108 
 
carries its limitations. Indeed, a number variations could easily be incurred when linking data 
with our own, especially relating to cancer cell lines, due to a number of factors. These could be 
differences in cell culturing techniques, buffers, passage numbers of cells tested, amongst 
others.  
 
Cytokine expression profiles between osteolytic and osteoblastic prostate cancer cell lines have 
already been investigated in a previous study by Lee et al (2003). As part of their study, they 
examined the expression of BMP-2, -4 and -6 between tumours caused by PC-3 and LAPC-9 and 
found that LAPC-9 tumours expressed all of the BMPs, while those produced by PC-3 expressed 
only BMP-4. This is more or less consistent with our current laboratory findings. Their findings 
also demonstrated that LAPC-9 cells caused purely osteoblastic lesions when injected in the 
tibias of severe combined immunodeficient (SCID) mice. From this, they supposed that this was 
in part due to the osteoinductive nature of BMPs.  
 
Since we hypothesise that the interplay between the BMPs and their antagonists may have a 
role in the spread of prostate cancer to the bone, it is also possible that this interplay may 
participate in determining the resulting bone lesion phenotype. As such, we also examined the 
expression of the BMP antagonists Noggin, FST and Gremlin isoforms, GREM1 and GREM2 in the 
different prostate cancer cell lines. A general overview of the results demonstrates that the 
osteolytic cell lines express varying levels of the BMP antagonists tested, with Noggin and FST 
being predominantly expressed by these cell lines. Meanwhile, the only BMP antagonist that 
appears to be expressed by the osteoblastic cell lines is Gremlin, with LNCaP expressing GREM2 
and VCaP expressing GREM1. This could therefore indicate a novel role for Gremlin in the 
formation of osteoblastic bone lesions. Indeed, a study of GREM1 and Noggin expression in a 
multitude of normal and cancer samples carried out by Laurila et al (2013) demonstrated that 
although not widely expressed in the tissues tested, GREM1 was weakly to moderately 
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expressed in prostate cancer tissues. They also demonstrated that this antagonist was 
moderately expressed in the bone marrow. With Pereira et al (2000) having previously described 
a feedback between BMP-2 and Gremlin on osteoblast function, this further hints at the 
potential importance of the BMP-Gremlin interplay in osteoblastic lesion formation.  
 
Although the expression profiles of Noggin and FST were not completely conclusive from our 
findings, contrary to Gremlin, these two antagonists have already been implicated in the 
prostate cancer process. As such, we cannot as of yet completely dismiss the possibility of their 
involvement in bone metastasis. For instance, a potential of Noggin has been highlighted in 
osteolytic lesions in particular, with studies demonstrating the inhibitory role of Noggin on BMP-
2, BMP-4 and BMP-6 mediated cellular proliferation, invasion and migration of osteolytic 
prostate cancer cells, PC-3 and DU145 (Haudenschild, Palmer et al. 2004, Feeley, Krenek et al. 
2006). Furthermore, on top of also demonstrating the predominant expression of Noggin in 
osteolytic prostate cancer cell lines, Schwaninger et al (2007) have demonstrated the 
abolishment of the osteoinductive abilities of prostate cancer cell line, C4-2B, following the 
forced expression of this antagonist. Previous research focusing on FST has also hinted at its 
importance in prostate cancer bone metastasis, with the most confounding evidence showing 
the correlation between FST serum expression with the presence with bone metastases 
(Tumminello, Badalamenti et al. 2010).  
 
The work presented in this chapter demonstrates the first step in elucidating the potential role 
of the interplay between BMPs and their antagonists in the formation of osteolytic and 
osteoblastic prostate cancer bone lesions. From the present findings we were able to assess the 
differential expression of these cytokines and thus give us an indication of their importance in 
the bone metastatic process. Additionally, the cytokine profiles obtained provide the baseline 
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expression of BMP signalling components, which would enable us to assess the underlying 
signalling pathways in play in subsequent experimentation.  
 
 
 
111 
 
 
  
 
 
 
 
 
 
 
 
  
 
The Influence of the Bone 
Environment on the Expression of 
BMPs and BMP antagonists in 
Prostate Cancer Cell Lines 
 
 
 
 
 
112 
 
4.1 Introduction 
 
The bone is a dynamic tissue that is constantly being remodelled through a balance of bone 
formation and bone resorption, a process that is regulated by a complex system of endocrine 
and paracrine growth factors. When cancer spreads to the bone, this balance is disrupted and 
skewed towards either end of the bone remodelling spectrum, creating osteolytic or 
osteoblastic bone lesions. Although the two characteristic features of metastatic prostate 
cancer, namely tropism for the bone and the predominant osteoblastic phenotype of bone 
lesions formed, were described a long time ago, the mechanisms behind how the lesions are 
formed remain largely unknown. However, it is believed that prostate cancer cells are able to 
establish and thrive in the skeleton, and eventually form bone metastases, due to the cross-talk 
between the cancer cells themselves and the bone microenvironment.  
 
Under normal physiological conditions, the bone is maintained based on the synchronisation of 
the bone producing cells, the osteoblasts, the calcified matrix resorbing cells, the osteoclasts, 
and the osteocytes. However, when tumour cells finally reach the bone, they disrupt this 
synchronisation and divert the bone environment to support their survival and to help their 
establishment in this new milieu. To do so, they employ a process called the “vicious cycle” 
(Mundy 2002). This concept brought forward by Mundy (2002) expands on Paget’s “seed and 
soil” theory to depict how osteolytic bone lesions may develop. According to this theory, with 
the bone being a highly restrictive and protective environment, tumour cells established in the 
bone must modify their surroundings for survival. As such, they aim to acquire “bone cell-like” 
properties by expressing a cytokine profile that would normally be expressed by resident cells 
of the bone in what is known as “osteomimicry” (Koeneman, Yeung et al. 1999). As a result, this 
enables the tumour cells to firstly, avoid detection by the immune system and secondly, 
establish colonies within the bone microenvironment. Indeed, during the osteolytic vicious 
cycle, tumour cells produce factors like the PTHrP, which, by stimulating the osteoblastic 
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production of RANKL, indirectly activates osteoclastogenesis, subsequently causing bone 
resorption (Mundy 2002). This in turn releases and/or activates other factors, including TGF-β, 
IGF, PDGF and BMP family members, from the bone that stimulate tumour cell proliferation, 
further increasing PTHrP levels and thus setting in motion the vicious cycle  (Mundy 2002).  
 
Although not originally described by Mundy, an osteoblastic vicious cycle also exists between 
tumour cells and bone cells. In fact, the osteolytic vicious cycle still occurs during osteoblastic 
lesion formation, though, on top of this, cancer cells within the bone also produce factors to 
stimulate osteoblast differentiation whilst simultaneously inhibiting osteoclasts (Ottewell 2016). 
Indeed, a number of factors produced by cancer cells are known to directly stimulate osteoblast 
activity. These are FGFs, TGF-β1 and TGF-β2, IGF-1 and IGF-2, PDGFs, WNT and BMPs (Mundy 
2002). However, among these different cytokines, BMPs are uniquely potent: not only do they 
induce the commitment of bone marrow MSCs, towards the osteoblastic lineage, but they also 
stimulate the differentiation of osteoprogenitors derived from MSCs into mature osteoblasts 
(Gazzerro and Canalis 2006). Indeed, when implanted ectopically, BMPs can initiate the 
complete bone formation cascade, including the stimulation of MSC migration and of osteoblast 
differentiation, with studies demonstrating BMP-2, 4, 6, 7 and 9 to be particularly effective 
(Yamaguchi, Ishizuya et al. 1996, Cheng, Jiang et al. 2003, Luu, Song et al. 2007, Geraghty, Kuang 
et al. 2015). To activate osteoblast differentiation, BMPs bind to and phosphorylate BMPRs on 
the surface of MSCs, initiating the canonical Smad-dependent pathway and the non-canonical 
p38 MAPK Smad-independent pathway. These pathways then converge within the nucleus at 
transcription factors, such as Runx2/Cbfa-1, with which they cooperate to carry out the 
osteoblast differentiation process, and thus subsequently induce bone formation (Wu, Chen et 
al. 2016). In fact, as part of the acquisition of osteomimicry by tumour cells, the latter have also 
been shown to also express Runx2/Cbfa-1 in vitro, adding to the osteoblastic vicious cycle.  
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Still, metastatic tumour cells are not solely responsible for the formation of bone metastases. In 
fact, this process also depends on the bone environment’s influence on the prostate cancer cells. 
The bone environment is a somewhat vague description for a highly complex biological and 
structural system which comprises of different lineages of both haematopoietic and 
mesenchymal cells and whose matrix is extremely rich in growth factors. Many of the latter, as 
previously mentioned, possess the ability to stimulate the proliferation of metastatic tumour 
cells within the bone. However, they may also promote the production and release of bone 
resorbing factors from tumour cells (Yin, Pollock et al. 2005). Resident bone cells also play a role 
in the bone metastatic process. For instance, although produced during the tumour cell-
mediated osteolytic vicious cycle, RANKL is also normally produced by osteoblasts to modulate 
osteoclast activity, which in a bone environment that is already corrupted by tumour cells, would 
only add to bone lesion formation. Furthermore, other cell types within the bone may also have 
a role in this process, like T cells which are known to produce osteoclast-activating factors, 
including RANKL, as well as TGF-βs and tumour necrosis factor (TNF). Aside from the growth 
factors in the bone environment, a number of non-collagenous bone matrix proteins have been 
shown to be implicated in the bone metastatic process as well. For example, the secreted 
adhesive glycoprotein, osteopontin (OPN), has been shown as a potential mediator of prostate 
cancer growth and progession due to its ability to stimulate the anchorage-independent growth 
of prostate cancer cell lines LNCaP and C4-2 in vitro (Yuen, Kwok et al. 2008).  
 
Taken together, the evidence above reveals the interplay that exists between prostate cancer 
cells and the bone environment. We have described the vicious cycle that drives the formation 
of osteolytic bone lesion formation through the initial release of PTHrp and RANKL; however, 
the osteoblastic vicious cycle is not as well understood. Since numerous studies have 
demonstrated the aberrant expression of certain BMPs in bone metastases, it is possible that 
these growth factors be involved in some way in this vicious cycle, which would be as a result of 
the interplay between prostate tumour cells and their bone environment. As such, it would be 
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of interest to evaluate the effects that the bone environment might have on their signalling 
profiles so as to assess any changes to the feedback loop between BMPs and their antagonists 
from normal conditions. 
 
4.2 Materials and Methods 
 
 Cell lines and Treatments 
 
A total of four prostate cancer cell lines were used in this study. PC-3 WT, DU145 WT and VCaP 
WT cells were maintained in DMEM with 10% FBS and antibiotics. LNCaP WT cells were 
maintained in RPMI with 10% FBS and antibiotics. All cell lines were kept at 37°C, 5% CO2 and 
95% humidity. To stabilise BMP signalling, cells were pre-treated with 5% FBS DMEM overnight. 
BME was extracted from femur bone tissues, standardised to 2 mg/ml, and 50 µg/ml in 5% FBS 
DMEM was used to treat cells.  
 
 RNA isolation and cDNA synthesis 
 
RNA was extracted from transfected cells using the TRI reagent® kit (Sigma-Aldrich, Poole, UK), 
and synthesised into cDNA by reverse transcription using the GoScript™ Reverse Transcription 
System (Promega, Southampton, UK), as respectively described in sections 2.4.2 and 2.4.3.  
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 qPCR  
 
qPCR was performed using the Amplifluor™ Universal Detection System (Intergen Company, 
New York, USA) under the cycling conditions detailed in section 2.4.6.  CT values obtained were 
analysed using ΔCT normalisation to GAPDH and the relative quantity was calculated using 2-CT. 
Each reaction was set up in triplicates and the experiments were carried out independently three 
times. Data analysis was carried out using unpaired t-test with Welch’s correction compared to 
control treatment. 
 
 RNA-Seq 
 
Targeted-sequencing of low passage PC-3 and VCaP incubated with either fresh 5% FBS DMEM 
or 5% FBS DMEM containing 50 µg/ml BME for 3 hours 37°C, 5% CO2 was undertaken. 10 ng of 
total RNA extracted from the prostate cancer cell lines was subsequently used for RNA 
sequencing. Heatmaps were generated using Microsoft Excel. 
 
 GEO database 
 
In the present study, we utilised the GEO dataset, GSE41619, generated by Larson et al (2013), 
who performed microarray hybridisation on RNA isolated from osteoblastic and osteolytic bone 
metastatic cores. Heatmaps of this data were generated using RStudio. Analysis of these samples 
was also performed by calculating the mean and SEM of these samples, and significance was 
assessed using unpaired t-test with Welch’s correction. These details can be found in the 
appendix. We also used GEO data (GSGE44143) from microarray gene analyses of monocultures 
and co-cultures of LNCaP cells and hOBs (Sieh, Taubenberger et al. 2014). This data was analysed 
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by calculating the means of all the repeats + SEM, and significance was analysed by unpaired t-
test using the Holm-Sidak method.  
 
4.3 Results 
 
 Expression of BMPs in Prostate Cancer Bone Metastasis 
 
According to our RNA-Seq results (figure 4.1A), BME treatment of PC-3 and VCaP caused a 
decrease in expression of most BMPs, with the exception of BMP-4, which was overexpressed 
in VCaP cells. Slight increases in expression were also seen for BMP-5 in PC-3 and BMP-8A in 
VCaP, as well as BMP-1 in both PC-3 and VCaP. More importantly, treatment of PC-3 cells caused 
a decrease in BMP-2, BMP-4 and BMP-6. BMP-7, which according to our findings in Chapter 3, is 
not normally expressed in PC-3, remains unexpressed following BME treatment. In contrast, its 
expression was reduced in VCaP cells in BME treatment conditions. We also assessed the 
expression of BMP-7 in DU145 and LNCaP cells in the absence or presence of BME by qPCR 
(figure 4.1B). This also demonstrated a decrease in BMP-7 expression following treatment with 
BME in both cell lines, although only LNCaP showed significance. Since we also posit that BMPs, 
BMP-7 in particular, have a role in late prostate cancer, especially in the osteoblastic nature of 
lesions of bone metastases, we aimed to assess their differential expression between osteolytic 
and osteoblastic lesion samples gathered and tested by Larson et al (2013). The results 
generated from their GEO dataset indicated that out of the different BMPs, BMP-1, 3, 13 and 15 
were downregulated in both types of lesions. The other BMPs on the other hand were all 
upregulated, with BMP-9 being upregulated in osteoblastic lesions and downregulated in 
osteolytic lesions. While no significant differences in BMP expression were seen between the 
different sets of samples (see figure A1), the results showed that BMP-1, 2, 3, 4, 6, 8A, 9 were 
more highly expressed in osteoblastic lesions than osteolytic lesions.   
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Figure 4.1: Expression of BMPs in BME-treated Prostate Cancer Cell Lines and in Prostate Cancer 
Bone Metastasis Samples. A. The RNA-Seq heatmap represent the changes in BMP mRNA 
expression in PC-3 and VCaP cells in the absence and presence of 50 µg/ml BME. B. DU145 and 
LNCaP cells were treated with either 5% FBS DMEM or 50 µg/ml BME for 3 hours. qPCR was 
performed to assess changes in BMP-7 mRNA expression. Readings were normalised against GAPDH 
and the ΔCT method was used to analyse the data. Results shown represents the mean and SEM of 
three repeats. Significance was assessed by unpaired t-test with Welch’s correction (* p ≤ 0.05). C.  
The heatmap shown demonstrates the expression profile of BMPs 1-15 in bone metastasis samples. 
It was generated from GEO data (GSE41619) available on NCBI, with 1-7 representing samples 
obtained from osteoblastic lesions and 8-14 representing samples obtained from osteolytic lesions. 
Data was obtained from a bone metastasis study Larson et al (2013).  
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We also wanted to assess the how interactions between prostate cancer cells and osteoblasts 
affected the BMP profiles of both cell types. To do so, we analysed microarray data from LNCaP 
monocultures, hOB monocultures and LNCaP-hOB co-cultures gathered by Sieh et al (2014) 
(figure 4.2). These results demonstrated only very slight changes in expression levels of all the 
BMPs in LNCaP cells when in the LNCaP-hOBs co-cultures. In comparison, hOBs demonstrated 
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Figure 4.2: BMP expression profile during LNCaP-hOB co-culture. The graphs presented 
here were generated using GEO data (GSE44143) obtained from Sieh et al (2014), who 
performed microarray gene analysis on both LNCaP cells or hOBs that were either 
monocultured or co-cultured with each other. The results shown represent the mean + SEM 
from these assays. Significance was assessed by unpaired ttest using the Holm-Sidak 
method (* p ≤ 0.05, **** p ≤ 0.0001). 
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the significant decrease of BMP-2 and BMP-4 (p = 1.8481 x 10-5 and p = 0.0111 respectively) and 
the significant increase of BMP-6 (p = 0.0494) when co-cultured with LNCaP. 
 
 Expression of BMP antagonists in Prostate Cancer Bone Metastasis 
 
As seen in figure 4.3A, RNA-Seq of PC-3 cells showed that BME treatment mostly caused a 
decrease in the expression of the BMP antagonists tested, with the exception of FSTL1, for which 
it caused an increase, while BME treatment of VCaP cells caused a decrease in all of the BMP 
antagonists tested. However, qPCR analyses (figure 4.3B) showed that BME treatment did not 
cause much effect on Noggin expression in DU145 cells but seemed to cause a very slight 
decrease in FST344 and Gremlin, although this was not significant. Similarly, BME treatment also 
cause a decrease in BMP antagonist expression in LNCaP. Although this was at a greater extent 
than in DU145 cells, it was again not significant. According to the data analysed from the Larson 
et al (2013) GEO dataset (figure 4.3C), there a low expression of Noggin and FST in both types of 
metastatic lesions, with FST expression being much lower than the reference sample levels. 
Overall expression of FSTL1 appeared to be upregulated in osteoblastic lesions and 
downregulated in osteolytic lesions, while no great change in expression was noted for FSTL4. 
On the other hand, while there was not much change in FSTL5 expression in osteoblastic lesions, 
osteolytic lesions showed an overexpression of the antagonist. Both Gremlin isoforms, GREM1 
and GREM2, seemed to be well expressed in both lesions. Analysis of the overall data showed 
significantly higher levels of FSTL3 and GREM2 in osteoblastic lesions in comparison to osteolytic 
lesions (p = 0.0058 and p = 0.0367 respectively; see figure 4.4). 
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Figure 4.3: Expression of BMP antagonists in BME-treated Prostate Cancer Cell Lines and in Prostate 
Cancer Bone Metastasis Samples. A. The RNA-Seq heatmap represent the changes in BMP antagonist 
mRNA expression in PC-3 and VCaP cells in the absence and presence of 50 µg/ml BME. B. DU145 and 
LNCaP cells were treated with either 5% FBS DMEM or 50 µg/ml BME for 3 hours. qPCR was performed 
to assess changes in mRNA expression. Readings were normalised against GAPDH and the ΔCT 
method was used to analyse the data. Results shown represents the mean and SEM of three repeats. 
Significance was assessed by unpaired t-test with Welch’s correction (* p ≤ 0.05). C. The heatmap was 
generated from GEO data (GSE41619) obtained from Larson et al (2013), analysing for the expression 
of BMP antagonists in samples acquired bone metastasis samples. 1-7 represent samples obtained 
from osteoblastic lesions and 8-14 represent samples obtained from osteolytic lesions.  
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When assessing the effects of the prostate cancer cell-osteoblast interplay on BMP antagonist 
expression in LNCaP cell (figure 4.5), the LNCaP microarray data demonstrated an increase in 
FST, GREM1 and GREM2 levels, while levels in Noggin mRNA were slightly decreased. In fact, a 
significant increase was observed for FST and GREM1 (p = 0.0012 and p = 0.0469 respectively). 
The hOBs data, on the other hand, showed that the interactions between the two cell types did 
not cause much effect on their antagonist expression levels, although a small decrease in FST 
was noted.   
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Figure 4.4: The differential expression of BMPs in osteoblastic and 
osteolytic bone metastatic lesions. The data represents mean + SD of BMP 
expression results from a microarray study by Larson et al (2003; GSE41619). 
Significance was assessed by t-test using the Holm-Sidak method (* p ≤ 0.05, 
** p ≤ 0.01). 
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Figure 4.5: BMP antagonist expression profile during LNCaP-hOB co-culture. The graphs shown 
above were generated using GEO data (GSE44143) obtained from Sieh et al (2014), who 
performed microarray gene analysis on both LNCaP cells or hOBs that were either monocultured 
or co-cultured with each other. The results shown represent the mean + standard deviation (SD) 
from these assays. Significance was assessed by unpaired ttest using the Holm-Sidak method (* 
p ≤ 0.05, ** p ≤ 0.01). 
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 Expression of BMPRs in Prostate Cancer Bone Metastasis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RNA-Seq of the samples demonstrated different responses in BMPR expression following BME 
treatment: PC-3 cells showed a decrease in BMPR-IA and ActR-IA expression, and an increase in 
BMPR-IB, BMPR-II and ActR-II, and VCaP cells showed a decrease in BMPR-II and ActR-IA 
expression, and an increase in BMPR-IA and ActR-II expression (figure 4.6A). Data obtained from 
Larson et al (2013) demonstrated that BMPR-IB was more distributed the bone lesions in 
comparison to the other receptors tested (see figure 4.6B). Furthermore, it was more distributed 
in osteoblastic lesions than in osteolytic lesions. BMPR-IA and ActR-IIA seemed to be moderately 
expressed in both lesion types. 
 
Figure 4.6: Expression of BMPRs in BME-treated Prostate Cancer Cell Lines and in Prostate 
Cancer Bone Metastasis Samples. A. The RNA-Seq heatmap represent the changes in BMPR 
mRNA expression in PC-3 and VCaP cells in the absence and presence of 50 µg/ml BME. B.  The 
heatmap shown was generated from GEO data (GSE41619) produced by Larson et al (2013) and 
tested for the expression of BMPR-IA, BMPR-IB and ActR-IIA in samples acquired bone metastasis 
samples. 1-7 represent samples obtained from osteoblastic lesions and 8-14 represent samples 
obtained from osteolytic lesions. 
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Microarray data (figure 4.7) from the co-cultures of LNCaP with hOBs demonstrated an increase 
in BMPR-IB and slight decrease in BMPR-II in the LNCaP cells following co-culture with hOBs. 
Meanwhile, the latter demonstrated a decrease in both receptors.  
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Figure 4.7: BMPR expression profile during LNCaP-hOB co-culture. The graphs 
shown were generated from GEO data (GSE44143) obtained from Sieh et al (2014). 
Using this data, the expression of BMPR-IA and BMPR-II was assessed in LNCaP 
and hOBs that were either monocultured or co-cultured with each other. The 
results shown represent the mean + SEM from these assays. Significance was 
assessed by unpaired ttest using the Holm-Sidak method. 
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 Expression of Smads in Prostate Cancer Bone Metastasis 
 
The data obtained from RNA-Seq of PC-3 and VCaP demonstrated different effects on the 
expression of BMP-specific R-Smads, Smad1, Smad5 and Smad8/9, following BME treatment. 
For example, in PC-3 cells, BME treatment caused an increase in Smad1 and a decrease in Smad5. 
It also caused a slight increase in Smad9. In VCaP cells, the treatment caused an increase in 
Smad5 and Smad9, and a slight decrease in Smad1. On the other hand, expression of the co-
Smad, Smad4, was reduced in both cell lines. Interestingly, both I-Smads, Smad6 and Smad7, 
were increased in PC-3, while only Smad7 was increased in VCaP cells, with Smad6 being 
reduced. qPCR was performed to assess the expression of the BMP-specific R-Smads and I-
Smads. Results showed that BME treatment caused a decrease in all the Smads, in all both 
DU145 and LNCaP. A significant decrease was observed for Smad1, Smad5 and Smad6 in LNCaP 
cells. The heatmap generated from data produced from Larson et al (2013) indicated that all the 
Smads were well expressed in both types of lesions, with Smad8/9 levels being the most 
pronounced (figure 4.8C). Overall analysis demonstrated that there was a significant 
upregulation in Smad5 levels and a significant downregulation in Smad6 levels in osteoblastic 
lesions in comparison to osteolytic lesions (p = 0.0179 and p = 0.0250 respectively; see figure 
A3).   
 
The LNCaP-hOB microarray data demonstrated that Smad expression was more or less 
unaffected in LNCaP cells (figure 4.9). However, LNCaP-hOB co-culture caused the decrease of 
Smad3, Smad6 and Smad7, and a significant increase in Smad8/9 (p = 0.0095). 
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Figure 4.8: Expression of Smads in Prostate Cancer Bone Metastasis. A. The RNA-Seq heatmap represent 
the changes in Smad mRNA expression in PC-3 and VCaP cells in the absence and presence of 50 µg/ml 
BME. B. The qPCR results show the changes in Smad expression in DU145 and LNCaP cells in the absence 
or presence of 50 µg/ml BME. Readings were normalised against GAPDH and the ΔCT method was used 
to analyse the data. Results shown represents the mean + SEM of three repeats. Significance was assessed 
by unpaired t-test with Welch’s correction (* p ≤ 0.05). C. The heatmap shown was generated using GEO 
data (GSE41619) and tested for the expression of Smads in samples acquired bone metastasis samples. 1-
7 represent samples obtained from osteoblastic lesions and 8-14 represent samples obtained from 
osteolytic lesions (Larson et al 2013).  
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Figure 4.9: Smad expression profile during LNCaP-hOB co-culture. Sieh et al (2014) 
performed microarray gene analysis on LNCaP cells and hOBs that were either monocultured 
or co-cultured together. The graphs presented here were generated from the GEO data 
(GSE44143) obtained from this experiment and shows the mean + SEM of the Smads 
expression readings. Significance was assessed by unpaired ttest using the Holm-Sidak 
method (** p ≤ 0.01). 
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4.4 Discussion 
 
In 1889, Sir Stephen Paget brought forth the ‘seed and soil’ theory to help explain the 
preferential metastasis of different cancer types to specific sites. His theory postulates that 
metastatic cancer cells (the ‘seeds’) disperse in all directions but can only accomplish metastases 
where the microenvironment (the ‘soil’) is permissive for their survival and growth (Paget 1889). 
While this is still widely accepted as the basic principle of metastasis after more than 120 years 
of scientific research, studies focussing on prostate cancer metastasis to the bone have since 
expanded on this theory. Indeed, these studies have shown evidence of bi-directional 
interactions between cancer cells and the bone that not only attract the cells to bone sites, but 
that also enables them to adapt and grow in the new, physiologically different environment. 
With BMPs being one of the family of growth factors through which these interactions occur, 
the aim of this current study is to investigate the impact of the bone environment on the 
BMP/BMP antagonist feedback loop and how this may eventually translate to the formation of 
osteoblastic bone lesions. 
 
In order to investigate the interplay between prostate cancer cells and the bone environment, 
we wanted a method of simulating the bone which we could use in vitro. This was achieved by 
the crushing and sonication of femoral heads obtained from patients undergoing hip 
replacements and collecting the supernatant extract, BME. Since we have already established a 
general idea of the baseline BMP signalling profiles of different prostate cancer cells lines in 
Chapter 3, the first step of the current study was to utilise this information to assess any changes 
that may occur within the bone environment, mimicked by treatment with BME, by RNA-Seq 
and qPCR. For ease of comparison between DMEM and BME RNA-Seq data, we included findings 
obtained from Chapter 3 alongside those from Chapter 4. Similar to Chapter 3, we utilised GEO 
data from other studies, which were also investigating the molecular mechanisms underlying 
prostate cancer bone metastasis, to obtain a more comprehensive overview of the BMP/BMP 
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relationship in this process. The first study we used, which was completed by Larson et al, 
provided more translational data, by performing microarray analysis on 14 clinical specimens 
from prostate cancer bone lesions, divided into the two bone lesion phenotype groups: 
osteoblastic or osteolytic. Results they obtained were then compared with a reference sample 
of pooled RNA isolated from prostate cancer cell lines, PC-3, DU145, LNCaP and CWR22. The 
authors of the second study we used, Sieh et al (2014), utilised a novel 3D, in vitro approach to 
co-culture LNCaP cells with hOBs. 
 
When assessing the BMP expression results (figure 4.1), data yielded from RNA-Seq following 
BME treatment showed that most of the BMPs that our research is particularly interested in, 
namely BMP-2, 4, 6 and 7, were downregulated in both the osteolytic PC-3 cells and the 
osteoblastic VCaP cells, with the exception of BMP-4, that was upregulated in VCaP. qPCR 
analyses were performed on the osteolytic DU145 and mixed lesion LNCaP cells, and solely 
focussed on the expression of BMP-7, the latter being reduced in both cell lines. This differs from 
data we analysed from Larson et al (figure 4.1C), which demonstrated the high expression of all 
of the BMPs of interest in both types of bone lesions. However, the evaluation of differential 
BMP expression between the two lesion phenotypes demonstrated higher levels of BMP-2, 4 
and 6 in osteoblastic lesions, while BMP-7 was slightly higher in osteolytic ones. Although the 
BMP-7 expression observations were not statistically significant (see figure 4.2), they were 
nonetheless surprising. Indeed, being one of the BMPs with the strongest osteogenic activity, 
various studies have implicated this BMP in the osteoblastic bone metastasis process. For 
instance, Masuda et al (2003) demonstrated the high expression of BMP-7 in 7 metastatic bone 
lesion samples in comparison to normal bone tissue. While the phenotypes of the lesion samples 
were not specified, the authors of this study deduced from their results the likelihood of BMP-7 
involvement in osteoblastic lesion formation. Their findings were mirrored in the previously 
mentioned studies by Spanjol et al (2010), Morrissey et al (2010), Buijs et al (2007), which also 
demonstrated the high expression of BMP-7 in bone metastatic samples. Despite the current 
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findings, previous evidence and the current understanding of BMP-7 functions still points 
towards the involvement of this BMP in the development of prostate cancer osteoblastic lesion. 
This possibly highlights the need for bigger sample pools for an empirical assessment of key 
factors in the bone metastasis process. However, analysis of the differential expression data for 
the other BMPs has brought up some interesting findings, none more so than BMP-11, which 
demonstrated poor expression in osteoblastic bone lesions and quite a drastic increase in levels 
in osteolytic lesions. As of yet, it seems that no studies have been performed to investigate the 
role of this BMP in prostate cancer or bone metastasis, although it has been to stimulate bone 
formation by mediating the increase in osteoblast function (Li, Zeng et al. 2011). Interestingly, 
this could tie in with the findings we extrapolated from the Larson et al GEO database. 
 
To help interpret the BMP/BMP antagonist relationship and its role in the establishment of 
prostate cancer bone metastases, we also assessed the expression levels of BMP antagonists in 
response to the bone environment. A general overview of these results highlights Noggin and 
FST to be of particular interest, showing both antagonists to be downregulated in the bone 
metastasis samples (figure 4.3C), with FST also being downregulated in the in vitro bone 
environment assays (figure 4.3A and figure 4.3B). This seems to agree with previous findings. 
For instance, although they focussed their research on osteolytic lesion formation, Feeley et al 
(2006) demonstrated through in vitro assays on PC-3 cells and in vivo experiments using SCID 
mice that Noggin inhibited the BMP-mediated formation of osteolytic bone lesions. 
Furthermore, Schwaninger et al (2007), who also demonstrated the low expression levels of 
Noggin in osteoblastic lesions, showed that the forced expression of Noggin in osteoblastic 
prostate cancer cell lines abolished the osteoblast response in in vivo intraosseus xenografts. 
Meanwhile, although FST has drawn more interest lately for its possible role in bone metastasis, 
its importance and role in this process remains to be ascertained. For example, previous findings 
from our laboratory on breast cancer progression have demonstrated that higher FST levels 
correlate with lower grade breast tumours, suggesting a role for this antagonist as a suppressor 
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of invasion and metastasis (Zabkiewicz, Resaul et al. 2017). In contrast, Tuminello et al (2010) 
demonstrated that serum FST levels of prostate cancer patients positively correlated with the 
presence of bone metastases. What was most striking about the current findings was the 
significant downregulation of GREM2 in osteolytic bone lesions in comparison to osteoblastic 
lesions (p = 0.0367, see figure 4.4), since this antagonist have never been previously implicated 
in the prostate cancer process before. Although no previous literature was seen on GREM2 in 
relation to this disease or the related bone metastasis, Laurila et al (2013) who, as previously 
mentioned, investigated the expression of the GREM2 isoform, GREM1, in a multitude of normal 
and cancer tissues, has demonstrated weak levels of GREM1 in the prostate and moderate levels 
in the bone marrow. GREM1 levels were then increased to weak to moderate levels in prostate 
adenocarcinoma. Moreover, GREM2 has been highlighted as a candidate gene in the study of 
osteoporosis, suggesting its importance in bone health. In combination with the current findings, 
it indicates the Gremlin isoforms as potential proteins of interest in prostate cancer progression 
and bone metastasis. 
 
Additional evidence for the importance of BMP signalling in prostate cancer metastasis can be 
seen through the expression profiles of BMPRs and Smads. Indeed, although the RNA-Seq data 
demonstrated that BME treatment caused varying effects on BMPR expression, they did show 
their high distribution throughout in both cell types, in both treatment conditions (figure 4.6A). 
This was reflected in data we analysed from GSE41619 (Larson, Zhang et al. 2013), which 
demonstrated the moderate expression of all the BMPRs tested. Of note, the results of both 
assays both showed the high expression of BMPR-IB in the osteoblastic VCaP cell line and 
osteoblastic lesions, even showing an increase in PC-3 following BME treatment. Although this 
contradicts previous studies that demonstrated the correlation between the loss of BMPR-IB 
and the Gleason score in prostate cancer patients, the current findings may imply the 
importance of the cognate BMPs of this receptor, namely BMP-2, 4, 6 and/or 7 in the 
osteoblastic lesion formation (Yamaji, Celeste et al. 1994, Ebisawa, Tada et al. 1999, Kim, Lee et 
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al. 2000, Lavery, Swain et al. 2008). Furthermore, although BME treatment demonstrated 
fluctuating changes in co-Smad levels as well as those of the different R-Smads and I-Smads, 
with the qPCR demonstrating a downregulation in most of the Smads tested, data from Larson 
et al showed the downregulation of Smad5 and upregulation of Smad6 in osteoblastic lesions. 
This further indicates that BMP function is in play in the osteoblastic reaction. 
 
When evaluating the LNCaP-hOB interplay on BMP and BMP antagonist expression levels, the 
overall results co-culture experiments strongly suggest a feedback loop between BMPs and their 
antagonists (see figures 4.2 and figure 4.5). Indeed, it was observed that these experiments 
mostly did not affect the expression profile of BMPs in LNCaP cells, only causing an increase 
BMP-6 levels. However, they did cause significant increases in the expression of BMP 
antagonists, FST, GREM1 and GREM2. Conversely, although hOBs in the co-cultures 
demonstrated a slight decrease in FST and minimal changes in levels of the other antagonists, 
they showed significant changes in BMP levels, causing a decrease in expression levels of both 
BMP-2 and BMP-4, and an increase in BMP-6 in the hOBs. The increase in BMP-6 ties in with 
previous findings, which demonstrated the high expression of this BMP with disease progression 
(Hamdy, Autzen et al. 1997, Autzen, Robson et al. 1998, Thomas and Hamdy 2000). As for the 
downregulation of BMP-2 and BMP-4, since LNCaP cells are typically associated with the 
formation of mixed lesions, this could explain the differing levels of the different osteogenic 
BMPs. Although this co-culture experiment only represents the early phases of metastasis, 
where cancer cells and resident bone cells would communicate to negotiate survival and the 
establishment of a secondary colonies, it apparent that part of this interaction occurs through 
BMP and BMP antagonist interplay. Furthermore, as the formation of osteoblastic lesions is 
driven by osteoblasts, the present results indicate that their actions are BMP-mediated, hence 
why the levels of BMP antagonists were mostly unchanged.  
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Reflecting the BMPR and Smad results discussed above, the analysis of the LNCaP-hOB 
demonstrated that the tested BMPRs, BMPR-IB and BMPR-II were well expressed in both LNCaP 
cells and hOBs in monocultures. Again, BMPR-IB levels seemed to be more affected than that of 
BMPR-II in LNCaP-hOB co-cultures, as evidenced by an increase in LNCaP cells and decrease in 
hOBs. The subsequently Smad signalling in LNCaP cells was mostly unchanged in co-culture 
conditions, however, hOBs demonstrated a significant increase in Smad9, supporting the 
implication that an interaction through BMPs is taking place between the two cell types.  
 
The chapter presented here summarises a wealth of information gathered with the aim to show 
whether BMP and their antagonists have a role during the initial establishment of prostate 
cancer cells in the bone and formation of bone lesions. As such, taken together, our data may 
support the hypothesis that BMP signalling in prostate cancer occurs through an interplay with 
BMP antagonists. Unfortunately, since our attempts to confirm these results on a protein level 
were unsuccessful, our data does not reflect any post-translational changes and regulations that 
could impact on these findings. Due to the level of promiscuity between the BMP antagonists 
and the BMPs, it is difficult to pinpoint which exact BMP/BMP antagonist interplay are of 
importance and how it may translate in bone metastasis. Therefore, it would be of interest to 
see how BMP antagonists impact cancer cell behaviour in subsequent experimentation.
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Overexpression of BMP 
antagonists and their 
Regulatory Role in Cellular 
Functions
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5.1 Introduction 
 
The progress from normal cell to cancerous growth is a multifaceted affair. Indeed, a cell must 
acquire a range of subversive characteristics as it evolves in order to escape the constraints of 
normal cellular physiology. To do so, neoplastic cells utilise the different cellular properties that 
are typically vital to normal cells and aberrantly activate them. Different cancers present with 
different combinations of these aberrant properties, although arguably, the most fundamental 
trait that cancer cells share is the ability to sustain chronic proliferation. Of the other cellular 
traits that may be corrupted during the cancer process, the adhesive, migratory and invasive 
properties of cancer cells are also of significance as they all contribute to metastatic potential 
(Hanahan and Weinberg 2011).  
 
Classically known for their roles in embryonic morphogenesis and postnatal development, BMPs 
carry out their tasks through the orchestration of cellular processes like the ones mentioned 
above (Hemmati‐Brivanlou and Thomsen 1995, Zou and Niswander 1996, Kobayashi, Lyons et 
al. 2005, Stewart, Guan et al. 2010). However, during the cancer process, neoplastic cells may 
hijack signalling mediated by certain BMPs. For example, while normal cells carefully control the 
production and release of growth-promoting signals, cancer cells in contrast actively deregulate 
them, and do so largely through the use of growth factors like BMPs (Hanahan and Weinberg 
2011). In fact, many have posited a significant role for BMPs in prostate cancer progression, with 
a number of studies testing this theory by examining the expression of these growth factors in 
prostatic tissue. As summarised in Chapter 3, the combined evidence of these studies showed 
the expression patterns of BMP-2, -4, -6, and -7 in the different stages of prostate cancer to be 
of particular interest as they suggested their implication in the formation of skeletal metastases 
(Bentley, Hamdy et al. 1992, Masuda, Fukabori et al. 2003, Bobinac, Marić et al. 2005, Spanjol, 
Djordjević et al. 2010). Of note, each of the BMPs mentioned above are known to have powerful 
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osteoinductive properties (Lavery, Swain et al. 2008). BMP-4, for example, has been shown to 
regulate limb development (Selever, Liu et al. 2004). On the other hand, BMP-2 and BMP-7, have 
already been approved for clinical use as therapeutic options for the treatment of long-bone 
nonunions (Govender, Csimma et al. 2002, Papanagiotou, Dailiana et al. 2015), while studies are 
being undertaken to test the viability of BMP-6 as a candidate in bone generation therapies 
(Mizrahi, Sheyn et al. 2013). Therefore, these BMPs present themselves as ideal candidates for 
the formation of osteoblastic bone lesions, with studies by Masuda et al implicating BMP-7 in 
particular having a key role in this process, specifically in prostate cancer (Masuda, Fukabori et 
al. 2003, Masuda, Fukabori et al. 2004). 
 
Since more and more studies have demonstrated the capacities of BMP antagonists to be 
beyond their canonical BMP-regulating role, it is possible that the interplay that exists between 
them and BMPs physiologically may also be in play pathophysiologically. The current study aims 
to elucidate if this is the case during prostate cancer and its spread to the bone. Thus, in order 
to achieve this, we decided to induce the overexpression of a number of BMP antagonists in 
prostate cancer cells and assess any downstream changes in their cellular activities. As different 
BMP antagonists have varying affinities for different BMPs, we chose to overexpress antagonists 
that will altogether interact with the BMPs we have identified to possibly be more implicated in 
bone metastasis, that is, BMP-2, BMP-4, BMP-6 and more importantly, BMP-7. These 
antagonists are Noggin, FST344 and Gremlin (Re'em-Kalma, Lamb et al. 1995, Yamashita, ten 
Dijke et al. 1995, Zimmerman, De Jesús-Escobar et al. 1996, Fainsod, Deissler et al. 1997, Hsu, 
Economides et al. 1998, Iemura, Yamamoto et al. 1998, Merino, Rodriguez-Leon et al. 1999, 
Haudenschild, Palmer et al. 2004, Zhu, Kim et al. 2006).  
 
Finally, if one were to fully understand the role of BMPs and their antagonists in the formation 
of osteoblastic lesions, one would also need to consider Stephen Paget’s ‘seed and soil’ 
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hypothesis. With the bone containing numerous non-collagenous proteins as well as a multitude 
of growth factors, all of which are able to interact with cancer cells and thus alter cancer cell 
behaviour, we would need to consider the influence of the bone environment in conjunction 
with the overexpression of the selected antagonists (Zheng, Zhou et al. 2013). Thus, the 
phenotypes of the overexpression cell lines under treatment with BME was also examined. 
Altogether, this study may offer insight into the underpinnings of BMP/BMP antagonist related 
bone metastasis and how it could be exploited in prostate cancer treatment and the prevention 
of osteoblastic bone metastasis. 
 
5.2 Materials and Methods 
 
 Materials 
 
All the primers used were synthesised and provided by Sigma-Aldrich (Poole, UK). Primer 
sequences are detailed in tables 2.2 to 2.4. 
 
 Cell lines and Treatments 
 
DU145 WT cells maintained in DMEM with 10% FBS and antibiotics at 37°C, 5% CO2 and 95% 
humidity were used this chapter. These cells were later transfected, and the stable cell lines 
produced were cultured in maintenance medium consisting of DMEM supplemented with 10% 
FBS, antibiotics and 0.5 µg/ml blasticidin thereafter. All cell lines were pre-treated in 
maintenance medium with 5% FBS and antibiotics overnight, preceeding any functional assays. 
The BME treatment used in this study was prepared as described in section 2.2.1 and 50 µg/ml 
in 5% FBS DMEM was used to simulate the bone microenvironment. 
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 Amplification of Noggin, Follistatin and Gremlin Coding Sequences 
 
Prior to the amplification process, the cDNA template first needed to be generated by reverse 
transcription of mRNA extracted from normal human prostate tissue using the GoScript™ 
Reverse Transcription System (Promega, Southampton, UK). The resultant cDNA was then 
combined with JumpStart™ AccuTaq™ LA DNA Polymerase Mix (Sigma-Aldrich, Poole, UK) and 
primers that were designed to amplify the entire coding sequences of Noggin, FST344 or Gremlin 
(see table 2.4). The reaction mixes were subsequently subjected to touchdown PCR, the 
parameters of which were pre-determined by gradient PCR. In brief, following an initial 
denaturation at 94°C for 5 minutes, the reaction mixes were subjected to 5 cycles of 
denaturation at 93°C for 20 seconds, annealing at 64°C, 62°C, 60°C or 58°C for 20 seconds, and 
elongation 72°C for 1.5 minutes. An additional amplification of 30 cycles was performed, 
whereby denaturation was carried out at 93°C for 20 seconds, annealing at 58°C for 20 seconds, 
and elongation 72°C for 1.5 minutes. This was followed by a final extension of 10 minutes at 
72°C. The PCR products were then run and visualised on a 1.5% agarose gel with bands 
corresponding to the expected sizes of the BMP antagonists excised. Extraction of the excised 
products was carried out as described in section 2.5.3.  
 
 Cloning of Noggin, FST344 and Gremlin into pEF6/V5-HIS-TOPO® TA vectors 
 
Following their isolation from agarose gel, the selected touchdown PCR products were directly 
incorporated into the pEF6/V5-HIS-TOPO® TA vector (Invitrogen, Paisley, UK) by TOPO TA 
cloning, as detailed in section 2.5.4. Then, the resultant vectors were transformed into One 
Shot® TOP10 Chemically Competent E. coli (Invitrogen, Paisley, UK), after which the correct 
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orientation of PCR products within the vectors expressed by transformants was verified. The 
correct constructs were then amplified and purified using the GenElute™ Plasmid MiniPrep Kit 
(Sigma, Poole, UK), based on the protocol provided. 
 
 Prostate Cancer Cell Transfection and Generation of Stable Transfectants 
 
Once purified, vectors expressing Noggin, FST344 or Gremlin were transfected into DU145 WT 
cells using an electroporator (Gene Pulser Xcell™ Electroporation System, Bio-Rad Laboratories, 
Hemel Hampstead, UK) set to 290 V. Empty pEF6/V5-HIS-TOPO® TA vectors were also 
electroporated into the prostate cancer cell line to serve as a negative control for subsequent 
experiments. Following transfection, cells were immediately transferred to 25 cm2 flasks 
containing 5 ml of pre-warmed 10% FBS DMEM and left to adhere overnight. A selection process 
was then implemented during which transfected cells were cultured in 10% FBS DMEM 
supplemented with 5 µg/ml Blasticidin S (Melford Laboratories Limited, Suffolk, UK) for about a 
week. Surviving cells were then cultured and maintained in 10% FBS DMEM with a reduced 
blasticidin concentration of 0.5 µg/ml to create the stably transfected cell lines DU145pEF, 
DU145NOG, DU145FST344 and DU145GREM. 
 
 RNA isolation, cDNA synthesis, RT-PCR and qPCR 
 
RNA was extracted from transfected cells using the TRI reagent® kit (Sigma-Aldrich, Poole, UK), 
and synthesised into cDNA by reverse transcription using the GoScript™ Reverse Transcription 
System (Promega, Southampton, UK), as respectively described in sections 2.4.2 and 2.4.3. The 
acquired cDNA was then used for RT-PCR or qPCR. RT-PCR was carried out using the GoTaq® 
Green Master Mix under the following cycling conditions: initial denaturation of 5 minutes at 
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94°C, 32 cycles of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds and 
elongation at 72°C for 1.5 minutes, before a final elongation step at 72°C for 10 minutes. The 
PCR products were then run on an agarose gel and visualised using SYBR safe DNA gel stain 
(Invitrogen, Paisley, UK). qPCR was performed using the Amplifluor™ Universal Detection System 
(Intergen Company, New York, USA) under the cycling conditions detailed in section 2.4.6.  CT 
values obtained were analysed using ΔΔCT normalisation to GAPDH and standardised to the pEF 
control. Each reaction was set up in triplicates and the experiments were carried out 
independently three times. Data analysis was carried out using unpaired t-test with Welch’s 
correction compared to DU145pEF. 
 
 In vitro Cell Proliferation Assay 
 
DU145pEF, DU145NOG, DU145FST344 and DU145GREM were seeded at a density of 3 x 103
 
cells/100 μl 
into 12 replicate wells of three 96-well plates. Cells were either treated with 5% FBS DMEM or 
50 µg/ml BME in 5% FBS DMEM and incubated for 1, 3 or 5 days. Following the appropriate 
incubation period, cells were then fixed in 4% formaldehyde and stained with 0.5% crystal violet. 
Once dried, cells were solubilised with 10% acetic acid and cell densities were determined by 
spectrophotometry at 540 nm. Growth rates were calculated using the absorbance measured at 
day 1 as a baseline. 
 
 In vitro Invasion Assay 
 
8 Transwell inserts with 8 µm pores (Greiner Bio-One, Stonehouse, UK) were coated with 50 µg 
of Matrigel (BD Biosciences, New Jersey, USA) and placed into wells of a 24-well plate containing 
5% FBS DMEM. The transfected cell lines were seeded into the inserts at a density of 3 x 104 
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cells/100 μl and treated with either 5% FBS DMEM or 50 µg/ml BME in 5% FBS DMEM. Cells 
were incubated over 3 days, after which they were fixed and stained, and the density of cells 
that had migrated through the Matrigel to the underside of the inserts were determined by 
spectrophotometry at 540 nm as explained above. 
 
 In vitro Adhesion Assay 
 
12 replicate wells of a 96-well plate were coated with 5 µg Matrigel, onto which 2 x 104 cells/100 
µl of DU145pEF, DU145NOG, DU145FST344 or DU145GREM was pipetted. Cells were treated with either 
5% FBS DMEM or 50 µg/ml BME in 5% FBS DMEM and incubated for 40 minutes before being 
fixed and stained. As with previous in vitro assays, the number of cells that had adhered to the 
Matrigel was determined by spectrophotometry at 540 nm. Any background reading from 
stained Matrigel was negated by measuring the absorbance of wells containing only Matrigel.  
 
 In vitro Migration Assay 
 
6 x 105/500 µl cells of DU145pEF, DU145NOG and DU145GREM, and 1 x 106/500 µl cells of DU145FST344 
were seeded into duplicate wells of a 24-well plate. Once grown into a monolayer, cells were 
scratched and treated with 5% FBS DMEM or 50 µg/ml BME in 5% FBS DMEM. Cell migration 
across the wound was imaged at 37°C, 5% CO2 using an EVOS™ FL Auto Cell Imaging System 
(ThermoFisher Scientific, Massachusetts, USA) for each hour over 20 hours. Images were 
analysed using ImageJ Software (National Institutes of Health, Bethesda, Maryland, USA). 
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 ECIS 
 
Cells were seeded at a density of 6 x 104 cells/100 µl for DU145pEF, DU145NOG and DU145GREM, 
and 8 x 104 cells/100 µl for DU145FST344 into 12 replicate wells of a 96-well array (Applied 
Biophysics). They were then treated with 5% FBS DMEM or 50 µg/ml BME in 5% FBS DMEM, and 
the resistance of the cells over 20 hours was measured at 4000 Hz using an Applied BioPhysics-
ECIS Software V 1.2.135 (Applied Biophysics, Troy, New York, USA).  Data was normalised using 
the resistance readings from the first time-point.  
 
5.3 Results 
 
 Overexpression of BMP Antagonists in DU145 
 
In order to assess the effects of BMP antagonists on the properties of prostate cancer cells, 
Noggin, FST344 and Gremlin expression was induced in the DU145 cell line by means of 
mammalian expression constructs. This was achieved by cloning the entire coding sequences of 
these BMP antagonists into the pEF6/V5-HIS-TOPO® vector and transfecting the resulting 
constructs into DU145 cells by electroporation. Once the stably transfected cell lines were set 
up, the success of these transfections was then assessed by RT-PCR and qPCR, as seen in figure 
5.1. Results from both techniques demonstrated significant increases in expression of the 
induced BMP antagonists in comparison to the pEF control. 
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 BMP Antagonist Overexpression Affects Prostate Cancer Cell Growth 
 
The effects of Noggin, FST344 and Gremlin overexpression were assessed in comparison to pEF 
over 3-day and 5-day periods using the crystal violet method. When only considering DMEM 
treatment (figure 5.2A), growth readings at Day3 showed that Noggin overexpression had no 
effect on DU145 cell growth, although interestingly by Day5, it caused a significant decrease (p 
< 0.05). Conversely, at Day3, Gremlin overexpression caused a significant increase in cell growth 
(p < 0.01), but by Day5 it caused no change to DU145 cell growth. On the other hand, 
Figure 5.1: Overexpression of BMP antagonists in the DU145 cell line. DNA sequences of Noggin, FST344 
and Gremlin were cloned into pEF6/V5-His TOPO TA vectors which were then transfected into DU145 cells 
along with empty vectors to act as control (pEF). A. The representative PCR analyses shown demonstrate 
the increased expression of the target genes in comparison to the pEF control. The negative control used 
nuclease-free water as replacement for cDNA. B. Representative qPCR analyses confirmed significant 
increase of target gene expression. qPCR readings were normalized against GAPDH and the ΔΔCT method 
was used against pEF for each gene (standardised to 1). Data shown represents mean values of three 
repeats, error bars represent standard deviation (* p ≤ 0.05, ** p ≤ 0.01). 
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overexpression of FST344 significantly decreased the proliferative ability of DU145 cells at Day3 
– an effect that lasted through to Day5 (p < 0.05 and p < 0.0001, respectively).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                  
 
 
 
 
 
 
 
 
 
Figure 5.2: Effects of BMP antagonist overexpression on DU145 cell growth. A. Proliferation of DU145 
cells following Noggin, FST344 and Gremlin overexpression at Day3 and Day5 in maintenance DMEM. 
One-way ANOVA was performed to test for significance. B. Proliferation of DU145 cells following 
Noggin, FST344 and Gremlin overexpression at Day3 and Day5 in 50 µg/ml BME medium (orange). For 
ease of comparison between the two growth media, data in A. (green) was replicated in this set of 
graphs. Two-way ANOVA analysis was performed to test for significance. All the data shown represents 
mean values of three separate experiments and error bars represent standard error of the mean 
(SEM). Significance was annotated as follows * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. 
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To investigate the influence of the bone microenvironment on the growth of the overexpression 
cell lines, BME treatment was also included in this assay and readings obtained from these wells 
were normalised against the pEF control in DMEM. Results (figure 5.2B) demonstrated that BME 
treatment seemed to decrease the cell growth of all the overexpression cell lines, however it did 
so significantly only for DU145NOG and DU145FST344 at Day3 (p ≤ 0.05 and p ≤ 0.01, respectively). 
This inhibitory effect was replicated at Day5, with BME treatment significantly affecting 
DU145pEF and DU145NOG growth (p ≤ 0.001 and p ≤ 0.0001, respectively).  
 
 Overexpression of BMP Antagonists Affects DU145 Cell Invasion 
 
As seen in figure 5.3, overexpression of all FST344 and Gremlin significantly inhibited the invasive 
ability of DU145 cells (p < 0.01 for both antagonists), while overexpression of Noggin caused no 
changes. More broadly, the two-way ANOVA analysis also indicated that there was no significant 
difference between DMEM and BME treatments.  
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A. 
B. 
Figure 5.3: Effects of BMP antagonist overexpression on DU145 cell invasion. The invasion rate 
of DU145 cells following Noggin, FST344 and Gremlin overexpression was measured by seeding in 
Matrigel-coated inserts and letting them migrate through the pores of the inserts over a period of 
three days. Cells were then fixed and cell density was assessed by cell spectrophotometry. To 
negate the effect of cell proliferation from the data gathered, readings were normalised against 
day 3 growth readings obtained from control cell-only wells set up during the experiment and day3 
growth data from the cell proliferation assay. A. Invasion rates of the overexpression cell lines 
when cultured in maintenance DMEM. One-way ANOVA was performed to test for significance. B. 
Invasion rates of overexpression cell lines when treated with 50 µg/ml BME medium (orange). For 
ease of comparison between the two growth media, data in A. (green) was replicated in this graph. 
Two-way ANOVA analysis was performed to test for significance. All the data shown represents 
mean values of three separate experiments and error bars represent standard error of the mean 
(SEM). Significance was annotated as follows: ** p ≤ 0.01. 
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 BMP Antagonist Overexpression Affects DU145 Cell Adhesion  
 
The ability of DU145 overexpression cell lines to adhere to a Matrigel basement membrane was 
assessed in maintenance DMEM or 50 µg/ml BME (figure 5.4A). Results demonstrated that 
overexpression of Noggin seemed to decrease adhesion of DU145 cells. In contrast, FST344 and 
Gremlin overexpression increased their adhesive abilities, with Gremlin overexpression doing so 
significantly (p < 0.01). Treatment with BME seemed to have varying effects on the different cell 
lines. For example, treatment with BME increased the adhesion of DU145pEF (not significant) and 
DU145NOG cells (p < 0.01), while it seemed to decrease adhesion of DU145FST344 and DU145GREM. 
Furthermore, two-way ANOVA analysis indicated that results obtained from BME treatment 
wells were as a result of an interaction between the BMP antagonist overexpressed and the BME 
treatment (p < 0.01).  
 
The adhesion of the overexpression cell lines was also assessed by ECIS over a period of 20 hours 
(figure 5.4B). These results demonstrated that overexpression of Noggin and FST344 caused a 
significant decrease in cell adhesion (p < 0.0001 for both), while overexpression of Gremlin 
seemed to cause a slight increase in resistance in comparison to DU145pEF, which may indicate 
a that cells were more densely packed. Treatment with BME caused a significant increase in 
DU145FST344 adhesion (p = 0.0018) only.  
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Figure 5.4: Effects of BMP antagonist overexpression on DU145 cell adhesion. A. Graphs demonstrate 
the adhesion of overexpression cell lines to Matrigel-coated cells when cultured in maintenance DMEM 
(green) or 50 µg/ml BME medium (orange). One-way ANOVA was performed to test for significance 
between DMEM treated cells and two-way ANOVA analysis was performed to test for significance between 
the treatment media. Significance was annotated as follows ** p ≤ 0.01. B. ECIS results demonstrated show 
the adhesion of the DU145 cell lines in maintenance DMEM or 50 µg/ml BME medium. The effects of the 
different treatments on each cell line is also shown. All the data shown represents mean values of three 
separate experiments and error bars represent standard error of the mean (SEM).  
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 BMP Antagonist Overexpression and DU145 Cell Migration 
 
The migration of the transfected DU145 cell lines was assessed in the presence of maintenance 
DMEM or 50 µg/ml BME. As seen in figure 4.4, the overexpression of Noggin and Gremlin did 
not have a noticeable effect on the migration rate of DU145 cells, while FST344 overexpression 
caused a significant decrease in cell migration (p < 0.0001). However, Noggin overexpression did 
hinder the overall migration of the cells since the distance travelled by the cells was significantly 
lower than that travelled by pEF cells (p = 0.0014) by the end of the assay.  
 
In contrast, although BME treatment seemed to decrease overall DU145NOG migration, there was 
not enough evidence to be proven significant. In contrast, the migration rate of DU145FST344 cells 
was shown to be significantly different between the two treatment media (p = 0.0242), which 
was denoted by an initial increase in migration rate, followed by a decreased migration rate in 
comparison to DU145pEF cells, while the overall migration seemed unchanged. There was no 
noticeable change in DU145GREM cell migration caused by the presence or absence of 50 µg/ml 
BME. 
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Figure 5.5: Effects of BMP antagonist overexpression on DU145 cell migration. The top two graphs show 
the migration of DU145 overexpression cell lines across a wound when treated with either maintenance 
DMEM or 50 µg/ml BME. The graphs underneath show the different responses that each individual cell 
line had to the different treatment media. The data above represents mean ± SEM from 4 individual 
experiments and any significant differences between the responses were assessed by linear regression.  
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5.4 Discussion 
 
For a primary tumour to form and progress to secondary sites, it is crucial for cells to gain certain 
aberrant characteristics to override the constraints of physiological cell architecture. In fact, 
cancer cells are defined by two heritable properties: (1) the ability to reproduce in defiance of 
the normal restraints on cell growth and division, and (2) the ability to invade and colonise 
territories normally reserved for other cells; both properties being a result the distortion of vital 
cellular processes such as, cell growth, invasion, adhesion and migration. This chapter aims to 
assess the role of the feedback loop that exists between BMPs, more specifically BMP-7, and 
their antagonists in these cellular processes and to investigate how it may relate to prostate 
cancer progression and metastasis to the bone.  
 
To help with the aim of this study, we decided to overexpress levels of BMP antagonists within 
prostate cancer cells and assess any resulting impact on their behaviour. However, due to the 
reported implication of various BMPs in the prostate cancer process, as well as the promiscuity 
that exists between BMP antagonists and the BMPs they inhibit, we opted to overexpress a 
selection of these antagonists in a prostate cancer cell line. We based our decision of which 
antagonists to overexpress on previous literature to ascertain whether they are able to inhibit 
BMP-2, 4, 6 and 7. Additionally, we also took into consideration preliminary expression profile 
work (Chapter 3 and Chapter 4) to gauge which BMP antagonist could be key in process cancer 
and bone metastasis. As a result, we selected BMP antagonists, Noggin, the FST isoform, FST344, 
and Gremlin for overexpression. 
 
 As part of this study, the BMP antagonist overexpression cell lines were generated through the 
transfection of DU145 cells. This cell line was used since attempts at transfecting other cells also 
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used in this study were unfortunately unsuccessful. Still, as DU145 cells do not appear to 
inherently express very high levels of the selected BMP antagonists (see figure 3.2) enabling us 
to ascertain that any changes in cell phenotype would be due to BMP antagonist overexpression. 
Once the candidate BMP antagonists were identified, the next step was to then create stable 
cell lines that would constitutively express them throughout the duration of the intended 
functional assays. As such, Noggin, FST344 and Gremlin overexpression vectors were generated 
by cloning using the pEF6/V5-HIS-TOPO® TA vector and these were subsequently electroporated 
in DU145 cells. Following a period of antibiotic selection, we were eventually able to obtain cell 
lines that significantly overexpressed the selected BMP antagonists as proven by RT-PCR and 
qPCR analyses. Again, we were unable to prove the downregulation of the BMP antagonists by 
Western Blot, despite many attempts. 
 
The most typical characteristic of cancer cells is their ability to proliferate uncontrollably. 
Therefore, once the stable cell lines were acquired, we aimed to elucidate if the overexpression 
of the BMP antagonists entailed a change in DU145 cell proliferation over a 3-day and 5-day 
period (figure 5.2). Results yielded demonstrated that at Day3, overexpression of Noggin did not 
seem to have any noticeable effect on cell growth, which seems to agree with a study by 
Secondini et al (2011) that demonstrated that knock down of Noggin did not have any effect on 
the cell growth of PC-3 cells. By Day5 however, overexpression of Noggin caused a significant 
decrease in cell proliferation. Since studies have demonstrated that BMP action may be time-
dependent (Ye, Lewis-Russell et al. 2008), it is also possible that the feedback caused by Noggin 
overexpression is also time-dependent. Overexpression of FST344, on the other hand, caused a 
significant decrease in cell growth at Day3, through to Day5. Sepporta et al (2013), despite 
focussing on the Activin/FST system, have highlighted a role for the FST in prostate cancer by 
demonstrating that the FST344 isoform, FST288, may have a stimulating effect on DU145 cell 
growth. This disagrees with our current findings. Interestingly, Gremlin overexpression caused a 
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significant increase in DU145 cell proliferation at Day3. This is supported by a study by Kim et al 
(2012) who demonstrated that Gremlin was able to promote cell proliferation of different cancer 
cell lines, although they did demonstrate that this occurred in a BMP-independent manner. Of 
note, BME caused a decrease in proliferation of all the overexpression cell lines, implying the 
need for BMP action in the cell proliferation of prostate cancer cells within the bone 
environment. 
 
The invasion of DU145 cells was also assessed as a result of BMP antagonist overexpression (see 
figure 5.3). Interestingly, the invasion of DU145FST344 and DU145GREM was significantly decreased 
in comparison to DU145pEF, and a slight increase was noted in DU145NOG. In terms of Noggin, 
these results seem to disagree with Feeley and colleagues (2006) who demonstrated that Noggin 
significantly inhibited cell invasion mediated by BMP-2. Furthermore, previous literature implied 
that FST and Gremlin may induce cell invasion, which contradicts the current findings (Kim, Yoon 
et al. 2012, Sepporta, Tumminello et al. 2013). Treatment with BME caused no significant 
changes in cell invasion, although it did appear to cause a noticeable stimulatory effect on 
DU145FST344 cells. This could potentially paint an interesting picture translationally, whereby 
FST344 in conjunction with the growth factors in the bone environment could increase the 
invasion capabilities of prostate cancer cells. 
 
Morphologically speaking, the loosening of cell-cell and cell-ECM contacts is crucial for 
carcinomas to progress. In fact, the loss of these restraints creates permissive conditions for the 
cells to migrate and invade through the ECM (Coman 1944, McCutcheon, Coman et al. 1948, 
Birchmeier and Behrens 1994). The adhesion of DU145 stable cell lines was examined using two 
methods, namely the in vitro Matrigel adhesion assay and ECIS (figure 5.4). The Matrigel assay, 
which indicated the differences in the initial adhesion of the different cell lines, demonstrated 
that DU145GREM adhesion was significantly enhanced in comparison to DU145pEF in normal 
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culture conditions, while DU145NOG adhesion was decreased. Interestingly, this loss in adhesion 
caused by Noggin overexpression was overcome by treatment with BME, as shown by a 
significant upregulation of adhesive abilities of DU145NOG cells. This could be quite telling in 
terms of prostate cancer metastasis: high levels of this antagonist would enable to cancer cells 
to sever their attachments, thus allowing them to migrate. Therefore, the adhesion results 
obtained from treatment with BME could indicate that once the migrating cancer cells reach the 
bone, the growth factors and non-collagenous proteins within that environment would induce 
re-attachment of the cancer cells. ECIS, in comparison, demonstrated the adhesion of the cell 
lines over a period of 20 hours. These results demonstrated that the overexpression FST344 
caused a drastic decrease in cell adhesion and reflected the Matrigel adhesion assay results in 
terms of a decrease in adhesion following Noggin overexpression. This is supported by studies 
that have implicated Noggin and FST344 in the prostate cancer metastasis (Tumminello, 
Badalamenti et al. 2010, Secondini, Wetterwald et al. 2011, Sepporta, Tumminello et al. 2013).  
 
Once cells have lost their cell-cell and cell-ECM contacts, they are able to migrate to distant sites 
and establish secondary sites. Only the overexpression of FST344 caused a significant decrease 
in cell migration. However, treatment with BME caused an increase in migration which indicates 
that although FST344 overexpression may have a protective effect on prostate cancer 
metastasis, it may be overridden by the presence of growth factors present in the bone 
microenvironment.  
 
Altogether, the data yielded in this chapter describes potentially important roles for each of the 
BMP antagonists in prostate cancer and its progression to the bone. In fact, overexpression of 
all the BMPs induced some cellular behavioural reaction that could impact on prostate cancer 
progression. For instance, while most of the behavioural effects caused by Noggin 
overexpression could be deemed as defensive again cancer, adhesion results demonstrated a 
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potential role of this BMP in the bone metastasis process. Meanwhile, we described novel, 
potentially protective roles implications for Gremlin in prostate in terms of its ability to decrease 
invasion and increase adhesion abilities of DU145 cells. However, the data from FST344 
overexpression assays were quite striking. Indeed, although it seems to have an inhibitory effect 
on most pro-cancer activities, once treated with BME, the effect seems to reverse to a pro-
cancer stance. This effect needs further analysis as to whether this may be as a result of a 
BMP/FST344 feedback loop.
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6.1 Introduction 
 
It has long been recognised that metastasis is inherently a very inefficient process (Weiss 1990). 
Indeed, by the time CTCs reach a secondary site that is suitable for their needs of survival and 
growth, they have already had to survive and escape haemodynamic forces, immunological 
stress and collisions with other cells (Key 1983, Weiss, Dimitrov et al. 1985, Wirtz, 
Konstantopoulos et al. 2011). Still, once they reach and extravasate into the new site, the 
disseminated cancer cells (DTCs) are faced with a yet another obstacle: the dense, cross-linked 
ECM of a physiologically different environment. In fact, only a minority of DTCs are able to 
negotiate and invade through this barrier to form macro-metastases (Luzzi, MacDonald et al. 
1998).  
 
Unspoken by Paget was the concept that even in their preferred metastatic sites, DTCs must still 
undergo certain phenotypic and morphological adaptations in order to colonise them. Indeed, 
several steps must be completed by DTCs to change their plasticity, one of the most important 
steps being EMT. The latter is a highly conserved and reversible process that involves the loss of 
cell-cell adhesion and apical-basal polarisation, the reorganisation of the cytoskeleton 
architecture, changes in the signalling programmes that convey cell shape, and the 
reprogramming of gene expression, all with the aim to bestow onto epithelial cells increased 
motility, invasiveness and the ability to degrade the ECM (Thiery 2002, Thiery, Acloque et al. 
2009, De Craene and Berx 2013, Lamouille, Xu et al. 2014). In fact, EMT should be more precisely 
described as a ‘group’ of biological programmes, all of which are orchestrated and networked 
by a group EMT-inducing transcription factors (EMT-TFs). The most studied and potent EMT-TFs 
are by far master EMT-TFs Snail, zinc finger E-box binding homeobox 1 (Zeb1) and Twist. 
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One fundamental hallmark of EMT is the ‘cadherin switch’, whereby expression of E-cadherin, 
an essential component of adherens junctions, is transcriptionally repressed by Snail and Twist, 
and the expression of the mesenchymal marker, N-cadherin, is upregulated (Batlle, Sancho et 
al. 2000, Vesuna, van Diest et al. 2008, De Craene and Berx 2013). This not only leads to the 
disassembly of adherens junctions, due to the loss of E-cadherin, but also the rearrangement of 
the cytoskeleton, lamellipodia formation, and the induction of pro-migratory and invasive 
signalling cascades by action of N-cadherin (Hazan, Phillips et al. 2000, Li, Satyamoorthy et al. 
2001, Shih and Yamada 2012). Another mechanism by which EMT may induced is by proteolytic 
degradation of E-cadherin by MMPs. While this process disrupts E-cadherin-mediated cell-cell 
adhesion, cleavage of the cadherin also yields an 80 kDa soluble E-cadherin (sEcad) fragment, 
which is capable of inducing EMT, invasion and proliferation in its own rights (Nawrocki-Raby, 
Gilles et al. 2003, David and Rajasekaran 2012). In fact, sEcad levels are significantly heightened 
in the sera and urine of cancer patients and are associated with invasive disease and/or poor 
prognosis in a variety different tumour types, including prostate cancer (Katayama, Hirai et al. 
1994, Kuefer, Hofer et al. 2003, De Wever, Derycke et al. 2007).  
 
Beyond their EMT-inducing functions, MMPs have a much broader role in the metastatic process 
and have a profound effect on the ability of cancer cells to colonise a secondary site. Indeed, as 
the members of the cancer degradome that are able to digest virtually any component of the 
ECM and basal membrane component, MMPs are the principle mediators of changes observed 
in the cancer microenvironment (Egeblad and Werb 2002, Kessenbrock, Plaks et al. 2010). Even 
during bone metastasis, MMPs can be derived from a number of cellular sources, however none 
more so than by the key players of this process, that is, the DTCs, the osteoblasts and the 
osteoclasts (Lynch 2011). While it would seem counterintuitive that osteoblasts would ever 
secrete proteinases given their role in bone formation, it seems that both types of bone cells, 
the osteoblasts and the osteoclasts, require MMPs for normal function. This notion is supported 
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by various studies, one of which demonstrated impaired skeletogenesis in MMP2 null mice 
(Mosig, Dowling et al. 2007). Therefore, it is unsurprising that MMP action would be involved in 
prostate cancer progression to the bone. In fact, MMP2, 3, 9, 12, 13 and 14 have all been 
detected in the prostate cancer bone microenvironment (Nemeth, Yousif et al. 2002, Chinni, 
Sivalogan et al. 2006, Bonfil, Dong et al. 2007, Nabha, dos Santos et al. 2008).  
 
While they are all necessary for normal physiology, the aberrant, combined action of disrupted 
cell-cell junctions, cytoskeletal readjustments and secreted MMPs drive cancer creates a perfect 
storm for cancer cell invasion through the stroma. As such, assessing for expression of the 
different components of these processes provides a good insight in the invasive capabilities, and 
thus aggressiveness of a cancer. For instance, the Snail, Twist and E-cadherin axis has been 
described in the majority of cancer types investigated so far, including breast, pancreas, liver, 
lung and prostate (Sánchez-Tilló, Liu et al. 2012). Therefore, our aim was to screen for these 
telling signs of EMT and invasion to get a better insight into the molecular mechanisms 
underlying the formation of osteolytic and osteoblastic lesions. Furthermore, having 
accumulated data on the phenotypic behaviour of prostate cancer cells under the influence of 
BMP overexpression, we also endeavoured to decipher which BMP-BMP antagonist interplay 
could be in play.  
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6.2 Materials and Methods 
 
 Materials 
 
All the primers used were synthesised and provided by Sigma-Aldrich (Poole, UK). Primer 
sequences are detailed in tables 2.2 to 2.4. 
 
 Cell lines and Treatments 
 
Stably transfected overexpression cell lines were cultured in maintenance medium consisting of 
DMEM supplemented with 10% FBS, antibiotics and 0.5 µg/ml blasticidin. All cell lines were pre-
treated in the maintenance medium with 5% FBS and antibiotics overnight, preceeding any 
treatment experiments. The BME treatment used in this study was prepared as described in 
section 2.2.1, and 50 µg/ml in 5% FBS DMEM was used to treat cells. 
 
 RNA isolation and cDNA synthesis 
 
RNA was extracted from the cells using the TRI reagent® kit (Sigma-Aldrich, Poole, UK), and 
synthesised into cDNA by reverse transcription using the GoScript™ Reverse Transcription 
System (Promega, Southampton, UK), as respectively described in sections 2.4.2 and 2.4.3.  
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 RNA-Seq 
 
Targeted-sequencing of low passage PC-3 and VCaP incubated with either fresh 5% FBS DMEM 
or 5% FBS DMEM containing 50 µg/ml BME for 3 hours 37°C, 5% CO2 was undertaken. 10 ng of 
total RNA extracted from the prostate cancer cell lines was subsequently used for RNA 
sequencing. Heatmaps were generated using Microsoft Excel. 
 
 qPCR  
 
qPCR was performed using the Amplifluor™ Universal Detection System (Intergen Company, 
New York, USA) under the cycling conditions detailed in section 2.4.6.  CT values obtained were 
analysed using ΔΔCT normalisation to GAPDH and the relative quantity was calculated using 2-
CT. Data analysis was carried out using unpaired t-test with Welch’s correction compared to the 
pEF control for the DMEM data. Two-way ANOVA was performed to assess significance in the 
BME data.  
 
 GEO Database  
 
In the present study, we utilised data from the GEO dataset (GSE41619) generated by Larson et 
al (2013), who performed microarray hybridisation on RNA isolated from osteoblastic and 
osteolytic bone metastatic cores. Expression data for genes of interest were extracted from the 
GSE41619 and heatmaps of this data were generated using RStudio. Analysis of these samples 
was also performed by calculating the mean and SEM of these samples, and significance was 
assessed using unpaired t-test with Welch’s correction. These details can be found in the 
appendix. We also extracted expression data from a GEO dataset produced from the microarray 
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gene analyses of LNCaP cells and primary hOBs monocultures and co-culture (Sieh, 
Taubenberger et al. 2014). This data was analysed by calculating the means of all the repeats + 
SEM, and significance was analysed by unpaired t-test using the Holm-Sidak method. 
 
6.3 Results 
 
 Differential Expression of EMT markers and MMPs in Osteolytic and Osteoblastic Cell 
Lines 
 
RNA-Seq analysis was run on PC-3 and VCaP cells to assess their invasiveness and EMT status 
(see figure 6.1A). According to these results, PC-3 appeared to express more of the mesenchymal 
markers, that is, Snail, Slug, Twist and N-cadherin, in comparison to VCaP, with the latter not 
even expressing Twist1. Upon BME treatment however, most of the markers that PC-3 
expressed were downregulated, with the exception of Snail, which was upregulated. Twist1 
levels remained more or less the same. Similarly, although VCaP expressed very low levels of the 
mesenchymal markers, they were all further downregulated following BME treatment.  Both cell 
types expressed high levels of epithelial marker, E-cadherin, although VCaP less so than PC-3. 
BME treatment also reduced levels of the marker in both PC-3 and VCaP. 
 
When assessing the levels MMPs in the different cell lines (figure 6.1B), we observed that PC-3 
expressed a higher proportion of the proteinases, and in generally higher levels than VCaP. In 
fact, PC-3 cells expressed MMP1, 2, 3, 7, 8, 9, 11, 13, 15, 16, 17, 23, 24, 25, 28 and extremely 
high levels of MMP14. Along with MMP21, VCaP expressed the same MMPs, with the exception 
of MMP3, 9, 16 and 23. BME treatment induced fluctuating changes to the levels of the different 
MMPs, however the most expressed ones were upregulated in both cell lines. 
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Figure 6.1: Differential Expression of EMT markers and MMPs between osteolytic and osteoblastic cell lines. The osteolytic cell line, PC-3, and the osteoblastic 
cell line, VCaP, were treated with 5% FBS DMEM or 5% FBS DMEM containing 50 µg/ml BME. RNA was extracted from the cells and RNA-Seq was performed on 
the samples. A. The heatmap presented demonstrates the changes in expression of the EMT markers, Snail, Slug, Twist1, Twist2, N-Cadherin and E-Cadherin in 
both cell lines following BME treatment. B. We also analysed the differing levels of MMPs between the cell lines, in the absence and presence of 50 µg/ml BME. 
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VCaP control 
VCaP + BME 
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 Expression Profiles of EMT Markers and MMPs in Osteoblastic and Osteolytic Bone 
Lesions  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. 
Figure 6.2: The EMT expression profile of osteoblastic and osteolytic bone lesions. A. Data 
was extracted from GEO data (GSE44143) produced by Sieh et al (2014) who performed 
microarray gene analysis of LNCaP cells and hOBs that were monocultured or co-cultured. 
The data shown represents mean + SD and significance was assessed by unpaired t-test 
using the Holm-Sidak method. B. The heatmap generated represents EMT marker 
expression data extracted from the GSE41619 microarray analysis of osteoblastic (1-7) and 
osteolytic lesions (8-14) (Larson et al 2013).  
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Using GEO data from Sieh et al (2014) and Larson et al (2013), we analysed the differential 
expression of EMT markers in the osteoblastic and osteolytic bone lesions (figure 6.2). Data from 
Sieh et al demonstrated that LNCaP cells expressed much higher levels of E-Cadherin in 
comparison to the mesenchymal markers. This was still the case following co-culture with hOBs, 
although levels of the Slug and N-cadherin were significantly increased (p = 0.0346 and p = 
0.0009, respectively). In contrast, Snail levels seemed to be decreased. hOBs demonstrated a 
different EMT profile altogether by expressing higher levels of all the mesenchymal markers in 
comparison to E-cadherin. However, this was reversed following co-culture with LNCaP, with 
Snail, Slug and N-cadherin showing significant downregulation (p = 0.0119, p = 0.0106 and p = 
0.0057, respectively) and E-cadherin being considerably upregulated (p < 0.0001).  
 
Analysis of EMT marker expression using data acquired from Larson et al demonstrated that 
while both types of bone lesions exhibited a high expression of Snail and Slug in comparison to 
the reference pool, N-cadherin was downregulated, and E-cadherin was only slightly 
upregulated. Twist1, on the other hand, was downregulated in both lesion types. Although not 
significant, certain differences were observed between the EMT marker levels of osteoblastic 
and osteolytic lesions (see figure A4). Indeed, an upregulation in levels of all the mesenchymal 
markers, Snail, Slug, Twist and N-Cadherin, was noted in the osteoblastic lesions when compared 
to osteolytic lesions. In contrast, levels of E-cadherin were higher in the osteolytic lesions.  
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 Differential Expression of MMPs in Osteoblastic and Osteolytic Bone Lesions 
 
Using the same GEO data from section 6.3.2, we analysed the expression of MMP expression 
profiles of osteoblastic and osteolytic bone lesions (see figure 6.3). From these findings we 
observed that LNCaP cells expressed all of the MMPs tested, with MMP2 and MMP17 being 
exhibiting higher levels than the others. Changes to MMP levels were variable following co-
culture with hOBs, although it caused a significant decrease in MMP2, 13, 17 and 28 (p = 0.0021, 
p = 0.0226, p = 0.0181 and p = 0.0178, respectively). Similarly, hOBs expressed all of the MMPs 
tested, with higher levels MMP2 and MMP17. Furthermore, co-culture with LNCaP cells also 
demonstrated variable changes. For instance, while MMP2, 3, 11, 27 and 28 were all significantly 
downregulated (p = 0.0098, p = 0.0406, p = 0.0034, p = 0.0177 and p = 0.0391, respectively), the 
co-culture experiments also caused a significant increase in MMP10, 15, 16 and 25 (p = 0.0001, 
p < 0.0001, p = 0.0009 and p = 0.0228, respectively). 
 
Again, MMPs were expressed at varying levels in both types of lesions. Overall analysis of the 
samples (see figure A5) have shown that out of the MMPs tested, levels of MMP1, the two 
variants (v) of MMP16, MMP16 v1 and MMP16 v2, and MMP17 were lower than that of the 
reference sample. All the other MMPs were more highly expressed in comparison, with MMP2 
and MMP26 showing the highest expression. Further analysis into the differential expression of 
the two types of lesions has demonstrated that their MMP profiles showed some differences, 
with MMP13 and MMP15 being significantly more expressed in osteolytic lesions (p = 0.0022 
and p =0.0438, respectively). Of note, while highly expressed in both lesions, MMP2 was more 
highly expressed in osteoblastic lesions.  
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Figure 6.3: The MMP expression profile in in osteoblastic and osteolytic prostate cancer bone lesions. A. Microanalysis GEO data (GSE44143) obtained from LNCaP-hOB 
monoculture and co-culture experiments performed by Sieh et al (2014) were analysed, assessing for MMP expression levels. The images above represent the mean + SD and 
significance was assessed using unpaired t-test using the Holm-Sidak method (* p ≤ 0.0.5, ** p ≤ 0.01, p ≤ 0.001, **** p ≤ 0.0001). The data demonstrates the difference in MMP 
expression between LNCaP monoculture and their co-culture with hOBs. B. The data demonstrates the differential expression of MMPs in hOBs between hOB monoculture and their 
co-culture with LNCaP cells as obtained from the GSE44143 dataset. C. The heatmap was generated from the GSE41619 dataset depicts the differential expression of MMPs between 
osteoblastic (1-7) and osteolytic (8-14) bone lesions. This data was obtained from Larson et al (2013). 
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 The MMP Expression Profile of the BMP Antagonist Overexpression Cell Lines 
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Figure 6.4: BMP-mediated expression of MMPs. The expression of ID1 and MMP2, 7, 9, 12 and 14 
was assessed in the overexpression cell lines DU145PEF, DU145NOG, DU145FST344 and DU145GREM, by 
qPCR. The data represents the mean + SD from one assay. Statistical significance was measured by 
unpaired t-test with Welch’s correction (* p ≤ 0.05, *** p ≤ 0.001). 
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qPCR analyses (figure 6.4) demonstrated that overexpression of all the BMP antagonists caused 
a decrease of ID1, with FST344 and Gremlin overexpression causing significant decreases (p = 
0.0381 and p = 0.0007). BMP antagonist overexpression also caused a decrease in most of the 
MMPs tested, although Gremlin overexpression seemed less efficient in downregulating MMPs 
than the other antagonists, even causing an increase in MMP9 levels. MMP2 levels were 
significantly reduced in both DU145FST344 and DU145GREM (p = 0.0270 and p = 0.0426). MMP7 
were decreased significantly in DU145FST344 (p = 0.0366) and MMP9 was significantly decreased 
in both DU145NOG and DU145FST344 (p = 0.0441 and p = 0.0449, respectively). While both MMP12 
and MMP14 were decreased following BMP antagonist overexpression, neither showed any 
significance.  
 
 The BMP/BMP Antagonist Feedback Loop in the Bone Environment 
 
qPCR analyses were performed on the cell lines generated from the experiments outlined in 
Chapter 5. These were either treated in maintenance medium with reduced FBS content (5%) or 
with this same medium supplemented with 50 µg/ml for 3 days (see figure 6.5). The data 
demonstrated that levels of all the BMPs tested were reduced following overexpression of 
Noggin and FST344, although BMP-4 downregulation by Noggin was minimal. The same could 
not be said would Gremlin overexpression, which downregulated expression of BMP-2 only, 
even causing an increase in expression for the other BMPs. Interestingly treatment with BME 
caused different effects on the levels of the BMPs tested. For instance, BME treatment caused 
the downregulation of BMP2 and an upregulation of BMP-4 in all the cell lines. BME caused a 
slight increase of BMP-7 in DU145PEF and DU145NOG cells, and a slight decrease in DU145FST344 
and DU145GREM. In contrast, BMP-6 levels were decreased in DU145PEF and DU145GREM, and 
increased in DU145NOG and DU145FST344. However, two-way ANOVA analysis of the results 
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indicated these changes in BMP levels did not result from the integrated action of the BMP 
antagonists and the BME.  
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Figure 6.5: The BMP/BMP antagonist feedback loop behind cancer cell behaviour in the bone 
environment. The BMP antagonist overexpression cell lines, DU145PEF, DU145NOG, DU145FST344 and 
DU145GREM, were pre-treated overnight in serum-reduced maintenance medium (5% FBS). Cells 
were then treated for 72 hours with fresh 5% FBS maintenance medium with or without 50 µg/ml 
BME. RNA was extracted, and qPCR analyses were carried testing for the levels of BMP-7 (A), BMP-
2 (B), BMP-4 (C) and BMP-6 (D). The data was analysed using the ΔΔCT method against DU145PEF 
in DMEM. The control data (DMEM) was replicated in the treatment graphs for ease of comparison 
data above show mean + SD from one assay. Statistical significance was measured by unpaired t-
test using the Holm-Sidak method (* p ≤ 0.05) and two-way ANOVA.  
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 The EMT Marker Profile of BMP Antagonist Overexpression Cell Lines in the Bone 
Microenvironment  
 
The levels of Snail and Slug in the overexpression cell lines following 3 days in a control, reduced 
FBS medium or in a BME treatment medium were assessed by qPCR (see figure 6.6). The data 
demonstrated that while in the control medium, Snail levels were decreased in both DU145FST344 
and DU145GREM, with DU145FST344 showing a significant decrease (p = 0.0349). DU145NOG showed 
a slight increase. In contrast, levels of Slug were increase in both DU145FST344 and DU145GREM, 
and reduced in DU145NOG. BME treatment demonstrated differing effects on the levels of the 
EMT markers. Indeed, despite causing an increase in both EMT marker levels in the control cell 
line, BME treatment caused a decrease in Snail levels and a drastic increase in Slug levels in the 
overexpression cell lines. Interestingly, while two-way ANOVA of the results demonstrated that 
the changes shown in Snail levels were not as a result of an interaction between BMP antagonist 
overexpression and BME treatment, they showed a significant chance that the combined action 
of these two factors caused changes in Slug expression (p < 0.0001). 
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6.4 Discussion 
 
Bone metastasis is by far the most devastating and challenging aspect of prostate cancer. 
Despite the advances in the diagnosis and management of this disease, once it reaches the bone, 
the only available options are mainly palliative. Skeletal metastases unfortunately result in 
significant complications that greatly diminish the quality of life of affected patients, causing 
such symptoms as bone pain, pathological fractures, symptomatic hypercalcaemia and spinal 
cord compression (Coleman 1997, Coleman 2006). In spite of these severe complications, there 
have not been many advances in the development of therapeutic strategies to prevent or treat 
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Figure 6.6: The EMT profile of the BMP Antagonist Overexpression Cell Lines in the Bone Environment. 
The cell lines were cultured in reduced FBS (5%) maintenance medium overnight. They were then 
treated with fresh reduced maintenance medium in the absence or presence of 50 µg/ml BME for 3 
days. RNA was extracted, and qPCR was performed on the samples. The data represents mean + SD from 
one assay. Statistical significance was assessed by unpaired t-test with Welch’s correction for the 
samples in control medium (DMEM) and two-way ANOVA was used on the both set of data.  
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these lesions. As such, gaining an understanding of the pathophysiological processes behind the 
formation of prostate cancer bone metastases is critical. In this study, we aimed to understand 
the metastatic differences of the osteolytic and osteoblastic lesions and how BMPs and their 
antagonists participate in this process. 
 
Since it is well recognised that the ‘successful’ establishment of prostate cancer in the bone 
depends on interactions between the cancer cells and the bone microenvironment, our first aim 
for this study was to assess how BME affects the metastatic status of the osteolytic PC-3 and 
osteoblastic cell lines VCaP cells. In order to do so, we assessed the differential expression of 
mesenchymal markers, Snail, Slug, Twist isoforms, Twist1 and Twist2, and N-cadherin, as well as 
the epithelial marker E-cadherin, in the cell lines in the absence and presence of BME (figure 
6.1A). From these findings, it was apparent that the PC-3 cell line expressed much higher levels 
of the mesenchymal markers than VCaP. This could be explained by the fact that this cell line is 
inherently more aggressive (Tai, Sun et al. 2011). Interestingly, with the exception of Snail which 
was upregulated in PC-3, all the EMT markers were downregulated in both cell lines. While the 
decrease in mesenchymal markers could indicate that factors in the BME are inducing a 
mesenchymal to epithelial transition (MET) response, however this is contradicted by the 
decrease in the levels of E-cadherin. It is possible that both are happening in parallel. It is 
generally known that DTCs need to undergo MET to allow adhesion and anchorage for the 
colonisation of the metastatic niche (Yao, Dai et al. 2011). Still, it is possible that an invasive 
response is still being triggered, as is manifested by the downregulation of E-cadherin. Although 
the BME treatment caused varying effects on the levels of the different MMPs (see figure 6.1B), 
the MMPs that were most highly expressed, that is MMP14 (also known as membrane type 1 
matrix metalloproteinase, MT1-MMP) in PC-3 and MMP10 and MMP15 in VCaP, were 
upregulated in response to BME. This could tie in with the previous suggestion that while some 
cancer cells are undergoing MET in response to BME, others are retaining their mesenchymal 
176 
 
and invasive phenotype to enable the infiltration of their new environment. Furthermore, the 
increase in MMP levels could explain the decrease in E-cadherin, due to their ability to degrade 
the EMT marker to the smaller sEcad fragment (Nawrocki-Raby, Gilles et al. 2003, David and 
Rajasekaran 2012).  
  
We also wanted to assess the EMT marker status of cancer cells in the early establishment of 
bone metastasis. This was done by analysing the expression of EMT markers in LNCaP cells in co-
culture with hOBs, as carried out by Sieh et al (2014; see figure 6.2A). Although the changes 
between the monoculture and co-culture conditions were minimal, all the mesenchymal 
markers, except Snail, were upregulated, along with E-cadherin. Although the 
pathophysiological conditions simulated in both experiments are different, this data 
demonstrates could agree with the RNA-Seq data, demonstrating a mixed EMT response. 
However, the GEO results also indicate that MMP-mediated EMT might not be occurring due to 
the downregulation of known EMT-inducing MMPs, MMP2, 3, 9, 13 and 28 (Gialeli, Theocharis 
et al. 2011; see figure 6.3A and B). Part of these MMPs, such as MMP2 and 9 are also known to 
be implicated prostate cancer cell invasion, thus their decrease could be indicative that co-
culture with the hOBs did not induce an osteolytic response (Nemeth, Yousif et al. 2002).  Using 
the data from Larson et al, we also assessed how the prostate cancer cell and osteoblast 
interplay affect the EMT status of hOBs (figure 6.2B). Interestingly, the data demonstrated that 
interaction with LNCaP caused the hOBs to undergo EMT, as manifested by the significant 
decrease of mesenchymal markers and significant increase of E-cadherin. If one were to consider 
a study by Stewart et al (2010) who investigated zebrafish bone regeneration, this could be 
reminiscent of the EMT undergone by osteoblasts in order to generate proliferative 
preosteoblasts following fin amputation. Although this study demonstrated that this process 
was Wnt-mediated, they also iterated the requirement of BMPs for the osteoblast 
differentiation. Therefore, altogether, observed findings could be indicative of an osteoblastic 
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response to the prostate cancer cells. While it known that osteoblasts express MMPs, the exact 
mechanism through which these MMPs contribute to osteoblast function remains mostly 
unknown. However, a study by Johansson et al (1997) have demonstrated the expression of 
MMP13 by osteoblasts and its importance in endochondral ossification and bone remodelling. 
With this in mind, the decrease in MMP13 levels in hOBs could indicate that the hOBs are not 
initiating an ossification process. Johansson et al also demonstrated that expression of BMP-2 
inhibited MMP13 expression, therefore it is possible that the decrease of MMP13 observed 
would be due to the BMP-2 produced by the LNCaP in co-culture.  
 
The analysis of the differential expression of EMT markers between the two types of bone 
lesions demonstrated that generally (figure 6.2C), osteoblastic lesions expressed higher levels of 
mesenchymal markers and lower levels of the epithelial markers, indicating that the cells in the 
lesions are more mobile and invasive in the osteoblastic lesions. This seems to be supported by 
the high expression of MMP2 and MMP15 (also known as MT2 MMP) in particular, with both 
MMPs known to be potent metalloproteinases (Nemeth, Yousif et al. 2002, Ito, Yana et al. 2010). 
Meanwhile, the high expression of MMP13 could be indicative of osteoblast activity. The 
increase observed in these MMPs could be as a result of BMP-2, 4, and 6 as they were all more 
highly expressed in osteoblastic lesions. In fact, BMP-4, for instance, has been shown to 
stimulate breast cancer cell invasion by enhancing MMP2 and MMP9 activity (Cyr-Depauw, 
Northey et al. 2016). The decrease in MMP2, 7, 9, 12 and 14 following BMP antagonist 
overexpression as seen by our qPCR analyses indicates that this could indeed be the case, 
especially with the BMP-responsive ID1 confirming a decrease in BMP activity (see figure 6.4).  
 
In order to assess the BMP/BMP antagonist feedback loop that could be in play during the 
phenotypic changes observed in Chapter 5, we treated the overexpression cell lines generated 
with BME. Since most of the functional assays were carried out for up to 3 days and BMP action 
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has been shown to be time-dependent, we opted to also carry out the treatment for 3 days. 
From these findings (figure 6.5), we were able to see that although BMP antagonist 
overexpression are extracellular regulators, their overexpression was also able to trigger a BMP 
downregulation at the mRNA level, except for Gremlin, which seemed to cause an 
overexpression of most of the tested BMP. However, treatment with BME caused varying 
responses in the different BMPs. For instance, it caused an increase in BMP-2 and a decrease in 
BMP-4 levels in all the stable cell lines. Meanwhile, BME treatment caused a mixed response in 
the expression of BMP-6, inducing an increase in expression in DU145NOG and DU145FST344, and a 
decrease in DU145GREM, and did not cause much change in BMP-7 expression, although it show 
a downregulation of this BMP in DU145FST344. Despite not being able properly measure statistical 
significance due to the low number of observations, the data gives us an idea of the BMP/BMP 
antagonist interplay in the bone. For instance, the results summarised in Chapter 5 have 
demonstrated that BME treatment instigated a decrease in growth in DU145FST344 cells, the qPCR 
therefore indicate that this could be as a result of BMP-7 downregulation or BMP-6 
upregulation. It is also possible that these changes were mediated by BMP-2 and BMP-4, 
however, one would expect that since the BME treatment caused the same response in the 
expression of these BMPs in all the cell lines, that they would also incite the same response 
phenotypically.  
 
Building on this information, we then wondered which BMP/BMP antagonist feedback loop 
participates in the invasion of prostate cancer cell. As such, we assess the expression of the 
mesenchymal markers Snail and Slug in the BMP antagonist overexpression cell lines (figure 6.6). 
These results demonstrated that while BME treatment induced an increase in the expression of 
Snail in the control DU145PEF, it also induced a decrease in the levels of the mesenchymal marker 
in the overexpression cell lines. Although this was not confirmed by two-way ANOVA, it indicates 
that BMP antagonist overexpression, together with the influence of BME reduced the 
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mesenchymal phenotype of the DU145 cells. However, the Slug results indicated otherwise in 
the DU145NOG and DU145GREM cell lines. Further experimentation might be needed to confirm 
these findings, such as assessing N-cadherin and E-cadherin levels as well. Still, with DU145FST344 
exhibiting a decrease in both Snail and Slug, it indicates that this cell line has more of an epithelial 
phenotype. This is supported by the ECIS and migration data, which both demonstrated a 
decrease in the adhesive and migratory properties of this cell line following BME treatment.  
 
Having gathered information on the differential expression of BMP and their antagonists in 
prostate cancer bone metastases in previous chapters, we aimed to evaluate how this translated 
in the downstream markers of invasive and migratory properties. This chapter summarises these 
findings, showing that the BMP/BMP antagonist feedback loop has a role in the expression of 
MMPs and that the bone environment may impact on this relationship, in some cases causing 
an increase in mesenchymal markers. Further experimentation is required to confirm and build 
on the current findings.
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As members of the TGF-β superfamily which are known not only for their strong osteoinductive 
capacities but also for their ability to coordinate cellular functions, such as proliferation, 
migration, adhesion and invasion, many have suggested a role for BMPs in the formation of the 
osteoblastic bone lesions typically seen in advanced-stage prostate cancer patients. Since the 
current understanding of BMP antagonists denotates them as being more than just BMP 
regulators but also as integral components of BMP function, we hypothesise that the feedback 
loop that exists between BMPs and their antagonists in normal physiology may also be key 
during prostate cancer progression and bone metastasis.  
 
In an effort to elucidate BMPs and antagonists of potential importance in the osteoblastic lesion 
formation, we first aimed to investigate their differential expression in prostate cancer cell lines 
associated with the different bone lesion phenotypes by RT-PCR, qPCR and by analysing GEO 
data from a prostate cancer cell line expression study performed by Barretina et al (2012). We 
especially focussed our attention on the expression of BMP-2, 4, 6 and 7 since previous literature 
has demonstrated them to be of potential importance due to their aberrant expression in 
prostate carcinoma and bone metastasis samples (Bentley, Hamdy et al. 1992, Bobinac, Marić 
et al. 2005, Spanjol, Djordjević et al. 2010). From our laboratory findings we observed that BMP-
4 and the antagonists Noggin and FST344 were most highly expressed in osteolytic cell lines, 
while BMP-2 and 7 and the antagonist Grem1 were mostly expressed in osteoblastic cell lines. 
Although there were some variations when we compared this data to the GEO data from 
Barretina et al, from this data we deduced that there may be a feedback loop between BMP-2 
and BMP-7 and Gremlin. Furthermore, this feedback loop could be of importance during the 
formation of osteoblastic lesions, especially with Pereira et al (2000) having shown the interplay 
between BMP-2 and Gremlin on osteoblast function. Since the osteoblastic VCaP cells 
demonstrated a high expression of BMP-7, while PC-3 did not exhibit any expression of this 
antagonist, its importance in the osteoblastic bone lesions is further indicated.  
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The next step in our study was to put this theory to the test by assessing how the BMP/BMP 
antagonist interplay may participate in the development of bone metastases. Although Sir 
Stephen Paget’s ‘seed and soil’ theory is still widely accepted, studies have since built upon this 
concept, demonstrating it is the dual interaction between cancer cells and the bone 
environment that enable the establishment of bone metastases. As such, we aimed to see how 
the bone environment would impact on the BMP/BMP antagonist feedback loop. To do so, we 
aimed simulate the bone environment in vitro by using the extract from femoral heads collected 
from patients who have undergone hip replacement surgeries. This extract, BME, was then used 
to treat osteolytic and osteoblastic cell lines, and the effect on BMP signalling was assessed by 
RNA-Seq and qPCR. These results demonstrated that the expression of BMP-2, 4 and 6 were all 
downregulated in the osteolytic PC-3 cell line, with BMP-7 remaining unexpressed. Meanwhile, 
BMP-4 was upregulated in the VCaP cells, while BMP-2, 4 and 7 were downregulated. The 
upregulation in BMP-4 could show a possible role in osteoblastic lesion formation, however the 
levels are so low in comparison to other BMPs, especially BMP-7, that it seems unlikely. Like 
with the BMPs, BME treatment caused a decrease in BMP antagonist expression. We also aimed 
to assess the BMP/BMP antagonist relationship in early osteoblastic establishment using GEO 
data from LNCaP-hOB co-culture assays performed by Sieh et al (2014). From this data, we 
deduced that BMP/BMP antagonist feedback loop was indeed in play between the LNCaP and 
the hOBs. This was evidenced by the increase in BMP antagonists FST, GREM1 and GREM2 in 
LNCaP, and the decrease in BMP-2 and 4 and increase of BMP-6 levels in hOBs during co-culture 
conditions. Since LNCaP cells are known to produce mixed lesions, it is difficult to discern which 
interplay would be especially key in osteoblastic bone formation. This is why the GEO data by 
Larson et al (2013) was useful due to its analysis of prostate cancer bone metastases, grouped 
into osteoblastic and osteolytic lesions. This data demonstrated that the expression of BMP-2, 
4 and 6 as well as the antagonists GREM2 were more highly expressed in osteoblastic lesions, 
while BMP-7 and Noggin were more highly expressed in osteolytic lesions. This ties in with our 
previous suppositions about the possible involvement of BMP-2 and Gremlin in the 
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development of osteoblastic lesions. However, the high expression of BMP-7 in osteolytic lesions 
in comparison to osteoblastic ones goes against the main hypothesis of this study, as well as 
previous studies who have documented the expression of BMP-7 in prostate cancer bone 
metastases (Buijs, Rentsch et al. 2007, Morrissey, Brown et al. 2010, Spanjol, Djordjević et al. 
2010). Although the phenotypes of the bone lesions processed in these studies were not 
specified, due to the small number of observations available in the study by Larson et al, we 
opted not to completely reject our main hypothesis.  
 
Having gathered information on differential expression of BMPs and their antagonists, as well 
as their signalling components, we aimed to assess the expression EMT markers and MMPs in 
the LNCaP-hOB culture assays performed by Sieh et al (GSE44143) and the prostate cancer bone 
metastasis samples analysed by Larson et al (GSE41619). Analysis of these findings suggested 
that while under the influence of the LNCaP cells, the hOBs seemed to undergo EMT. With our 
findings having already shown co-culture conditions induced significant changes in BMP 
expression in hOBs, the EMT changes observed could be as a result of these changes. The 
differential expression of BMPs and their antagonists in the prostate cancer samples 
demonstrated that mesenchymal markers were more highly expressed in osteoblastic lesions in 
comparison to the osteolytic lesions. This too could be due to the higher expression of BMP-2, 
4 and 6, although more observations, as well as further experimentation are required to 
investigate this.  
 
To further investigate the role of BMP/BMP antagonist feedback loop in prostate cancer and its 
establishment in the bone, we overexpressed BMP antagonists, Noggin, FST344 and Gremlin in 
the prostate cancer cell line DU145 and subjected the resultant cell lines to different functional 
assays. This data demonstrated that in general, Noggin overexpression had caused a decrease 
in cell proliferation, Matrigel and ECIS adhesion, and migration. While BME treatment of the 
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DU145NOG cell line caused further inhibition of most of the tested cellular properties, it also 
caused an increase in adhesion as shown by the in vitro Matrigel assay. When we assessed the 
downstream target genes by qPCR, we observed the functional data was supported by the 
downregulation of MMP2, 7, 9, 12 and 14 and the downregulation of mesenchymal marker Snail 
upon treatment with BME. BME treatment also induced the expression of BMP-2 and 6 in this 
cell line as well, it is possible that the interplay between these BMPs and Noggin are the cause 
for this increase in adhesion.  
 
Similar to these results, FST overexpression also caused a decrease in cell proliferation, invasion, 
ECIS adhesion and migration. However, it also caused an increase in Matrigel adhesion, although 
this was not statistically significant. BME treatment further inhibited most of these cellular 
properties, except for invasion and long-term adhesion shown by ECIS. As with DU145NOG cells, 
the inhibition of cellular properties seen in the absence of BME seems to be due to the inhibition 
of BMP action, as shown by the decrease in the BMP-responsive ID1, and the decrease in 
invasion was as a result of MMP downregulation. The increase in invasion observed in BME 
seemed to agree with Slug upregulation in the same treatment conditions, although the other 
mesenchymal marker tested, Snail, was downregulated. It is possible that both Noggin and 
FST344 have a protective effect on prostate cancer and bone metastasis. The current 
observations regarding Noggin are supported by Feeley and colleagues who demonstrated that 
this antagonist inhibited the development of BMP-mediated osteolytic and osteoblastic prostate 
cancer lesions (Feeley, Gamradt et al. 2005, Feeley, Krenek et al. 2006). As for FST, studies have 
described this antagonist as a potential therapeutic target and bone metastasis marker in 
prostate cancer (Sardana, Jung et al. 2008, Tumminello, Badalamenti et al. 2010, Sepporta, 
Tumminello et al. 2013), which disagrees with the current findings.  
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Unlike the other antagonists, Gremlin overexpression showed a stimulation in cell proliferation, 
adhesion and migration, as well as an inhibition of cell invasion. Furthermore, BME treatment 
of the DU145GREM cell line did not seem to affect cellular function as much as it did for the other 
cell lines. However, it did appear to cause a decrease in Matrigel adhesion and an increase in 
ECIS adhesion and migration. The increase in adhesion and migration observed seem to be 
contradictory. Indeed, the cellular properties needed for adhesion, such as strong cell-cell and 
cell-matrix contacts, are precisely the ones that cells need to lose in order to migrate. Although 
this could be explained by different responses shown by the mesenchymal markers to treatment 
with BME, as with the downstream results obtained for the other cell lines, more observations 
are needed for confirmation. While overexpression of Gremlin also appeared to inhibit BMP 
action as seen by the downregulation of ID1, it did not appear to cause a downregulation of all 
the BMPs tested as the other antagonists did, causing a downregulation of BMP-2 only. This 
finding would agree with a previous study by Church et al (2015) who described the preferential 
binding of GREM1 to BMP-2 over BMP-4 and 7. This may bring further evidence to the BMP-2-
Gremlin interplay previously described.  
 
Future work 
 
Although the main hypothesis of this study was investigating the role of the BMP-7/BMP 
antagonist feedback loop in particular and understanding its role in prostate cancer and bone 
metastasis, we still gathered some promising information a possible BMP-2/Gremlin interplay 
and the potential protective capacity of Noggin and FST344 in prostate cancer metastasis. Since 
our study is also primarily focused on osteoblastic lesion formation, the use of the osteolytic 
DU145 cell line for BMP overexpression and subsequent functional assays was not ideal. 
However, various attempts at transfecting both the LNCaP and VCaP cell lines using the pEF6/V5-
HIS-TOPO® TA vector were unsuccessful. Hence, further work might require the use of 
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osteoblastic cell lines for better representation, the genetic modulation of which could be 
achieved either through use the use of other methods of transfection, such as lentiviral 
transfection, or exogenous treatment using recombinant proteins. Furthermore, due to the 
multiple processes that occur beyond transcription to contribute to the establishment of 
expression levels of a protein, our current work needs verification at protein levels by Western 
blot. Indeed, assessing the phosphorylation of downstream Smads would be more conclusive in 
assessing if the Smad signalling pathway is being triggered. In parallel, examining downstream 
components of the Smad-independent pathway, such as p38, would also be of interest to help 
map the signalling of interplay between BMPs and their antagonists.  
 
To further investigate the BMP/BMP antagonist relationship in prostate cancer, future 
experimentation could involve treatment of the overexpression cell with recombinant BMPs. 
The results obtained from the recombinant BMP experiments could also be compared with 
those obtained from BME treatment. A more detailed analysis of BMP/BMP antagonist interplay 
could be achieved by co-immunoprecipitation (co-IP). By taking samples from the culture 
medium of the transfected and treated cells and studying them by co-IP, we could ascertain how 
the BMP/BMP antagonist feedback loop is being affected from genetic modulation and BME 
treatment. While the functional assays used in this study are acceptable for a preliminary 
examination of the cellular properties of the overexpression cell lines, more three-dimensional 
assays could also be used for a better representation of in vivo conditions. An example would 
be a spheroid assay using Matrigel to assess cell invasion as described by Berens et al (2015). 
Finally, to get a clearer role for the BMP/BMP antagonist interplay in prostate cancer progression 
and bone metastasis, in vivo models would eventually need to be used, potentially through the 
injection of stable cell lines into immunodeficient mice.  
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 PC-3  DU-145 LNCaP 
BMP-7 Very low 
Moderately high (3) 
Moderately high (4) 
Very high 
Very high (3) 
Higher (4) 
High (2) 
Very low (1) 
Very low (3) 
Very low (4) 
BMP-2 High (1) 
Moderately high (2) 
Very low (3) 
Moderately high (1) 
Very low (3) 
Very low (1) 
Very high (2) 
Moderately high (3) 
BMP-4 Very high (1) 
High (2) 
High (3) 
High (1) 
Very high (2) 
Very low (3) 
High 
Very high (3) 
BMP-6 Very low (1) 
Moderately high (3) 
Moderately high (1) (3) High (1) 
Very low (3) 
Noggin Very high (3) Very high (3) Very high (3) 
Follistatin Very high (3) High (3) Very high (3) 
BMPRII High (1) 
Very low (2) 
High (3) 
High (1) 
Extremely high (2) 
High (3) 
Very high (1) 
Extremely high (2) 
Moderately high (3) 
ActRI High (2) Very high (2) Very high (2) 
ActRII Higher (1) 
High (2) 
High (1) 
Extremely high (2) 
High (1) 
Extremely high (2) 
ActRIIB High (1) 
Very high (2) 
Higher (1) 
Extremely high (2) 
Moderately high (1) 
Very high (2) 
ALK1 Very low (1) Very low (1) Very low (1) 
ALK2 Higher (1) Higher (1)  High (1) 
ALK3 
(BMPR-1A) 
Very high (1) 
High (2) 
Very high (1) 
Extremely high (2) 
High (1) 
Very high (2) 
ALK4 High (1) Higher (1) High (1) 
ALK5 
(TGF-βRI) 
High (1) Higher (1) High (1) 
ALK6 
(BMPR-IB) 
Very high (1) 
Higher (2) 
Extremely high (3) 
Moderately high (1) 
Very high (2) 
Extremely high (3) 
Very low (1) 
Very high (2) 
High (3) 
Smad1 Higher (1) Higher (1) High (1) 
Smad2 Higher (1) Very high (1) Very high (1) 
Smad3 High (1) Very high (1) Moderately high (1) 
Smad4 High (1) Moderately high (1) Very high (1) 
 
Smad5 Very high (1) Extremely high (1) Very high (1) 
Smad6    
Smad7    
Smad8/9 Moderately high (1) Extremely high (1) High (1) 
References: 1 – Miyazaki, Watabe et al. 2002; 2 – Yang, Zhong et al. 2003; 3 – Ye, Lewis-Russell et al. 2007; 4 – Ye. Lewis-Russell et 
al. 2008 
 
Table A1: Expression of BMPs and their signalling components in different studies. The table lists some 
of the different results obtained from studies that assessed the expression of BMP and their signalling 
components in different prostate cancer cell lines.
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Figure A1: Differential expression of BMPs in osteoblastic and osteolytic prostate cancer bone lesions. 
The data represents mean + SD of BMP expression results from a microarray study by Larson et al (2003; 
GSE41619). Significance was assessed by t-test using the Holm-Sidak method. 
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Figure A2: Differential expression of BMPRs in osteoblastic and osteolytic prostate cancer bone lesions. 
The data represents mean + SD of BMP expression results from a microarray study by Larson et al (2003; 
GSE41619). Significance was assessed by t-test using the Holm-Sidak method. 
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Figure A3: Differential expression of Smads in osteoblastic and osteolytic prostate cancer bone lesions. 
The data represents mean + SD of BMP expression results from a microarray study by Larson et al (2003; 
GSE41619). Significance was assessed by t-test using the Holm-Sidak method (*p ≤ 0.05). 
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Figure A4: Differential expression of EMT markers in osteoblastic and osteolytic prostate cancer bone 
lesions. The data represents mean + SD of BMP expression results from a microarray study by Larson et 
al (2003; GSE41619). Significance was assessed by t-test using the Holm-Sidak method. 
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Figure A5: Differential expression of MMPs in osteoblastic and osteolytic prostate cancer bone lesions. 
The data represents mean + SD of BMP expression results from a microarray study by Larson et al (2003; 
GSE41619). Significance was assessed by t-test using the Holm-Sidak method (* p ≤ 0.05, ** p ≤ 0.01).
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